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Abstract 
The role of the skeletal muscle protein Immunoglobulin-like and fibronectin 
type III domain containing 1 (IGFN1) has proved elusive. There are several 
IGFN1 isoforms, none of which contain catalytic domains. Each isoform has a 
domain composition of immunoglobulin and fibronectin domains, suggesting a 
structural role in the sarcomere. IGFN1 was first discovered as an interacting 
partner of the disease-associated protein KY, and the current literature 
implicates IGFN1 in both atrophy and myoblast fusion.  
Here, characterisation of fusion and differentiation indexes. compared to 
wildtype, of a CRISPR/Cas9-generated, C2C12-derived, IGFN1 knockout cell 
line revealed fusion and differentiation defects. Furthermore, these cells 
display increased globular to filamentous actin ratios, indicating decreased 
actin polymerisation which potentially underlies the fusion defects observed. 
Crucially, the above phenotypes are ameliorated through expression of the 
IGF1_V1 isoform.  
Next, to identify IGFN1 interaction partners, IGFN1 fragments were purified 
and pull-down analysis was performed revealing the actin nucleator COBL as 
a potential interacting partner. This interaction subsequently validated through 
immunoprecipitation and colocalization. The role of COBL in myoblast fusion 
was investigated through overexpression experiments and the generation of a 
C2C12-derived knockout cell line. Initial characterisation points towards a role 
for COBL in myoblast fusion. Taken together, it is possible that IGFN1 
influences actin remodelling, and therefore myoblast fusion, through its 
interaction with COBL.  
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Chapter 1: Introduction 
1.1 Overview 
Skeletal muscle comprises 30-40% of total body mass in humans, making it 
the largest organ system by mass in the body. The primary role of skeletal 
muscle is the conversion of chemical energy into mechanical energy. The 
hydrolysis of ATP provides the energy for contractions which produce 
movement or maintain posture. Alongside this, skeletal muscle tissue acts as 
a reservoir for amino acid storage, as well as helping to maintain body 
temperature due to its high metabolic activity. There is also evidence that 
skeletal muscle acts as a secretory organ, releasing so-called myokines which 
act in an autocrine/paracrine way on the muscle tissue itself, or in an endocrine 
manner, facilitating communication between the muscle and other organs (for 
a review see (Pedersen, 2013)).  
Skeletal muscle is a highly plastic tissue, able to respond to the physiological 
challenges placed on it, and the body as a whole. Physical activity such as 
running and climbing, or in the modern world resistance training in the gym, 
stimulate an increase in skeletal muscle mass. Skeletal muscle growth allows 
the organism to adapt to its environment, providing a survival advantage as it 
will be able to better respond to the challenges placed upon it in the future. 
During starvation however, muscle mass falls. Amino acids stored in the 
muscle tissue are released to help maintain blood glucose levels through 
gluconeogenesis, or processed into ketones. Muscle mass loss also helps to 
reduce the metabolic requirements of an organism during scarcity. The 
processes of increasing and decreasing muscle mass are controlled by 
several complex and interconnected pathways, which under normal 
physiological conditions are balanced to maintain a constant muscle mass. 
In the modern developed world starvation is no longer a major issue in society. 
However, inactivity, an aging population, and the atrophy induced by many 
disease states mean that muscle wasting is an increasing concern. Loss of 
muscle mass is common during ageing (sarcopenia). Sarcopenia increases 
the risk of all-cause mortality (Liu et al., 2017) and leads to a reduction in 
quality of life (Tsekoura et al., 2017), as people become less able to perform 
14 
 
everyday tasks. Muscle wasting is also observed in many disease states 
including cancer and AIDS (cachexia), where it is a positive indicator of the 
chance of death from the underlying disease (Bourdel-Marchasson et al., 
2016). While exercise and nutritional interventions are often successful in 
preserving, and even increasing muscle mass and function (Evans, 1999), 
these interventions are not always appropriate for all patients. High protein 
diets are not appropriate for some patients with chronic kidney disease (Ko et 
al., 2017), and exercise may not be possible in the time immediately post-
surgery or for critically ill patients. Understanding the processes involved in 
muscle mass maintenance may help to develop novel therapies to improve the 
lives of those suffering with sarcopenia and cachexia. 
Muscle wasting diseases can also have a genetic cause, with mutations in 
genes directly involved with muscle function. These congenital myopathies are 
characterised by a poor quality of life due to muscle weakness, which becomes 
progressively more severe and often results in early death (for a review see 
(Ravenscroft et al., 2018)). The most common group of congenital myopathies 
are muscular dystrophies, with Duchenne muscular dystrophy (DMD) being 
the most common of these. DMD is caused by a mutation in the gene coding 
for the dystrophin protein, which is responsible for anchoring the contractile 
machinery of the sarcomere to the costameres (Hoffman et al., 1987). 
However, the underlying genetic causes and pathogenic mechanisms of many 
muscular dystrophies and other myopathies are less well understood, making 
the understanding of the structure and function of skeletal muscle all the more 
pertinent. 
The ky/ky mutant mouse is a model of kyphoscoliosis, characterised by an 
inability to respond to mechanical load with hypertrophy, with postural muscles 
in particular showing pathological hallmarks (Blanco et al., 2001). Examples 
of human myopathies associated with KY deficiency have recently come to 
light (Hedberg-Oldfors et al., 2016; Straussberg et al., 2016; Yogev et al., 
2017), emphasising the importance of the KY protein in muscle mass 
maintenance. While there is evidence that KY may play a role in protein 
turnover through Chaperone Assisted Selective Autophagy (CASA) (Beatham 
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et al., 2004a; Jokl et al., 2018), no definitive role for KY in skeletal muscle has 
been established. 
Immunoglobulin-like and fibronectin type III domain containing 1 (IGFN1) was 
identified as an interacting partner of KY at the z-disc (Baker et al., 2010). The 
domain composition of IGFN1 consists of immunoglobulin and fibronectin-like 
domains, similar to that of sarcomeric proteins involved in maintaining the 
structural integrity of the muscle fibre. While there is evidence implicating 
IGFN1 in both atrophy (Chen et al., 2014; Mansilla et al., 2008; Rahimov et 
al., 2011), and myoblast fusion (Li et al., 2017), the function of IGFN1 has 
proved elusive and may be crucial to understanding the role of the disease-
associated KY protein. This research presented in this thesis was performed 
with the goal of interrogating the functional role of IGFN1 in skeletal muscle 
through the use of a CRISPR/Cas9 generated IGFN1 knockout C2C12-
derived cell line and the identification and validation of IGFN1 interaction 
partners. 
 
1.2 Skeletal Muscle Structure and Contraction 
1.2.1 Skeletal Muscle Structure 
A single skeletal muscle is comprised of bundles of muscle fibres, known as 
fascicles (fig.1.1). Each muscle fibre is made up of a bundle of myofibrils 
running in parallel with one another. An individual fascicle is surrounded by the 
perimysium, a layer of connective tissue which acts to provide structural 
integrity to the tissue. These fascicles are encased in a further layer of 
connective tissue, the epimysium, which provides a further degree of structural 
integrity. Tendons connect muscles to the bone, typically at both sides of a 
joint, allowing for the transmission of the contractile force of the muscle to the 
joint, resulting in movement. Muscle tissue is heavily innervated by motor 
neurons which trigger these contractions, and an abundant supply of blood 
vessels sustain its high metabolic activity. 
Muscle fibres are post-mitotic and multinucleated, formed through the fusion 
of numerous myoblasts. The traditional theory is one of a single myonucleus 
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controlling the protein production of a defined region, or nuclear domain 
(Pavlath et al., 1989). This seems to happen in a coordinated manner so that 
similar proteins are produced throughout the muscle fibre. However, non-
uniformity of protein expression across a muscle fibre has been reported 
(Wilkins et al., 2001), with myonuclei at the neuromuscular and myotendinous 
junctions expressing subsets of genes relevant to the specialized regions 
(Merlie and Sanes, 1985).  
Because muscle fibres are post-mitotic, muscle stem cells, otherwise known 
as satellite cells, are required in the event of injury to regenerate the damaged 
tissue, or to contribute to muscle growth by providing additional myonuclei. 
Satellite cells are found under the basal lamina of the muscle fibre, and are 
able to self-renew and contribute to muscle regeneration by fusing with 
damaged fibres (for a review see (Morgan and Partridge, 2003)). It is thought 
that satellite cells are required once the upper size limit of the myonuclear 
domains of the existing myonuclei is reached during muscle fibre growth. 
However, this paradigm has been brought into question, with highly flexible 
myonuclear domains, and hypertrophy independent of satellite cell fusion 
observed (for a review see ((Murach et al., 2018)). 
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Figure 1.1. Skeletal muscle structure. Whole tissue to myofibril, showing a nested 
set of bundles. Muscle fibres formed by a bundle of myofibrils, followed by fascicles 
formed by a bundle of muscle fibres which make up the muscle belly encased in the 
epimysium. Image taken from http://library.open.oregonstate.edu/aandp/chapter/10-2-
skeletal-muscle/. 
 
 
 
 
1.2.2 Skeletal Muscle Contraction 
The individual contractile units of the muscle fibre are the sarcomeres, which 
are organised end on end to form a myofibril. The sarcomere consists of actin 
thin filaments anchored to the z-disc and myosin thick filaments anchored to 
the M-line, which marks the centre of the sarcomere (fig. 1.2). Actin and 
myosin filaments overlap at the A band where they mediate muscle contraction 
by pulling against one-another in a cross bridge cycle, thereby shortening the 
length of the sarcomere and the muscle itself (Huxley, 1957).  
This process is reliant on ATP, myosin heads detach from actin upon the 
binding of ATP. ATP is then hydrolysed, providing the energy for the myosin 
head to move and bind to the next actin molecule and perform a power stroke, 
pulling the actin filaments towards the M-line. An influx of Ca2+ ions caused by 
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an action potential, initiated by a motor neuron at the neuromuscular junction, 
is required for this process to occur. Tropomyosin masks the myosin binding 
sites of actin at rest. Upon Ca2+ ion influx troponin displaces tropomyosin, 
allowing myosin heads to bind to the actin filaments (Parry and Squire, 1973). 
 
1.2.3 Muscle Fibre Type 
The myosin thick filament is made up of a myosin heavy chain (MYHC), a 
myosin light chain (MYLC), and myosin binding protein C (MYBC). Different 
isoforms of MYHC are expressed in different muscle fibre types, in accordance 
with the physical demands placed on the muscle. Type I “slow twitch” muscle 
fibres are oxidative and produce sustained slow contractions and are often 
involved in maintaining posture. Type IIb “fast twitch” muscle fibres are 
glycolytic and produce short, powerful contractions required for dynamic 
movement. Type IIa muscle fibres are intermediate muscle fibres which 
display features of both fast and slow muscle fibre types.  
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Figure 1.2 Sarcomeric Structure. Top: electron microscopy image of the sarcomere 
with significant regions labelled. Adapted from 
https://commons.wikimedia.org/wiki/File:Sarcomere.gif reproduced under a creative 
commons licence. Bottom: Schematic of the sarcomere with key structural 
components from the M-line to z-disc shown. Myomesin crosslinks myosin thick 
filaments at the M-line, while α-actinin crosslinks actin at the z-disc. Titin spans the 
length of the M-line to the z-disc. Dystrophin provides stability and a signalling 
function between the z-disc and the costamere via dystroglycans (DGs) and 
sarcoglycans (SGs). 
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1.2.4 Sarcomeric Structural Proteins 
The structural integrity of the sarcomere is maintained by a complex network 
of crosslinking proteins, which anchor the contractile apparatus in place (fig. 
1.2). Titin is the largest protein in the human body, consisting of hundreds of 
immunoglobulin and fibronectin domains. It spans the sarcomere form the z-
disc to the M-line and performs numerous functions, providing a scaffold for 
many other structural proteins to bind to (for a review see (Tskhovrebova and 
Trinick, 2003)). Nebulin is another giant muscle protein, known to help regulate 
the length of actin filaments by acting as a molecular ruler (Bang et al., 2006; 
Witt et al., 2006). However, how nebulin regulates actin filament length is 
clearly not the sole function of the protein, with links to sarcoplasmic Ca2+ 
handling and myofibrillar force generation (Chu et al., 2016). 
It is increasingly clear that many proteins assumed to perform only structural 
or scaffolding roles may be responsible for more complex cellular processes, 
such as mechanosensing and signalling. Titin is known to provide structural 
integrity to the sarcomere as it contracts and relaxes. Atomic force microscopy 
(AFM) has demonstrated that the immunoglobulin domains of titin are able to 
unfold and refold in response to mechanical tension, allowing it to act as a 
mechanical spring to absorb contractile forces (Rief et al., 1997). In addition, 
there is evidence that titin may play role in mechanotransduction, potentially 
as a mechanosensor, due to its elastic properties (Gautel, 2011; Kruger and 
Kotter, 2016; van der Pijl et al., 2018).   
α-actinin is a z-disc protein which forms antiparallel homodimers which interact 
with the n-terminus of titin (Atkinson et al., 2001), and is responsible for 
crosslinking actin filaments at the z-disc. In addition to this structural role, α-
actinin is known to interact with a number of proteins implicated in mechanical 
strain sensing. One such protein is actinin-binding muscle LIM protein 
CSRP3/MLP, believed to be a mechanosensing protein (Boateng et al., 2009). 
At the M-band another titin binding partner, myomesin, is responsible for the 
crosslinking of myosin. Like α-actinin myomesin forms antiparallel dimers 
which interact with the c-terminal end of titin (Lange et al., 2005). Interestingly, 
as with titin, the immunoglobulin domains of myomesin have been shown to 
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act as mechanical springs, able to absorb the contractile forces placed upon 
the M-band and maintain its structural integrity (Schoenauer et al., 2005).  
Integration of the structural components of the muscle fibre to the extracellular 
matrix (ECM) is another mechanism of maintaining sarcomeric structure. The 
Z-disc is anchored to the ECM through the costamere, made up of a protein 
complex including dystrophin and desmin, which are bound to integrins within 
the cell membrane. These integrins are connected to ECM components 
including collagen and proteoglycans. Mutations in costameric proteins often 
result in severe myopathies, and in the case of dystrophin, Duchenne 
muscular dystrophy (Hoffman et al., 1987). 
 
1.2.5 The C2C12 Cell Line as a Model for Skeletal Muscle in vitro 
The C2C12 cells line is a mouse myoblast cell line, a subclone of a line 
originally isolated from the leg muscle of an adult mouse (Blau et al., 1983; 
Yaffe and Saxel, 1977). It proliferates in high serum media (typically ~10% 
serum), and upon transfer to low serum media (typically ~2% serum) 
differentiation is initiated. C2C12 myoblasts form myocytes and multinucleated 
myotubes upon fusion. Further differentiation of these cells results in the 
formation of striations, reflecting the contractile machinery observed in vivo. 
Under ideal conditions contraction can be observed in C2C12 cells 
differentiated for long periods of time. These properties make C2C12 cells a 
valuable model for skeletal muscle in vitro, particularly when studying myoblast 
fusion and differentiation. 
 
1.3 Myoblast Fusion  
Myoblast fusion allows for the formation of multinucleated muscle fibres during 
development, as well as satellite cell fusion in response to growth signals or 
muscle damage. It is a process underpinned by remodelling of the 
cytoskeleton throughout each stage: migration, recognition, adhesion, 
membrane alignment, and membrane pore formation and resolution (Rochlin 
et al., 2010). Much of the early evidence regarding myoblast fusion came from 
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Drosophila, however many of the genes identified have vertebrate 
orthologues. A summary of the myoblast fusion machinery in Drosophila and 
in mammals can be seen in figure 1.3. 
 
1.3.1 Myoblast Fusion in Drosophila 
Cytoskeletal changes are crucial for proper cell migration. During myoblast 
migration in Drosophila; Kette, a conserved member of the SCAR/WAVE 
regulatory complex (Gildor et al., 2009), regulates the actin nucleator Arp2/3 
(Ibarra et al., 2005) to drive the migration of a fusion competent myoblast 
(FCM) to a founder cell (FC). This is followed be recognition of the FC and 
adhesion. Immunoglobulin super family (IgSF) members Dumbfounded (Duf) 
and Roughest (Rst) are expressed in the FC. While Sticks and Stones (Sns) 
and Hibris (Hbs) are expressed in the FCM. The interaction between Duf and 
Sns, and Rst and Hbs is required for cell recognition and adhesion of the FC 
and the FCM. (Artero et al., 2001; Bour et al., 2000; Dworak et al., 2001; Ruiz-
Gomez et al., 2000; Strunkelnberg et al., 2001).  
Upon the adhesion of fusing cells, an actin “focus” is formed in the FCM and 
a thin actin “sheath” forms in the FC. Without the formation and dissolution of 
these structures, fusion cannot proceed (Kesper et al., 2007; Kim et al., 2007; 
Richardson et al., 2007). The formation of this actin focus is dependent on the 
Kette-SCAR-Arp2/3 pathway. It is thought that the actin focus provides a 
positional cue for membrane targeting of vesicles required at the onset of pore 
formation (Rochlin et al., 2010). Again Arp2/3 is implicated in the expansion of 
these pores, with actin providing a force generating mechanism (Berger et al., 
2008). Pore expansion allows the nucleus of the FCM to enter the FC, hence 
completing the fusion process. 
 
 
 
 
23 
 
1.3.2 Myoblast Fusion in Vertebrates 
As in Drosophila, myoblast migration in mice depends on actin remodelling. 
Myoblasts treated with latrunculin A or cytochalasin D, which block actin 
polymerisation, show reduced migration in vitro (Constantin et al., 1995; 
Sanger and Holtzer, 1972), and pharmacological inhibition of F-actin 
remodelling leads to an inability of myoblasts to migrate, resulting in reduced 
myoblast fusion (Dhawan and Helfman, 2004; Nowak et al., 2009).  
Cell recognition is meditated by nephrin, the vertebrate ortholog of Sns, which 
localises to the membrane of fusing cells (Sohn et al., 2009). Recognition is 
then followed by adhesion, mediated by M/N-cadherin (Hollnagel et al., 2002; 
Radice et al., 1997) as well as by integrin family members, which help to 
properly align the myoblasts. Beta1-integrin knockout myoblasts adhere but 
plasma membrane alignment and breakdown does not occur, preventing 
fusion from occurring (Schwander et al., 2003). 
While there is no evidence for an F-actin focus in vertebrates as yet, there is 
evidence that an actin wall forms along the pre-fusion myoblast. This structure 
regulates cell fusion through vesicle trafficking, and its formation requires non-
muscle myosin type IIA (Duan and Gallagher, 2009). The formation of this 
actin wall is also dependent on Nap1 the mammalian homologue of Kette, 
which acts through the N-WASP complex to promote Arp2/3 mediated actin 
remodelling (SCAR in Drosophila) (Nowak et al., 2009).  
Additionally, Similar to Drosophila mbc mutants, Dock1-null mice embryos 
exhibit severely impaired myoblast fusion and skeletal muscle content is 
reduced (Laurin et al., 2008). Dock1 (mbc) is a GEF which activates the 
GTPase Rac. In a conditional Rac1 knockout mouse model, the recruitment of 
Arp2/3 and F-actin to the cell-contact site is reduced, resulting in impaired 
myoblast migration and fusion (Vasyutina et al., 2009). G-protein coupled 
receptors BAI 1 and 3 also feed into the Dock/Rac1/Arp2/3 pathway, providing 
signal transduction from the membrane to the cytoskeleton (Hamoud et al., 
2014; Hochreiter-Hufford et al., 2013). 
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Figure 1.3. Comparison of recognition, adhesion, and actin remodelling during 
myoblast fusion in Drosophila (Top) and Mammals (Bottom). Orthologues are 
shown in the same colour. Proteins spanning both cells are involved in membrane 
recognition and/or adhesion. Arrows represent signalling cascades. 
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1.3.3 The Fusogens: Myomaker and Myomerger 
Several proteins and pathways are known to be involved in recognition, 
adhesion, and cytoskeletal remodelling during fusion. However, until recently, 
no one protein which is able to directly induce myoblast fusion had been 
identified and decoupling of the fusion and differentiation pathways has proved 
challenging. The recent discovery and characterisation of Myomaker and 
Myomerger/Minion/Myomixer has provided the first examples of muscle 
specific fusogens. Myomaker and Myomerger are expressed in myoblasts 
and/or myotubes of vertebrates during differentiation and are not expressed in 
any other tissue, or in adult skeletal muscle. It is not yet known whether any 
orthologues are expressed in invertebrates, however it is possible that 
functional homologs, lacking sequence similarity, do exist. 
Myomaker knockout cells fail to fuse, but it is the effect of Myomaker 
expression in non-muscle cells which is particularly interesting. Myomaker 
expressing non-muscle fibroblasts are able fuse with C2C12 cells, providing 
the first example of a muscle specific fusogen (Millay et al., 2016; Millay et al., 
2013). A second example soon followed with the discovery of Myomerger. 
Myomerger too was sufficient to allow fusion between muscle and non-muscle 
cells, with expression of both Myomaker and Myomerger allowing the fusion 
of two non-muscle cells with one another (Bi et al., 2017; Quinn et al., 2017; 
Zhang et al., 2017). It was found that Myomaker is required symmetrically, on 
both fusing cells, while Myomerger is required asymmetrically, on only one of 
the cells in a fusing pair. This could be evidence of a Drosophila-like model of 
myoblast fusion, with a founder cell expressing both Myomaker and 
Myomerger, and a fusion competent myoblast expressing only Myomaker. 
The mechanism of action of both Myomaker and Myomerger remains elusive. 
It is likely that Myomaker is involved in fusion competence, whereas 
Myomerger may activate fusion through pore formation. There is some 
evidence of interaction between the two proteins (Bi et al., 2017), but this is 
disputed (Deng et al., 2017). What is clear is that remodelling of the actin 
cytoskeleton is crucial for Myomaker and Myomerger to perform their roles. 
The fusogenic activity of Myomaker and Myomerger is lost through 
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pharmacological inhibition of F-actin polymerisation (Millay et al., 2013; Zhang 
et al., 2017), emphasising the importance of cytoskeletal remodelling in 
myoblast fusion.   
 
1.4 Skeletal Muscle Hypertrophy 
Increases in skeletal muscle mass can occur through two distinct processes, 
hyperplasia and hypertrophy. Hyperplasia refers to the generation of new 
muscle fibres through satellite cell fusion. Whereas hypertrophy refers to the 
increase in size of a muscle fibre, driven by a net increase in protein synthesis. 
Hypertrophy is the main driver of muscle mass increases. 
 
1.4.1 The IGF-1/Akt signalling pathway 
The canonical pathway for skeletal muscle hypertrophy is the Insulin-like 
Growth Factor (IGF-1)/Protein Kinase B (Akt)/ Mammalian Target of 
Rapamycin (mTOR) pathway (fig 1.4). Growth hormone (GH) is produced by 
the pituitary gland in response to numerous stimuli, including diet and exercise. 
GH stimulates the upregulation of IGF-1 in most tissues, but the liver is 
primarily responsible for increasing serum IGF-1 levels in response to GH 
(Mathews et al., 1986). However, it is the autocrine/paracrine effect of IGF-1 
expressed in muscle itself in response to GH that appears to be the main driver 
of muscle hypertrophy (Velloso, 2008). 
IGF-1 binds to its tyrosine kinase receptor IGFR1, thereby inducing the 
phosphorylation of Insulin Receptor Substrate 1 (IRS-1). This then results in 
the activation of Akt through Phosphatidylinositol 3 Kinase (PI3K) (Rommel et 
al., 2001). Akt goes on to activate mTOR via repression of the tuberous 
sclerosis 1/2 (TSC1/2) complex, which in turn releases the repression of Ras 
Homolog Enriched in Brain (Rheb) a GTPase which upregulates mTOR 
activity. mTOR serves as a central regulator of protein synthesis in the muscle 
cell, promoting protein synthesis through the activation of translational 
regulators p70S6K and eIF4E (Hara et al., 1997; Inoki et al., 2002). mTOR can 
also be activated independently of IGF-1 signalling, notably through the 
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availability, above a given threshold, of amino acids such as leucine (Burnett 
et al., 1998; Hara et al., 1998; Kimball et al., 1999), and through mechanical 
loading, as discussed below.  
 
1.4.2 Loading-Induced Hypertrophy Independent of IGF-1/Akt 
The traditional paradigm of muscle hypertrophy, with IGF-1 activating mTOR 
through Akt, is now being challenged. It is clear that mTOR, and its 
downstream effectors, are activated independently of IGF-1 signalling. 
Pharmacological inhibition of IGF-1 using wortmannin does not prevent 
p70S6K activation during mechanical loading of the muscle (Hornberger et al., 
2004). This result provided the first evidence of an IGF-1 independent model 
of muscle hypertrophy in response to mechanical load.  
Knock-in of a dominant negative IGF-1 receptor (IGFR1) abolishes IGF-1 
signalling and results in mice with muscles around 30% smaller than in 
wildtype littermates. However, upon mechanical loading mutant mice 
displayed a similar hypertrophic response to the wildtype and had normal 
p70S6K phosphorylation (Spangenburg et al., 2008). Another study 
demonstrated that mTOR was a central regulator of hypertrophy, which does 
not rely on PI3K signalling, and can be activated independent of PI3K through 
overexpression of Rheb (Goodman et al., 2010). While this study did not 
employ mechanical overload, it provides genetic evidence for mTOR activation 
independent of the IGF-1/Akt axis. 
Tracking of protein phosphorylation levels during a 10-day bout of mechanical 
overload in mice revealed that mTOR is activated after just a single day. This 
was accompanied by an increase in p70S6K phosphorylation. In contrast, Akt 
phosphorylation was not increased until 2-3 days of overload, suggesting 
another pathway for the activation of mTOR early in muscle overload. The 
authors identified the mitogen-activated protein kinase kinase 
(MEK)/extracellular signal-regulated kinase (ERK), signalling through 
tuberous sclerosis 2 (TSC2), as a possible pathway for the early activation of 
mTOR in mechanical overload (Miyazaki et al., 2011). 
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While the IGF-1/Akt/mTOR signalling pathway during muscle hypertrophy is 
relatively well understood, very little is known about how mTOR is activated in 
response to mechanical overload. There has been no definitive identification 
of any mechanosensors thus far. Titin has been proposed as a potential 
mechanosensing protein. Its size, coupled with its spring-like properties, and 
interactions with numerous signalling proteins make it an ideal candidate as 
protein with the potential to detect mechanical load and initiate hypertrophic 
signalling (Kruger and Kotter, 2016). There are a number of other candidates 
with similar domain compositions to titin, at both the z-disc and the M-line 
which may serve as mechanosensors, however the evidence thus far is 
scarce. Indeed, more work is required to unravel the complex signalling 
pathways upstream of mTOR. 
 
1.5 Skeletal Muscle Atrophy 
Muscle atrophy is a loss in muscle mass caused by net protein degradation 
which does not simply reflect a lack of hypertrophy. Atrophy can occur in 
congenital myopathies, ageing, and during starvation. These different 
physiological inputs serve to upregulate forkhead box transcription factors 
(FOXO), through Akt repression. FOXO transcription factors also upregulate 
genes involved in the ubiquitin-proteasome system (fig. 1.4). Models for 
atrophy in vivo include denervation, starvation, and immobilisation of a limb. 
In vitro, myotubes derived from differentiated C2C12 cells can be used, with 
pharmacological interventions, such as treatment with dexamethasone, used 
to induce atrophy. 
 
1.5.1 The Ubiquitin-Proteasome System 
The Ubiquitin-Proteasome System (UPS) is found across all cells of the body, 
where it targets proteins for degradation by the proteasome through addition 
of ubiquitin (ubiquitination). For ubiquitination, three enzymes are required, an 
E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme, and an 
E3 ubiquitin-ligating enzyme. E1 ubiquitin-activating enzymes ligase ubiquitin, 
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facilitating its transfer to an E2 ubiquitin-conjugating enzyme. The E2 ubiquitin-
conjugating enzyme then binds to an E3 ubiquitin-ligase, this complex binds 
to and ubiquitinates a substrate protein, signalling it for degradation in the 
proteasome (Hershko and Ciechanover, 1998). E3 ubiquitin-ligases provide 
the substrate specificity for the Ubiquitin-Proteasome System. 
The role of the UPS in skeletal muscle atrophy has been well established 
(Jagoe et al., 2002; Tawa et al., 1997), and the main E3 ubiquitin-ligases 
identified as Muscle Ring Finger1 (MuRF1) and Atrogin-1 (Bodine et al., 2001). 
Both MuRF1 and atrogin expression are promoted by FOXO transcription 
factors (Lee et al., 2004; Sandri et al., 2004; Stitt et al., 2004), which in turn 
are regulated through Akt. MuRF1 and atrogin expression can also be 
increased independently of FOXO. MuRF1 expression is increased through 
NF-κB signalling (Cai et al., 2004), while atrogin expression is increased 
through the p38 MAPK pathway (Li et al., 2005). Both pathways are positively 
regulated by TNFα, a pro-inflammatory secreted cytokine released in several 
atrophic conditions including cancer, disuse, and starvation. 
 
1.5.2 Autophagy  
Autophagy refers to the breakdown of cellular components within a 
membrane-bound compartment, the lysosome. Targets can be small, as in 
microautophagy, or large, as in macroautophagy, where whole organelles can 
be degraded. This process can be selective, such as the degradation of a 
damaged mitochondrion, or non-selective as is the case during atrophy. 
Selective autophagy requires the recruitment of chaperones to target the 
protein for degradation.  
One proposed mechanism for the selective degradation of damaged proteins 
in muscle is Chaperone Assisted Selective Autophagy (CASA) (Arndt et al., 
2010; Ulbricht et al., 2013). This process involves the binding of several 
chaperones including BAG3, which itself is upregulated in response to 
mechanical tension, to damaged filamin-c (FLNC). The E3 ubiquitin-ligase 
CHIP binds and ubiquitinates the damaged protein, targeting it to the 
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autophagosome. In addition to facilitating the breakdown of damaged FLNC, 
BAG3 promotes YAP/TAZ signalling, resulting in the upregulation of FLNC. 
Thereby contributing to overall protein turnover and not only degradation. 
CASA is required for muscle mass maintenance (Arndt et al., 2010; Ulbricht et 
al., 2013), and CASA components are upregulated in response to resistance 
training in humans (Ulbricht et al., 2015). Thus, CASA may help to maintain 
healthy muscle, and even facilitate new muscle growth, through the clearance 
of damaged cytoskeletal crosslinkers and prevention of the formation of 
crosslinker aggregates which result in cellular stress. 
 
1.6 Myostatin 
Myostatin is a negative regulator of skeletal muscle mass; myostatin-null mice 
display a double muscle phenotype (McPherron et al., 1997), this effect is also 
observed in Belgian Blue cattle, which carry a frameshift mutation in the 
myostatin gene (McPherron and Lee, 1997). Myostatin mutations have been 
identified in humans (Schuelke et al., 2004), where gross muscle hypertrophy 
is observed. This conservation demonstrates the importance of myostatin in 
regulating skeletal muscle mass in mammals. 
Myostatin binds to activin type II receptor (ActRII) on the surface of the muscle 
cell, initiating a cascade of phosphorylation which results in the inhibition of 
the activity of the protein kinase Akt, therefore inhibiting IGF-1 mediated 
protein synthesis. This inhibition of the Akt/MTOR pathway releases the 
inhibition of the FOXO transcription factors, thereby allowing the increased 
expression of atrophy-associated ubiquitin ligases atrogin and MuRF1 (Sandri 
et al., 2004; Stitt et al., 2004). Phosphorylation of Smad2 and 3 also occurs as 
a result of ActRII activation (Rebbapragada et al., 2003). Phosphorylated 
Smad2 and Smad3 Smad2 and 3 translocate to the nucleus where they 
downregulate gene transcription independent of blocking mTOR signalling 
(Elkina et al., 2011) (fig. 1.4). 
Myostatin, and its and downstream signalling pathway, have been proposed 
as potential druggable targets in muscle wasting diseases (Tsuchida, 2008). 
31 
 
It is important to understand the mechanism by which myostatin acts, including 
any genes which are up/downregulated through myostatin signalling, to 
provide more insight into its potential as a therapeutic target. 
 
 
 
 
Figure 1.4. Simplified schematic of skeletal muscle hypertrophy and atrophy 
pathways. Up-regulators of protein synthesis are shown in green, down-regulators in 
red. Some intermediates have been omitted. 
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1.7 The KY Protein 
1.7.1 The ky/ky Mouse 
The ky/ky mouse is the result of a spontaneous mutation of the Kyphoscoliosis 
Peptidase (Ky) gene in the BDL mouse strain. This mutation produced a strain 
of mice with kyphoscoliosis (Dickinson and Meikle, 1973). The Ky gene was 
identified and the mutation giving rise to the ky/ky mouse was discovered to 
be a GC deletion, resulting in a premature stop codon (Blanco et al., 2001). 
Postnatally these mice display abnormal spinal curvature, most likely caused 
by the weakening of the paraspinal muscles, which also prevents mice from 
reaching to a ledge during the placing response test. No phenotype is detected 
during the embryonic development of these mice, reflecting the need for 
mechanical loading of the muscles to reveal the muscular defects (Blanco et 
al., 2001).  
While muscle mass is consistently lower overall in ky/ky mice compared to 
wildtype (Marechal et al., 1995), it is mostly the constantly active, type I fibre 
dominant muscles that are affected by this mutation. Between 6 and 25 days 
after birth prominent necrosis and regeneration in the soleus, gracilis, 
paraspinal, and back muscles is observed (Bridges et al., 1992). Electron 
microscopy has also demonstrated the accumulation of autophagic vesicles, 
as well as z-disc thickening and A-band streaming in these postural muscles. 
The absence of KY results in an inability of type II(A&B) fibres to respond to 
an increase in mechanical load with hypertrophy, suggesting that the KY 
protein plays a role in all muscle types during tension-induced hypertrophy 
(Blanco et al., 2001). Additionally, the Ky mutant mouse displays aggregation 
of the actin cytoskeleton-associated proteins FLNC (Beatham et al., 2004a) 
and Xin (Beatham et al., 2006), a sign of a reduced ability to degrade and 
replace damaged cytoskeletal proteins. 
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1.7.2 KY-Associated Human Myopathies 
Three independent cases of human myopathies associated with a mutation 
resulting in non-functional KY have so far been reported. Each case was the 
result of a different mutation resulting in KY loss of function. There is significant 
overlap in the pathologies observed between the cases. Some variability is 
seen, likely accounted for by the highly inbred populations causing the 
accumulation of other deleterious mutations. 
A girl presenting with severe and progressive walking difficulties, resulting from 
generalised muscle weakness, was the first patient identified with a KY loss of 
function mutation. This patient suffered from mild contractures in the 
shoulders, hips, and feet, along with cavus feet and lordosis. Some small 
muscles fibres were observed with some of these having abnormal 
sarcomeres with thickened Z-discs and small nemaline rods. Internalised 
nuclei, an indicator or muscle fibre regeneration, were also observed. As in the 
ky/ky mouse, aggregation of FLNC was observed. Whole-exome sequencing 
revealed a homozygous one-base deletion in Ky, predicted to result in a 
truncated protein (Hedberg-Oldfors et al., 2016). 
The second example of a KY-associated myopathy comes from two brothers 
sharing a mutation resulting in an early stop codon in exon 6 of the Ky gene. 
Both brothers display atrophy and weakness of the lower limbs, as well as 
tongue atrophy and kyphosis. The younger sibling also suffers from upper 
extremity weakness, speech difficulties, and impaired intellectual development 
in addition to the phenotypes observed in his elder brother. FLNC aggregation 
was also observed in this patient. Autozygosity mapping and whole exome 
sequencing revealed a homozygous variant, which constitutes a premature 
termination codon in Ky exon 6, hypothesised to lead to nonsense-mediated 
mRNA decay (Straussberg et al., 2016). 
Genetic analysis of twelve individuals from a Bedouin Israeli tribe, presenting 
with autosomal recessive progressive spastic paraplegia, revealed a single 
homozygous variant within Ky resulting in a frame-shift and loss of function. 
Spasticity of the lower limbs, hyperreflexia, and toe walking were observed in 
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all patients, with kyphoscoliosis evident in older patients. Most also had 
atrophy of the tongue and muscle biopsies showed some small angular fibres 
and some with centralised nuclei. The observed pathology was detectable by 
age two (Yogev et al., 2017). 
The involvement of KY in human disease, with similar hallmarks as the 
observed phenotypes in ky/ky mice, demonstrates the importance of KY in 
skeletal muscle mass maintenance, especially in postural muscles.   
 
1.7.3 KY and Autophagy 
KY is required for tension-induced hypertrophy (Blanco et al., 2001). FLNC 
accumulation and mis-localisation is a hallmark of loss of function of KY in both 
mice and humans (Beatham et al., 2004a; Hedberg-Oldfors et al., 2016; 
Straussberg et al., 2016). As well as this, FLNC and KY interact at the z-disc 
(Baker et al., 2010; Beatham et al., 2004a). As CASA is responsible for 
turnover of damaged FLNC and is required for hypertrophy, it has been 
hypothesised that KY plays a role in CASA. 
Recent examination of KY deficient mice, zebrafish, and C2C12 cells has 
provided further evidence of a link between KY and CASA. Differentiated, KY 
deficient, C2C12-derived clones show a trend of increased transcription of 
CASA factors. bag3 and flnc are also found to be upregulated in the muscle of 
a KY knockout zebrafish model. While these fish lack overt pathology, 
swimming in viscous media does not produce the further increase of bag3 or 
flnc expression which is observed in wildtype fish. Finally, ky/ky mice have 
elevated bag3 expression in the exterior digitorum longus (EDL), a non-
pathological tissue, and BAG3 turnover is impaired in the soleus (Jokl et al., 
2018). These results point towards KY helping to maintain and increase 
muscle size through CASA directed protein turnover, however, a direct 
mechanism has not yet been discovered. It is possible that KY deficiency 
simply disrupts the structure of the z-disc and accumulation of damaged cross-
linkers results from this, rather than a block on CASA. 
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1.7.4 The KY Protein and Interacting Partners 
According to predictions from sequence analysis the KY protein is a 
transglutaminase-like protein (Baker et al., 2010). However, to date, no 
evidence of catalytic activity exists, and it is possible that the transglutaminase 
domain has been co-opted for protein-protein interactions (Anantharaman et 
al., 2001). Indeed, KY has been shown to interact with several proteins, 
including FLNC as outlined above. As well as FLNC, KY interacts with IGFN1 
at the z-disc (Baker et al., 2010). At the time this interaction was uncovered 
very little was known of the function of IGFN1, warranting further investigation 
to develop the understanding of KY and its role in disease. 
 
1.8 IGFN1 
1.8.1 IGFN1 Discovery, Structure, and Interactions 
IGFN1 is a large skeletal muscle protein localised to both the z-disc and the 
nucleus (Baker et al., 2010; Mansilla et al., 2008). It was identified through a 
yeast two-hybrid screen as an interacting partner of KY at the z-disc (Baker et 
al., 2010).  
The Igfn1 locus is complex with multiple putative ATG start sites, which, along 
with alternative splicing, produce multiple IGFN1 isoforms (fig. 1.5). Full-length 
IGFN1 consists of 11 Immunoglobulin/Immunoglobulin-like (IG/IG-like) and 
fibronectin type 3 (FN3) domains, separated by a large unstructured region. 
IGFN1_V1 is an isoform resulting from alternative splicing which lacks the 
unstructured region. Two other isoforms consisting of the c-terminal globular 
domains have also been confirmed, expressed from internal promoters within 
the Igfn1 gene (Baker et al., 2010).  
The Igfn1 gene is highly conserved across mammals, with the exception of the 
sequence coding for the unstructured region (Baker et al., 2010), suggesting 
the amino acid composition of this region is not relevant to its function. Regions 
such as this have been proposed to provide flexibility to a protein, allowing 
conformational changes to occur, potentially exposing binding sites for 
different clients (Dyson and Wright, 2005). Therefore, IGFN1 is likely to 
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undergo conformational changes in response to some stimulus, possibly in 
response to mechanical tension. 
The domain composition of IGFN1 is like that of sarcomeric proteins involved 
in maintaining the structural integrity of the sarcomere through cycles of 
contraction and relaxation. Titin and myomesin both contain globular domains 
which allow these proteins to act as molecular springs, absorbing the forces 
of contraction (Rief et al., 1997; Schoenauer et al., 2005). The position of 
IGFN1 at the z-disc, an area integral to sarcomeric structure, and its domain 
composition make it an ideal candidate to help maintain the structure of the 
sarcomere. 
IGFN1 has no apparent catalytic domains. It is therefore likely that any function 
IGFN1 performs occurs through protein-protein interactions via its globular 
domains. Along with KY, through Y2H and pull-downs, IGFN1 was found to 
interact with FLNC, titin, and actin (Baker et al., 2010), all important proteins 
for maintaining sarcomeric structure. These proteins have also been 
implicated in mechanotransduction and hypertrophy, with FLNC and KY likely 
to be integral to CASA.  
As well as the above, IGFN1 interacts with MLK-Like Mitogen-Activated 
Protein Triple Kinase 20 (MLTK)/ Leucine Zipper-and Sterile Alpha Motif-
Containing Kinase (ZAK) (Baker et al., 2010). Recessive ZAK mutations are 
implicated in human disease (Vasli et al., 2017). IGFN1 also interacts with 
Eukaryotic translation elongation factor 1A (eEF1A) (Mansilla et al., 2008), a 
guanine-nucleotide binding protein, which transports aminoacylated tRNA to 
the ribosomal A site during protein synthesis (Negrutskii and El'skaya, 1998). 
The significance of the interaction between IGFN1 and ZAK, and IGFN1 and 
eEF1A will be discussed below. 
Finally, knockdown of IGFN1 in C2C12 cells results in a lack of fusion (Li et 
al., 2017). Though these initial experiments did not include a rescue of the 
wildtype fusion phenotype through expression of IGFN1. IGFN1 expression 
was also found to fluctuate throughout myoblast fusion and differentiation, 
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suggesting it plays a relevant role in these processes. This thesis will expand 
on this work, examining the role of IGFN1 in myoblast fusion. 
 
 
Figure 1.5. Domain composition of IGFN1 isoforms. Top, exons of Igfn1, with ATG 
sites shown, adapted from (Baker et al., 2010) with authors permission. Bottom, 
IGFN1 isoforms produced from the Igfn1 locus via putative internal ATG promoter 
sites or alternative splicing. Immunoglobulin (IG), Immunoglobulin-like (IG-like), and 
Fibronectin type III domains (FN3) are indicated.  
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1.8.2 IGFN1 and Atrophy 
IGFN1 expression is positively correlated with atrophic conditions. 
Denervation of a muscle induces muscle fibre atrophy and is a common model 
for muscle atrophy in vivo (Pellegrino and Franzini, 1963). IGFN1 expression 
was found to be increased in response to denervation (Mansilla et al., 2008). 
In addition to this IGFN1 was found to interact with eEF1A, leading the authors 
to propose a mechanism whereby IGFN1 downregulates muscle protein 
synthesis, in response to denervation, by repressing eEF1A activity. 
Along with denervation, IGFN1 expression is correlated with myostatin 
signalling, a negative regulator of skeletal muscle mass. Using soluble activin 
type B receptors (ActRIIB) to sequester myostatin in vivo led to significant 
increases in muscle mass (Rahimov et al., 2011). This was accompanied by 
a significant reduction of IGFN1 mRNA expression. Furthermore, when 
myostatin signalling is increased via injection of adenoviral vectors in mice, 
muscle mass decreases and IGFN1 mRNA expression increases (Chen et al., 
2014).  
These findings raise the possibility that IGFN1 is involved in atrophy, possibly 
acting as an effector of the myostatin signalling pathway. However, no direct 
mechanism whereby IGFN1 causes atrophy has been identified thus far.  
 
1.8.3 IGFN1 and ZAK 
IGFN1 interacts with ZAK (Baker et al., 2010), a mixed lineage kinase family 
member with two isoforms, ZAKα and ZAKβ (Gotoh et al., 2001). ZAKα is 
primarily expressed in the heart where it induces cardiac hypertrophy when 
overexpressed in vivo (Christe et al., 2004). Overexpression of ZAKα in 
cardiomyocytes in vitro also results in hypertrophy (Huang et al., 2004). ZAKβ 
is primarily expressed in skeletal muscle where its overexpression through 
electroporation induces an increase in muscle fibre cross-sectional area (Li, 
2016). Dominant-negative Zak mutations in mice result in hindlimb duplication, 
implicating ZAK in limb development (Spielmann et al., 2016). Human patients 
with ZAK deficiency do not show abnormal limb development. However, they 
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suffer from muscle weakness, scoliosis, and reduced ambulant ability, 
underpinned by a predominance of type I muscle fibres of varying sizes 
displaying centralised nuclei (Vasli et al., 2017), hallmarks shared with patients 
with mutations in the Ky gene. 
ZAK is known to increase p38 phosphorylation (Gotoh et al., 2001). p38 
activation through phosphorylation is implicated in both hypertrophy and 
atrophy. p38 is activity is increased in response to immobilisation (Kim et al., 
2009) and denervation (Paul et al., 2010), and p38 activity is responsible for 
the upregulation of MuRF1 (Li et al., 2005). On the other hand, p38 
phosphorylation is increased in response to mechanical tension, suggesting a 
role in hypertrophy (Boppart et al., 2001; Carlson et al., 2001; Hornberger et 
al., 2004). The roles of p38 during skeletal muscle development (Keren et al., 
2006), and in satellite cell function (Segalés et al., 2016), further complicate 
this picture and reflect the fact that p38  is not one single protein and in fact  
represents a family of four MAP kinases (Cuenda and Rousseau, 2007). 
The upregulation of ZAK in the EDL of the ky/ky mouse provides a further 
functional link between the KY/IGFN1 complex and ZAK (Blanco et al., 2004). 
It is possible that IGFN1 acts to aid ZAK in signalling, acting either as a 
scaffold, or as a mechanosensor to upregulate p38 in response to mechanical 
tension. IGFN1 may also act to inhibit ZAK signalling, thereby preventing ZAK-
induced hypertrophy.    
 
1.9 Hypotheses and Objectives 
1.9.1 Hypotheses 
The function of IGFN1 has thus far been elusive. Based on the literature 
presented above several hypotheses as to the function of IGFN1 were outlined 
at the outset of this project (fig.1.6). These hypotheses are not mutually 
exclusive, it is possible that IGFN1 performs many different overlapping and 
inter-related roles, especially as multiple isoforms of IGFN1 are expressed. 
The initial hypotheses identified are as follows: 
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• IGFN1 is a structural protein. The most simple hypothesis regarding 
the role of IGFN1 is that it acts as a structural protein. Its localisation to 
the z-disc, lack of catalytic activity, and its domain composition make it 
an ideal candidate to perform such a role. IGFN1 also interacts with 
many sarcomeric proteins involved in maintaining the structural integrity 
of the sarcomere, such as titin and actin. 
 
• IGFN1 is a scaffold for signalling/effector proteins. IGFN1 contains 
several immunoglobulin domains, these domains are often implicated 
in protein-protein interactions. Indeed, IGFN1 has been found to 
interact with numerous proteins including the signalling kinase ZAK. It 
is possible that IGFN1 acts as a central signalling scaffold at the z-disc, 
with its unstructured region allowing for conformational changes 
exposing different binding sites to potential interacting partners. 
 
• IGFN1 is a mechanosensor. IGFN1 may act to sense mechanical 
tension at the z-disc and relay this to signalling proteins, facilitating 
muscle hypertrophy. The globular domains of IGFN1 may be able to 
unfold and refold in response to mechanical tension, as has been 
observed in other muscle proteins with similar domains, providing a 
mechanism for detecting mechanical load. This hypothesis overlaps 
with the two hypotheses proposed above and would require interactions 
with relevant signalling proteins. The interaction of IGFN1 and KY 
provides a mechanism by which IGFN1 could act as a mechanosensor 
in CASA. However, the association between IGFN1 and atrophic 
signalling places some doubt on this hypothesis. 
 
• IGFN1 is part of the myoblast fusion machinery. Preliminary data at 
the outset of this project suggests a role for IGFN1 in myoblast fusion. 
The suggested interaction between IGFN1 and actin may facilitate its 
role in myoblast fusion as actin remodelling is critical for this process. It 
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is likely that any role in actin remodelling requires interacting partners, 
due to the lack of catalytic domains in IGFN1. 
 
• IGFN1 is a facilitator of atrophy. Although no direct evidence of 
IGFN1 inducing atrophy currently exists, IGFN1 expression is positively 
correlated with atrophic conditions. Again, it is unlikely that IGFN1 acts 
to induce atrophy directly, requiring interacting partners to facilitate any 
role in atrophy. 
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Figure 1.6. Summary of proposed roles for IGFN1 in skeletal muscle. IGFN1 
expression is influenced by myostatin signalling, it also interacts with KY and 
ZAK, possibly facilitating a role in CASA or muscle mass maintenance 
through another unknown pathway. Its domain composition and position at 
the z-disc points towards a role in structural stability of the z-disc. A role for 
IGFN1 in myoblast fusion has also been suggested by fusion deficiency in 
knockdown cells. 
 
 
1.9.2 Objectives  
 
In order to explore the above hypotheses, the initial objectives, with 
associated aims, of this project were: 
 
Characterisation of a C2C12-derived IGFN1 knockout cell line.  
• Determine the effect of IGFN1 knockout on cell size, in untreated 
conditions and following induction of atrophy   
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• Examinine the effects of IGFN1 knockout on fusion and differentiation, 
through calculation of relevant indexes 
• Determine the G:F actin ratio of knockout cells to reveal any actin 
remodelling deficits 
• Rescue of any phenotypes observed through IGFN1 expression 
 
Production and purification of IGFN1.  
• Develop a protocol produce and purify the IGFN1_V1 isoform in E.coli 
for use in future AFM experiments. 
• If the above fails, produce and purify smaller IGFN1 fragments 
 
 
Identification and validation of IGFN1 interaction partners.  
• Perform pull-downs of mouse muscle lysates against the proteins 
produced above for LC-MS/MS identification of potential interaction 
partners 
• Validate interactions identified through pull-downs, co-localisation, and 
functional analysis 
As the project progressed and more evidence came to light these objectives 
were further developed to allow new avenues of research to be followed, as is 
discussed in the following chapters. 
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CHAPTER 2: 
MATERIALS AND 
METHODS 
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Chapter 2: Materials and Methods 
2.1 Solutions and Reagents 
 
Name Formula Notes 
10X Running 
Buffer 250mM Tris, 1.9M Glycine, 35mM SDS Dilute in dH2O 
10X Transfer 
Buffer 250mM Tris, 1.9M Glycine 
Dilute 1:2:7 
Buffer:Methanol:dH2O 
50X TAE 
2M Tris base, 950mM Acetic Acid, 500 mM 
EDTA, pH 8 Dilute 1:49 in dH2O 
Blocking 
Buffer PBST + 4% Skimmed Milk Powder   
Coomassie 
Destain 40% Methanol, 10% Acetic Acid, 50% H2O   
Coomassie 
Stain 
1g/l Coomassie Brilliant Blue (VWR, R-250), 
in 30% Methanol, 10% Acetic Acid, 60% H2O   
Differentiation 
Media 
DMEM + 2% FBS + Penicillin Streptomycin to 
1X (Gibco, 15140122)   
Elution Buffer 
50mM NaH2PO4, 0.5M NaCl, 250mM 
Imidazole pH8   
Freezing 
Media 10% DMSO, 40% GM, 50% FBS   
Growth Media 
DMEM + 10% FBS + Penicillin Streptomycin 
to 1X (Gibco, 15140122)   
LB Agar LB as above + 7.5g Agar   
LB Broth 
In 1l H2O: 10g Tryptone, 10g NaCl, 5g Yeast 
Extract, pH 7   
Mowiol  
2.4g Mowiol 4-88, 6g glycerol, 6ml ddH20, 
12ml 0.2M Tris   
Native 
Binding 
Buffer 50mM NaH2PO4, 0.5M NaCl, pH8   
Native Wash 
Buffer 
50mM NaH2PO4, 0.5M NaCl, pH8, 20 mM 
imidazole  
PBS 
140mM NaCl, 2.7mM KCl, 9.6mM NaH2PO4, 
1.5mM KH2PO4, pH 7.3 
Tablets from Thermo 
Scientific BR0014 
PBST PBS as above with 0.1% Tween-20   
Resolving Gel 
Solution 
0.5Xml 30% Bis-Acrylamide, 3.75ml 1.5M 
TRIS NCl pH 8.8, 11-X ml dH2O, 150μl 10% 
SDS, 10μl TEMED, 120μl 10% APS 
X=Desired gel % 
TEMED and APS 
added last. 
Stacking Gel 
Solution 
1.32ml 30% Bis-Acrylamide, 2.52ml 0.5M 
TRIS NCl pH 6.8, 6 ml dH2O, 100μl 10% SDS, 
15μl TEMED, 80μl 10% APS 
TEMED and APS 
added last. 
Stripping 
Buffer 
10M Tween-20, 200mM Glycine, 3.5mM SDS, 
pH2   
Wash Buffer 
50mM NaH2PO4, 0.5M NaCl, 20mM Imidazole 
pH8   
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2.2 Antibodies 
2.2.1 Primary Antibodies 
 
Antibody Supplier 
Product/Project 
code 
WB 
Concentration  
IF 
Concentration 
Anti-actin  Cytoskeleton AAN01 1:300 N/a 
Anti-α-actinin 
(EA53) abcam ab9465 N/a 1:250 
Anti-His-HRP    BIORAD MCA1396P 1:300 N/a 
Anti-GAPDH Sigma G9295 1:50000 N/a 
Anti-IGFN1 
Kip1 
21st 
Biochemicals PR0671-2686 1:250 1:150 
Anti-IGFN1 
Kip1b 
21st 
Biochemicals 1159A 3413V11 1:250 N/a 
Anti-IGFN1 
Kip1c 
21st 
Biochemicals 1159B 3413V12 1:250 N/a 
Anti-COBL SIGMA HPA019167 1:300 1:150 
Anti-V5 SIGMA V8137 1:250 N/a 
 
2.2.2 Secondary Antibodies 
 
Antibody Supplier 
Product 
code 
WB 
Concentration  
IF 
Concentration 
Anti-rabbit IgG 
HRP Abbkine A21020 1:10000 N/a 
Anti-mouse 
IgG HRP Santa Cruz sc-2314 1:10000 N/a 
Anti-mouse 
IgG TRITC Abcam ab6718 N/a 1:100 
Anti-mouse 
IgG FITC Abcam ab6717 N/a 1:100 
Anti-rabbit IgG 
FITC Abcam ab6785 N/a 1:100 
AlexaFluor 488 
anti-rabbit Invitrogen R37116 N/a 1 drop per ml 
AlexaFluor 488 
anti-mouse Invitrogen R37120 N/a 1 drop per ml 
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2.3 Primers 
 
Primer Sequence Purpose 
COBL 
FWD 1 
CACCATGGACGCGCCGCGTGCACTGG Cloning of 
COBL 
COBL 
REV 1 
CACGAGCAAGGGAACCTTTCTTAGT 
COBL 
FWD 2 
CACCATGGACCCCACAGGAAGGAAGATGAA 
COBL 
REV 2 
GAGCAAGGGAACCTTTCTTAGTCT 
d1-d3 
FWD 1 
AACAGATCGAAGGTCGTCAGAGCATCAGGCAGCT
GGTG 
Cloning of 
IGFN1 
fragments 
into Im9 
vector 
d1-d3 
REV 1 
CTATCAACAGGAGTCCAAGCCCAGGCACTGGAGG
CATG 
d6-d11 
FWD 1 
AACAGATCGAAGGTCGTCACCTGGAGGTTCAGGA
TTGC 
d6-d11 
REV 1 
CTATCAACAGGAGTCCAAGCGAGGGTGGCTGTGC
TGAC 
COBL 
qPCR 
FWD 1 
GCCTGTCATTCAAAGGCCAC qPCR 
amplification 
of COBL 
COBL 
qPCR 
REV 1 
CTGCAGTCTTCCGGAGCTTT 
MYH7 
qPCR 
FWD 1 
ACCCTCAGGTGGCTCCGAGA qPCR 
amplification 
of MYH7 
MYH7 
qPCR 
REV 1 
TGCAGCCCCAAATGCAGCCA 
HPRT 
qPCR 
FWD 1 
GTTGGATACAGGCCAGACTTTGTT qPCR 
amplification 
of HPRT 
(housekeepi
ng control) HPRT 
qPCR 
REV 1 
GATTCAACTTGCGCTCATCTTAGG 
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COBL 
seq 1 
CACCATGGACGCGCCGCGTGCACTGG Sequencing 
of COBL 
constructs 
COBL 
seq 2 
GCTCCTGAGAAATCTGTACGACTGGT 
COBL 
seq 3 
AGACATGAAGAAGCGCAGAGCC 
COBL 
seq 4 
TGAGCTCTCCCTCAGATGCCA 
COBL 
seq 5 
TCATCTGTCCCCATCTCAGACT 
COBL 
seq 6 
CGGAAGCAGGACCATATCCCCA 
COBL 
seq 7 
CCAGGAAAGATGATGCAGCTCCC 
COBL 
seq 8 
ACAGATGGTCAAGACGCAGA 
COBL 
seq 9 
CATCCGCTCGGGCACAGGAG 
TG1F1 TTGGAGGCAAGCGTAAAACC Validation of 
COBL 
Knockout in 
C2C12 
myoblasts 
TG1R1 AACCACACTCTGCTTCTCCA 
TG2F1 TTTCTCCTTTTCAGCCACGC 
TG2R1 GTTCTCAGACAATCCACGGG 
TG3F1 ATCCTGCCATACCCAATCCT 
TG3R1 CTTCCCATGCCCACCTCTAG 
LoxP 
Fwd 
CAA CGT GCT GGT TGT TGT GC 
LoxP 
Rev 
CTT CGG GCA TGG CGG ACT TG 
Actn1 
Fwd 
GACCATTATGATTCCCAGCAGAC 
Actn1 
Rev 
CGGAAGTCCTCTTCGATGTTCTC 
COBL 
11-12 
Fwd 
AGAAAGCCACCATGCCTACC COBL Colony 
PCR  
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COBL 
11-12 
Rev 
TTCCATGACCTGCCTGTGTC 
 
 
2.4 Cell Culture 
2.4.1 Proliferation 
Cells were thawed and immediately transferred to flasks containing pre-
warmed growth media (GM) and incubated at 37°C, 5% CO2. Upon reaching 
70-80% confluency cells were split by washing twice with PBS and incubating 
with 0.05% trypsin (SIGMA, 59427C) at 37°C until cells detached. 
Trypsinisation was stopped by adding a few drops of FBS (Foetal bovine 
serum, South American, Invitrogen, 10270-106) and cells were transferred into 
new flasks containing fresh pre-warmed growth media. For applications 
requiring cell counting prior to reseeding, cells were counted using a 
haemocytometer and then seeded at an appropriate density. 
 
2.4.2 Freezing 
Cells were trypsinised as above then centrifuged at 1200rpm for 12 minutes 
to form a pellet. The pellet was then resuspended in freezing media (in 
general, 3ml of freezing media per T75 flask) and immediately transferred to 
cryotubes and placed at -80°C for short term storage, aliquots were transferred 
to liquid nitrogen for long term storage. 
 
2.4.3 Differentiation 
Cells were grown in GM until they reached 100% confluency whereupon the 
GM was exchanged for differentiation media (DM) (Blau et al., 1983). DM was 
changed daily, and cells observed under a light microscope until the desired 
state of differentiation was reached. 
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2.4.4 Transfections 
Transfections were performed using the GenJet transfection reagent 
(SignaGen, Cat # SL100488) following the provided protocol. For Cos7 and 
3T3 cells, DNA was diluted in DMEM to the appropriate concentration 
(specified in the SignaGen protocol), before transfection reagent diluted in 
DMEM was added to the DNA solution and incubated for 5 minutes to form a 
transfection complex. This complex was then added to cells. For C2C12 
transfections an enhanced protocol was used, whereby cells were trysinised, 
pelleted, and then resuspended in the transfection complex before being 
incubated at 37°C for 20 minutes. Cells were then transferred into an 
appropriate growth vessel containing pre-warmed GM. In both cases GM was 
replaced 16-24 hours post-transfection. 
 
2.4.5 Staining and Immunofluorescence  
Cells were fixed by washing with PBS followed by 1 minute incubation with ice 
cold acetone:methanol (1:1) and another PBS wash. For permeabilisation 
cells were incubated in 4% BSA PBS with 0.1% triton for 30 minutes. Blocking 
was performed using incubation in 4% BSA PBS for 1 hour and primary 
antibody incubations were performed using antibody at the appropriate 
concentration in 4% BSA PBS overnight at 4°C. Secondary antibody 
incubations were performed following 3 PBS washes using antibody at the 
appropriate concentration in 4% BSA PBS for a minimum of 2 hours. Following 
incubation 3 PBS washes were performed, followed by a final wash in dH2O 
(Renshaw, 2016). Cells grown on coverslips were mounted onto slides using 
MOWIOL with DAPI and left to set before imaging. Cells grown on 6-well plates 
(differentiating cells) had coverslips fixed to them using MOWIOL+DAPI.  
For phalloidin staining, fixed and permeabilised cells were washed twice in 
PBS before phalloidin (either: Phalloidin CruzFluor 488 Conjugate, Santa 
Cruz, sc-363791. Or: Rhodamine Phalloidin, Cytoskeleton, PHDR1) was 
added, and the cells incubated for 30 minutes in the dark (Capani et al., 2001). 
Cells were then washed, and slides/coverslips mounted as above. 
51 
 
2.4.6 Cell Stretching 
C2C12 cells were plated onto Bioflex Collagen-I plates (FlexCell) (Banes et 
al., 1985) at 3x105 cells per well in growth medium. After 24hrs plates were 
loaded onto the Flexcell 4000T baseplate. Stoppers were applied to prevent 
stretching of control cells. Experimental wells were subjected to a cyclic 
stretching programme of 10% elongation for 2hrs at 1.3Hz. Cells were 
immediately processed via fixation for imaging.  
 
2.4.7 Fluorescence Calculations 
Phalloidin stained cells were imaged using a Zeiss Upright 710 confocal 
microscope. All settings including gain and exposure time remained constant 
between samples. Images were analysed using ImageJ (NIH). Cells were 
outlined using the Threshold feature and corrected total cell fluorescence 
(CTCF) was calculated as: CTCF = Integrated Density - (Mean Value Grey of 
background x Area of cell). 
 
2.4.8 Scratch Wound Assay 
Cells were grown to 100% confluency in a 6-well plate. A 200µl pipette tip was 
used to scrape cells from the growth surface in a single vertical line (t=0) 
(Rodriguez et al., 2005). Cells were imaged at a number of timepoints using 
an Evos XL core microscope (Thermofisher). For determination of wound 
closure three measurements per well, per timepoint, were taken and averaged. 
An average percentage wound closure was then calculated compared to the 
wound at t=0. 
 
2.5 CRISPR/Cas9 targeting in C2C12 
2.5.1 Constructs 
Pre-designed plasmids were purchased from Santa Cruz. Cordon-bleu 
CRISPR/Cas9 KO Plasmid (m): sc-419728 and Cordon-bleu HDR Plasmid 
(m): sc-419728-HDR were obtained for CRISPR/Cas9 targeting and homology 
directed repair respectively. For more details regarding specific target sites 
see chapter 7.5. 
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2.5.2 Transfection and Clonal Selection 
Both sets of constructs were co-transfected into wildtype C2C12 cells, using 
the GenJet system, as described above. After 24hrs growth media was 
changed for growth media containing 4μg/ml puromycin for selection. 
Following 3-4 days of puromycin selection, protein extracts were taken (see 
below), or cells were seeded for clonal selection using a serial dilution starting 
with a stock of ~100 cells/well in a 96 well plate. Dilutions of this stock were 
made at 1:10, 1:50, 1:100, 1:200, and 1:500, and seeded across the plate. 
Cells were observed and wells in which single colonies formed were selected 
for expansion and analysis. 
 
2.6 Protein Extraction 
2.6.1 Extraction of Protein from Cultured Cells 
As per Abcam protocols, cells were washed twice with PBS on ice, followed 
by addition of minimal ice-cold RIPA buffer (Sigma, R0278) with protease 
inhibitors (Sigma, P8340). A cell scraper was used to remove cells from the 
growth surface, the resulting sample was then placed on a shaker at 4°C for 
30 minutes. The sample was then centrifuged (15 minutes, 12,000rpm, 4°C) 
and the resulting supernatant placed in a fresh tube and placed on ice for 
immediate use, or at -80°C for longer term storage. 
 
2.6.2 Extraction of Protein from Tissues 
Tissue was finely chopped and placed into ice-cold RIPA buffer with protease 
inhibitors (3ml RIPA per 1g muscle tissue) for 10 minutes on ice. Tissue was 
then snap frozen in liquid nitrogen and homogenised in a pestle and mortar. 
The resulting homogenised tissue was then added back into the original RIPA 
buffer and incubated at 4°C for 2 hours with shaking. Samples were then 
centrifuged (15 minutes, 13,000g, 4°C) and the resulting supernatant placed 
in a fresh tube and placed on ice for immediate use or at -80°C for longer term 
storage (Li et al., 2017). 
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2.7 SDS-PAGE Gel electrophoresis 
2.7.1 Sample Preparation and Bradford Assay 
Sample concentration was determined via Bradford assay with BradfordUltra 
reagent (Expedeon; BFU) on an MRX microplate reader and Revelation 
software (Dynex Technologies). In order to prevent detergents from interfering 
with readings a 10-fold ddH2O dilution was used and a standard curve 
generated, with BSA diluted in 10% RIPA buffer to known concentrations 
(Bradford, 1976).  
Typically, 20-50µg of protein was used per sample along with 4x NuPage LDS 
buffer (Invitrogen; NP0008) and 10x NuPage sample reducing agent 
(Invitrogen; NP004) ddH2O was used to make up the remaining volume 
(typically 10-15μl loaded per well). Samples were then heated to 90°C for 10 
minutes prior to loading on gels. For E. coli pellets, samples were briefly 
centrifuged at low speed to facilitate easier pipetting due to high levels of DNA 
in the samples. 
 
2.7.2 Gel Pouring and Running 
8-12% Bis-Acrylamide resolving gels were made up, depending on the size of 
the protein of interest, by pipetting resolving gel solution between two glass 
slides and leaving to set. Once set, stacking gel solution was added along with 
plastic combs to form wells, this was then left to set. Once set, combs were 
removed, and gels were placed into a BioRad tank along with running buffer 
supplemented with NuPage antioxidant (NP0005) and samples loaded. 
Typically, gels were run at 160v (dependent on size of protein of interest) until 
the dye front migrated to the bottom of the gel (Laemmli, 1970). 
 
2.7.3 Transfer and Western Blotting 
Wet transfers were performed to transfer from gels to nitrocellulose 
membrane. Gels were placed onto the transfer buffer-soaked membrane in 
between filter paper and fibre pads, also soaked in transfer buffer. This was 
placed in a cassette and loaded into a BioRad tank and filled with transfer 
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buffer. For 1 hour transfers the tank was placed on ice to prevent overheating 
and run at 100v, for overnight transfers 10v was used as per BioRad 
instructions. 
Following transfer, membranes were blocked in 4% skimmed milk powder in 
PBST (0.01% Tween-20) for 1 hour. Primary antibodies at an appropriate 
dilution were added in blocking buffer and incubated at room temperature for 
1 hour or overnight at 4°C. Membranes were then washed in PBST 3 times 
and HRP-conjugated secondary antibody (if applicable) diluted in blocking 
buffer was added and incubated for 1 hour at room temperature. Detection 
was then performed, following a further 3 PBST washes, using Immobilon 
Western Chemiluminescent HRP Substrate (Millipore, P09718) in a Chemi-
Imager (BioRad VersaDoc), or via an X-ray processor (Konica Minolta) 
(Towbin et al., 1979). Images were processed using ImageJ with densitometry 
used to compare band intensity between samples. Bands were outlined using 
the rectangle tool, with ctrl+1 to select the first lane, ctrl+2 to select subsequent 
lanes, and ctrl+3 to plot lanes. The straight-line tool was then used to define 
the bottom of the curve, and the wand tool used to measure the area as a 
proxy for band intensity. 
For reuse of a blot where the expected band from the second blot was of a 
similar size to the first, the blot was stripped by incubating in stripping buffer 
for 1-2 hours followed by 5 PBST washes of 5-10 minutes. Following this the 
incubations were carried out as above. 
All antibody incubations and washes were performed with shaking. 
 
2.7.4 Coomassie Staining 
For Coomassie staining, gels were incubated in Coomassie staining buffer for 
1-2 hours followed by several washes in distaining buffer until bands were 
clearly visible and distinguishable from the background (Meyer and Lamberts, 
1965). This usually consisted of 3-4 washes of 30 minutes each. An image of 
the resulting gel was then taken using the BIO RAD Gel Doc EZ Imager and 
Image Lab 5.2.1 software 
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2.8 Immunoprecipitation  
Cell extracts were precleared on mouse IgG-Agarose beads (Sigma, A0919) 
for 1 hour at 4°C on a rotating wheel, 25µl of bead slurry was used per 0.5mg 
of protein. This was then centrifuged at 3000g for 3 minutes at 4°C and the 
resulting supernatant harvested.  
A sample of the supernatant was aliquoted for western blot analysis as an 
“input” sample, the rest was divided between either mouse IgG-Agarose beads 
or Anti-V5 antibody-coupled agarose beads at a concentration of 0.5mg of 
protein per 25µl of slurry. This was then incubated overnight at 4°C on a 
rotating wheel. 
Samples were then centrifuged at 3000g for 3 minutes at 4°C and the resulting 
supernatant removed. Bead pellets were then washed with PBS and pelleted, 
this process was repeated a further three times. After the final wash 4x 
NuPage LDS buffer (Invitrogen; NP0008) and 10x NuPage sample reducing 
agent (Invitrogen; NP004) were added in appropriate volumes and the 
samples were placed on a heat block at 90°C for 10 minutes before loading 
into gels for SDS-PAGE western blot analysis. 
 
2.9 G:F Actin Ratio Assay 
The G-actin/F-actin In Vivo Assay Kit (Cytoskeleton, BK037) was used to 
isolate G-actin and F-actin fractions following the instructions provided. Briefly, 
LAS2 lysis and F-actin stabilization buffer were added to cells and a cell 
scraper used to detach cells. Cells were homogenised using a 200µl pipette 
tip and incubated at 37°C for 10 minutes. This sample was then centrifuged to 
pellet cell debris and the resulting supernatant was removed into an 
ultracentrifuge tube. The sample was spun at 100,000g for 1 hour at 37°C, 
leaving an F-actin pellet and a G-actin supernatant, which was removed into 
another tube for analysis. The F-actin pellet was the resuspended in F-actin 
depolymerisation buffer (using the same volume as the volume of the initial 
sample). G-actin and F-actin samples were then analysed via SDS-PAGE 
western blotting. 
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2.10 In Vivo Analysis 
2.10.1 In vivo electroporation 
One hour before the electroporation procedure, mice (C3H/HeJ, 5-8 weeks 
old) were injected with 10μl of 0.4U/μl hyaluronidase (in 0.9% saline). DNA 
was diluted to 800-1200 ng/μl in ddH2O and 10μl loaded into a sterile syringe. 
Mice were placed in an anesthetizing box with 4% isoflurane in O2 supplied by 
an approved gas anaesthetic machine until deeply anaesthetised. Mice were 
then removed to a heating pad (37°C) and continually anesthetized with a 
rodent face mask. Toe pinch reflex was used to test the anaesthetic depth.  
The extensor digitorum longus/ tibialis anterior (EDL/TA) muscles were 
chosen for these experiments as they are physically confined within the 
hindlimb and easy to access. 3mm wide electrodes were placed within the 
muscle and DNA injected between the electrode sites. Pulses were delivered 
using a NEPA21 machine (Nepagene, Japan). Three 50msec-long pulses at 
100V, followed by three more pulses of the opposite polarity were 
administered to each injection site at a rate of one pulse per second (Titomirov 
et al., 1991).  
Mice were sacrificed 7 days after the electroporation. Animals were sacrificed 
by a schedule one killing (cervical dislocation). All animal procedures have 
been carried with approval from the University of York Ethics committee and 
followed the UK Animals (Scientific Procedures) Act 1986 Amendment 
Regulations 2012, performed by under project licence PPL 70/6827 within an 
approved establishment (licence 5002510). EDL/TA muscles were dissected, 
fixed for 10 minutes in 4% PFA and snap frozen in liquid nitrogen-cooled 
isopentane and stored at -80C. 
 
2.10.2 Immunofluorescence of mouse muscle sections                                                
12micron longitudinal sections of muscle tissue were cut using a cryostat. 
Sections were permeabilised and blocked using 3% BSA in PBS + 0.3% Triton 
X100 for 1hr. Sections were then incubated overnight at 4°C with primary 
antibodies against COBL (Sigma, HPA019167 1:100) or ɑ-actinin (abcam, 
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ab9465 1:100). Slides were washed in PBST and incubated for 2hrs with 
appropriate combinations of compatible secondary (either Alexa Fluor 488 
goat anti-rabbit or goat anti-mouse, Invitrogen R37116/R37120) at RT in the 
dark before three washes with PBS for 5 minutes (Renshaw, 2016). Slides 
were mounted with Mowiol plus DAPI to stain nuclei and imaged using a Zeiss 
Upright 710 confocal microscope. 
 
 
2.11 Polymerase Chain Reaction (PCR) 
2.11.1 PCR 
PCR reactions were typically prepared as follows: 
• 15µl x2 PCR Master Mix (Thermo Scientific) 
• 1µl 10µM forward primer 
• 1µl 10µM reverse primer 
• 1-2µl DNA 
• Up to 30µl with PCR water (Thermo Scientific) 
Reactions were performed on a Geneamp 9700 Thermocycler (applied 
biosystems) with reaction conditions adjusted according to the primers used 
and the expected product size. 
 
2.11.2 Colony PCR 
Colony PCR reactions were prepared as above. However, instead of DNA 
samples being added, a pipette tip containing cells from an individual E. coli 
colony was placed in each well and mixed, allowing the amplification of DNA 
from that colony. The tip was then used to inoculate a fresh colony on a new 
LB Agar plate (with appropriate antibiotic) and labelled for subsequent 
identification and use. 
 
2.11.3 Agarose Gel Electrophoresis 
Products were mixed with 6x DNA loading dye (NEB) and loaded on an 
agarose gel (agarose percentage dependent on the size of the DNA being 
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analysed) containing 1:10,000 V/V dilution of SYBR Safe DNA Gel Stain 
(Invitrogen, 10328162). Electrophoresis was performed using a BioRad power 
pack with a voltage of 50-100v dependent on the size of the DNA. Bands were 
then visualised using the EZ Gel Doc Imager (BioRad). 
 
2.11.4 PCR Product Purification 
Where required, excess primers, nucleotides, and enzymes were removed 
from PCR products using a PCR purification kit (Qiagen, 28106) as per 
manufacturer’s instructions. 
 
2.11.5 Sequencing 
Sequencing of PCR products (and DNA plasmid constructs) was performed 
using the GATC Biotech Light Run sequencing service according to their 
instructions regarding sample and primer concentrations and volumes. 
 
2.11.6 RNA Isolation and cDNA Conversion 
Cells were incubated in an appropriate volume of TRIZOL (typically 300μl per 
well of a 6-well plate) at 50°C until homogenous. Chloroform (at an equal 
volume to that of TRIZOL) was then added, and the sample was shaken by 
hand before centrifugation (12,000g, 4°C, 15mins). The clear aqueous phase 
was then removed to a fresh tube and isopropanol added to precipitate RNA, 
followed by further centrifugation (12,000g, 4°C, 10mins) to pellet RNA. The 
RNA pellet was then washed twice with 70% ethanol, this was then dried and 
resuspended in DNAse/RNAse free water. RNA concentration and quality 
were then measured using the NanoDrop (Rio et al., 2010). 
For conversion of RNA to cDNA the following reaction was set up:  
4µl 5x ReadyScript Master Mix (Sigma, RDRT) 
Xµl RNA (to give 1µg) 
20-X-4µl RNAse/DNAse free water. 
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The reaction was then run in a thermocycler: 5mins 25°C, 30mins 40°C, 5mins 
80°C, 4°C hold. Samples were kept on ice for immediate use of frozen at -80°C 
for long term storage. 
 
2.11.7 qPCR 
qPCR reactions were prepared as follows: 
10µl 2X SYBR Green Fast qPCR Mix (Applied Biosciences, 4385612) 
1µl each of forward and reverse primer (7µM) 
1µl cDNA (or water for controls) 
8µl PCR water  
All reactions were performed in triplicate giving three technical replicates per 
biological sample. qPCR was performed on the QuantStudio 3 Real-Time PCR 
System (Applied Biosciences) using the standard fast protocol with melt curve 
analysis. Data was analysed using the DDCt method (Livak and Schmittgen, 
2001) measuring target gene expression against a Hprt control. 
 
2.12 Cloning 
2.12.1 Transformation 
Transformation of chemically competent E. coli was performed via heat-shock 
as follows. E. coli aliquots were thawed on ice prior to addition of plasmid DNA 
and incubation on ice for up to 30 minutes. Cells were then heat-shocked for 
30 seconds at 42˚C. S.O.C Medium (Thermofisher, 15544034) was then 
added, and the cells incubated at 37°C for 1 hour with shaking. Following 
incubation, cells were spread onto LB agar plates containing the relevant 
antibiotic (Froger and Hall, 2007). 
 
2.12.2 Minipreps 
Minipreps were performed using the QIAprep Spin Miniprep Kit (Qiagen, 
27104) according to the manufacturer’s instructions. 
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2.12.3 Gateway Cloning 
The pENTR Directional TOPO Cloning Kit (Invitrogen, 25-0434) was used to 
clone COBL into Gateway vectors for mammalian expression. COBL was 
amplified from a mouse skeletal muscle cDNA library using primers designed 
to leave blunt-end PCR products with a 5’ CACC to overlap with the GTGG 
overhang found on the pENTR TOPO Vector (see primer list and chapter 6.4 
for more details). The cloning reaction was set up as outlined in the product 
manual and the resulting vector was transformed into One Shot chemically 
competent E. coli (Invitrogen, C4040-10). Colony PCR was performed to 
validate the resulting colonies followed by minipreps to isolate the desired 
plasmids.  
An LR recombination reaction (recombination reaction between attL and attR 
sites) was used to shuttle the COBL from the entry vector into the desired 
Gateway destination vectors. Reactions were catalysed using LR Clonase II 
Enzyme Mix (Invitrogen, 11791-020) according to manufacturer’s instructions. 
The resulting constructs were then transformed into One Shot chemically 
competent E. coli and validated through colony PCR as above. 
 
2.12.4 NEBuilder High-Fidelity DNA Assembly Cloning 
IGFN1 fragments were cloned into the pQE2-Im9 vector using the NEBuilder 
High-Fidelity DNA Assembly Cloning system (New England Biolabs, E5520S). 
The vector was cut using a double restriction digest, and IGFN1 fragments 
were amplified using primers that left complementary overhangs to the digest 
sites (see primer list 2.3 and chapter 5.4 for more details). The PCR product 
and digested vector were then assembled using the Assembly Master Mix 
according to manufacturer’s instructions. The resulting vector was then 
transformed into One Sot chemically competent E. coli and validated through 
colony PCR as above.  
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2.13 Protein Expression and Purification 
2.13.1 Protein Expression 
Expression protocol optimisation is outlined in chapter 5. Typically, 15ml LB 
with the appropriate antibiotic was inoculated with a single colony of 
expression-competent E. coli and incubated in a shaker overnight at 37°C. 1ml 
of this culture was then used to inoculate 100ml warm LB with antibiotic and 
grown to and OD600 of 0.6, from here expression protocols differed as 
described in chapter 5. Samples were taken at various timepoints to validate 
protein expression, OD600 measurements were taken to allow for sample 
concentration equilibration prior to SDS-PAGE and Coomassie and/or western 
blot analysis. 
 
2.13.2 Protein Purification 
Protein was purified from bacterial cultures using the ProBond Purification 
System (Life Technologies, K850-01) under native conditions. Protein 
expression was performed, and cells harvested via centrifugation. The 
resulting pellets were resuspended in Native Binding Buffer with lysozyme 
(1mg/ml) and protease inhibitors (Sigma, P8849). Cells were then sonicated 
using six 10 second bursts with at least 10 seconds on ice between each burst. 
Lysates were the centrifuged at 10,000g for 15 minutes to remove cellular 
debris. Ni-NTA agarose beads (Invitrogen, R901-01) were equilibrated in 
Native Binding Buffer before adding the lysate and incubating for 1 hour with 
gentle agitation. Beads were then washed in Native Wash Buffer four times, 
and the sample collected in 1ml fractions using Native Elution Buffer.  
 
2.13.3 Dialysis 
Dialysis was performed using 14kDa BioDesignDialysis Tubing (Thermofisher, 
D011) which was soaked in ddH20 and clipped at one end. Protein sample 
was the pipetted into the tube at the open end and clipped, avoiding leaving 
any bubbles. Filled tubing was then incubated, in the desired buffer, on a 
magnetic stirrer at 4°C overnight. 
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2.14 Pull-downs 
IGFN1 fragments were expressed and purified as described above, with the 
protein left immobilised on the beads, and incubated with 1ml mouse skeletal 
muscle extract (3ml RIPA per 1g muscle tissue, described in 2.6.2) for 1 hour 
with gentle agitation. Beads were then washed in 8ml Native Wash Buffer four 
times and 12μl loaded directly onto a 10% Bis/Acrylamide gel. This was run 
until the dye front was ~1cm down the resolving gel. The lane was cut out and 
sent for LC-MS/MS analysis. 
 
 
2.15 Thermal Unfolding 
A Prometheus NT.48 Nano DSF with PR.ThermControl v2.1.2 software 
(NanoTemper) was used for thermal unfolding experiments. Experiments were 
performed with three technical replicates. Unfolding was performed from 15-
95°C with a 1.3°C/min gradient. 350nm/330nm ratio first derivatives were 
calculated to reveal unfolding temperatures (Cieplak and Sulkowska, 2005). 
 
 
2.16 Atomic Force Microscopy (AFM) 
2.16.1 Cantilever Calibration  
Tip C (predicted spring constant 0.01N/m) of an MLTC-Bio cantilever 
(BRUKER) was used for mechanical unfolding experiments. Touch calibration 
was performed with the EasyAlign probe holder using “peak force QNM in 
fluid” on a sapphire surface. 
 
2.16.2 Mechanical Unfolding 
Protein was loaded onto a Ni-NTA coated coverslip (attached to a slide via 
double-sided tape) before the addition of buffer (25mM Tris-HCl, 150mM NaCl, 
pH 7.4) to give a final protein concentration of 100μg/ml in a total of 150μl. 
This was incubated at room temperature for 10 minutes before washing with 
300μl of buffer, and replacement of buffer on top of the coverslip held in place 
through surface tension. The coverslip was then placed into the AFM and 
experiments carried out using the “contact in fluid-FASTForce” program. 
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Parameters such as pulling speed and contact time contact time were adjusted 
accordingly. 
 
 
2.17 Proteomic Analysis 
Mass spectroscopy was performed by Adam Dowle at the University of 
York Department of Biology Technology Facility. 
 
2.17.1 Digestion                                                                                                                          
In-gel tryptic digestion was performed after reduction with dithioerythritol and 
S-carbamidomethylation with iodoacetamide. Gel pieceswere washed two 
times with aqueous 50% (v:v) acetonitrile containing 25 mM ammonium 
bicarbonate, then once with acetonitrile and dried in a vacuum concentrator 
for 20 min.  Sequencing-grade, modified porcine trypsin (Promega) was 
dissolved in 50 mM acetic acid, then diluted 5-fold with 25 mM ammonium 
bicarbonate to give a final trypsin concentration of 0.02 g/L.  Gel pieces were 
rehydrated by adding 25 L of trypsin solution, and after 10 min enough 25 mM 
ammonium bicarbonate solution was added to cover the gel pieces.  Digests 
were incubated overnight at 37°C. Peptides were extracted by washing three 
times with aqueous 50% (v:v) acetonitrile containing 0.1% (v:v) trifluoroacetic 
acid, before drying in a vacuum concentrator and reconstituting in 50 L of 
aqueous 0.1% (v:v) trifluoroacetic acid.   
 
2.17.2 LC-MS/MS  
Samples were loaded onto an UltiMate 3000 RSLCnano HPLC system 
(Thermo) equipped with a PepMap 100 Å C18, 5 µm trap column (300 µm x  5 
mm Thermo) and a PepMap, 2 µm, 100 Å, C18 EasyNano nanocapillary 
column (75 m x 500 mm, Thermo). The trap wash solvent was aqueous 0.05% 
(v:v) trifluoroacetic acid and the trapping flow rate was 15 µL/min. The trap 
was washed for 3 min before switching flow to the capillary column.  
Separation used gradient elution of two solvents: solvent A, aqueous 1% (v:v) 
formic acid; solvent B, aqueous 80% (v:v) acetonitrile containing 1% (v:v) 
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formic acid. The flow rate for the capillary column was 300 nL/min and the 
column temperature was 30°C. The linear multi-step gradient profile was: 3-
10% B over 7 mins, 10-35% B over 30 mins, 35-99% B over 5 mins and then 
proceeded to wash with 99% solvent B for 4 min. The column was returned to 
initial conditions and re-equilibrated for 15 min before subsequent injections.  
The nanoLC system was interfaced with an Orbitrap Fusion hybrid mass 
spectrometer (Thermo) with an EasyNano ionisation source (Thermo). 
Positive ESI-MS and MS2 spectra were acquired using Xcalibur software 
(version 4.0, Thermo). Instrument source settings were: ion spray voltage, 
1,900 V; sweep gas, 0 Arb; ion transfer tube temperature; 275°C. MS1 spectra 
were acquired in the Orbitrap with: 120,000 resolution, scan range: m/z 375-
1,500; AGC target, 4e5; max fill time, 100 ms. Data dependant acquisition was 
performed in top speed mode using a fixed 1 s cycle, selecting the most 
intense precursors with charge states >1.  Easy-IC was used for internal 
calibration. Dynamic exclusion was performed for 50 s post precursor selection 
and a minimum threshold for fragmentation was set at 5e3. MS2 spectra were 
acquired in the linear ion trap with: scan rate, turbo; quadrupole isolation, 1.6 
m/z; activation type, HCD; activation energy: 32%; AGC target, 5e3; first mass, 
110 m/z; max fill time, 100 ms.  Acquisitions were arranged by Xcalibur to inject 
ions for all available parallelizable time. 
Peak lists were converted from .raw to .mgf format using MSConvert 
(ProteoWizard 3.0.9974) before submitting to a locally-running copy of the 
Mascot program using Mascot Daemon (version 2.5.1, Matrix Science).  Data 
were searched against the mouse and E. coli subsets of the UniProt database 
(39,956 sequences - 13 Oct 2017) with the following criteria specified: 
Enzyme, trypsin; Max missed cleavages, 2; Fixed modifications, 
Carbamidomethyl (C); Variable modifications, Oxidation (M), Deamidated 
(NQ), Gln->pyro-Glu (N-term Q), Glu->pyro-Glu (N-term E), Acetyl (Protein N-
term) Peptide tolerance, 3 ppm (# 13C = 1); MS/MS tolerance, 0.5 Da; 
Instrument, ESI-TRAP.  Mascot results in .dat format were imported into 
Scaffold (version Scaffold_4.8.4, Proteome Software Inc.) and a second 
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database search was performed using the X!Tandem engine with the same 
criteria specified. Search results were combined in Scaffold and peptide 
identifications were accepted if they could be established at greater than 
86.0% probability to achieve an FDR less than 1.0% by the Scaffold Local FDR 
algorithm. Protein identifications were filtered to require a minimum of two 
unique identified peptides.  Protein probabilities were assigned by the Protein 
Prophet algorithm (12). Proteins that contained similar peptides and could not 
be differentiated based on MS/MS analysis alone were grouped to satisfy the 
principles of parsimony. Proteins sharing significant peptide evidence were 
grouped into clusters.  
Complete mass spectrometry data sets are available to download from 
MassIVE (MSV000083637, 
https://massive.ucsd.edu/ProteoSAFe/user/login.jsp?url=https%3A%2F%2F
massive.ucsd.edu%2FProteoSAFe%2Fdataset.jsp%3Ftask%3D89d53176c6
c0446285d7365ea1027b1a) and ProteomeXchange (PXD013278, 
http://proteomecentral.proteomexchange.org/cgi/GetDataset?ID=PXD01327
8).  
 
2.17.3 Statistical Rationale                                                                        
Immunoprecipitations from three samples were analysed with three biological 
replicates. Samples comprised two regions of IGFN1 and were contrasted with 
LacZ, which was used as a negative control for non-specific binding.  LC-
MS/MS sample acquisition was randomised within biological replicate batches 
– i.e. all samples from biological replicate batch 1 were run before batch 2 but 
the order of IGFN1(d1-d3), IGFN11(d6-d11) and LacZ within each batch was 
changed each time. Samples were compared qualitatively using the following 
criteria. Acceptance of sample group protein identifications as significant to the 
pull-down required protein identification probability of greater than 95% in at 
least two of three biological replicates.  Classification of protein absence from 
the pull-down required protein identification probability of less than 95% in all 
three biological replicates. 
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2.18 Statistical analysis 
Statistical analysis of data was performed using SPSS (IBM). Data were tested 
for normality using the Shapiro-Wilk test. Unpaired two-tailed Student’s t-tests 
were used for single comparisons and ANOVA for multiple comparisons with 
the Tukey HSD multiple comparison test for post-hoc identification of 
significantly different means. For co-localisation analysis, Pearson’s 
correlation coefficient was calculated using Volocity software (Quorum 
Technologies), with the Costes method (Costes et al., 2004) used to set 
thresholds. 
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Chapter 3: Characterisation of a Fusion Defect in the 
IGFN1 Knockout C1C12-derived Cell Line 
3.1 Introduction 
This chapter describes the characterisation of actin remodelling and fusion 
defects in an IGFN1 knockout myoblast cell line, originally produced by Li et 
al (Li et al., 2017). 
Up to this point the functional role of IGFN1 in skeletal muscle has remained 
elusive. Interactions with KY and FLNC as well as with actin have been 
revealed and imply a role for IGFN1 at the z-disc (Baker et al., 2010). 
Knockdown of IGFN1 in C2C12 cells has previously been shown to result in 
decreased myoblast fusion as well as aberrant cell morphologies. However, 
these defects were never successfully rescued (Li et al., 2017). The domain 
composition of IGFN1 suggests a role in maintaining sarcomeric integrity 
under mechanical tension due to similarity with other proteins that perform this 
role (Otey et al., 2009), but until recently the tools to investigate the role of 
IGFN1 in any of these processes were not available. 
The development of IGFN1 knockout myoblast cell lines using CRISPR/Cas9 
technology, targeting exon 13 of IGFN1, provided a valuable tool to further 
evaluate the role of IGFN1 in skeletal muscle. Initially, to examine the role 
IGFN1 plays in cells undergoing mechanical tension, myoblasts were 
stretched in a cyclical manner, and morphological changes were to be 
measured. Instead of morphological changes, this led to the identification of 
an actin remodelling defect in knockout cells, and when differentiated these 
cells displayed similar fusion and morphology defects to those seen previously 
in IGFN1 knockdown cells. The role for IGFN1 in myoblast fusion was then 
further examined using several co-culture experiments and antibody staining 
of cells throughout differentiation. 
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3.2 Western Blot Confirmation of IGFN1 Knockout 
The IGFN1 knockout cell line KO19 has previously been validated via qPCR, 
demonstrating significant reductions in IGFN1 expression (Li et al., 2017). To 
validate this knockout at protein level, SDS-PAGE western blots were 
performed, using antibodies raised against the C-terminus of IGFN1 (fig. 
3.1A). Western blots revealed a complex band pattern (fig. 3.1B), as has been 
seen previously (Baker et al., 2010), rendering interpretation difficult. 
However, a band matching the molecular weight of IGFN1_V1 was observed 
to be consistently absent in samples from the knockout cell line, for all 
antibodies used. This band was always present in both skeletal muscle 
extracts, and wildtype C2C12 cells, for each antibody used. This confirms that 
the knockout of at least the IGFN1_V1 isoform was successful. 
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Figure 3.1. IGFN1_V1 is not present in IGFN1 knockout cells. A) Representation 
of full-length IGFN1 and the region to which the given polyclonal antibodies bind 
highlighted in red boxes (adapted from (Baker, et al. 2010)). B) Top: western blots 
against IGFN1 using the antibodies in A on samples from a wildtype skeletal muscle 
extract, wildtype cells (C2C12) and IGFN1 knockout cells (KO19), a complex pattern 
of bands is seen, with at least one band missing in the knockout cell line. The absence 
of a band at ~135kDa (red box) likely represents the loss of the IGFN1_V1 isoform in 
the KO19 cell line. Bottom: loading control against GAPDH showing equal loading of 
the two cell extracts. 
 
 
 
 
 
 
 
71 
 
3.3 IGFN1 Knockout Cells Display Altered Actin Remodelling 
It was initially hypothesised, due to the localisation of IGFN1 to the z-disc, and 
its similar domain composition to a number of sarcomeric structural proteins, 
that IGFN1 may play a role in maintaining sarcomeric structure during 
contraction and relaxation cycles. In order to investigate this, wildtype, and two 
IGFN1 knockout C2C12 cells lines (KO19 and KO33) were subjected to 
mechanical stretching using the FlexCell system (Materials and Methods 2.4.6 
for details). Cells were stained with phalloidin and imaged to allow for changes 
in cell size or morphology to be measured (fig. 3.2A). 
No changes in cell size or morphology were observed either between cell lines 
or between stretched and non-stretched cells (data not shown). However, it 
was observed that wildtype cells after stretching appeared to show more 
intense fluorescence from phalloidin staining, reflecting an increase in actin 
polymerisation. This affect was not observed in either knockout cell line. In 
order to quantify this effect, cells were imaged using a confocal microscope 
with identical settings between samples. ImageJ was then used to measure 
fluorescence of individual cells, normalised to background fluorescence. 
Quantification revealed an increase in fluorescence following stretching in 
wildtype cells, while knockout cells showed either a reduction in fluorescence 
(KO19) or no change (KO33) (fig. 3.2A and B). This result indicated that actin 
polymerisation in response to mechanical tension is diminished in knockout 
myoblasts. 
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Figure 3.2. The actin cytoskeleton of proliferating wildtype and IGFN1 knockout 
cells show different responses to mechanical tension. A) Representative 
confocal slices of phalloidin (polymerised actin) and DAPI (nuclear) stained 
proliferating wildtype (C2C12) and IGFN1 knockout cell lines (KO19 and KO33) 
without or without mechanical stretching (control or stretched, respectively) being 
applied (2hrs, 1.3Hz, 10%). B) Quantification of mean Corrected total cell 
fluorescence (CTCF) in each cell line in either stretched or non-stretched cells, n≥70. 
One-way ANOVA revealed there was a significant effect of cell type and condition on 
fluorescence at the p<0.01 level [F(5, 499)=11.77, p<0.01]. Post-hoc comparisons 
using the Tukey HSD test revealed a significant difference between the mean CTCF 
of KO19 control and stretched cells, and between C2C12 stretched cells and KO19 
stretched cells, KO33 control cells, and KO33 stretched cells (*p<0.01). Error bars 
represent standard error. C) Mean CTCF following stretching as a percentage of 
mean CTCF of control cells. 
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A similar experimental protocol was to be followed in differentiated myotubes 
in both wildtype and knockout cell lines, to give a more accurate reflection of 
actin dynamics in skeletal muscle. It was observed that differentiated knockout 
cells display a distinct morphology from wildtype cells, which is explored in 
detail below. While knockout cells appeared to display lower overall phalloidin 
fluorescence, this approach was not viable. It was not possible to distinguish 
between individual cells due to cells being in contact or overlapping, especially 
in wildtype samples, meaning any analysis of phalloidin intensity would be 
unreliable (fig. 3.3). 
 
 
 
Figure 3.3. Individual differentiated myoblasts stained with phalloidin cannot 
be distinguished. Representative widefield images of phalloidin-stained cells 
following 7 days of differentiation. Cells lines shown are wildtype (C2C12), IGFN1 
knockout (KO19) and KO19 stably expressing IGFN1_V1 (KO19+V1).  Scale bar=100 
microns. 
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Because actin polymerisation could not be accurately measured through 
phalloidin staining of differentiated cells, the ratio of globular actin (G-actin) 
and filamentous actin (F-actin) in C2C12, KO19 (IGFN1 deficient) and 
KO19+V1 (KO19 stably transfected with IGFN1_V1-tdTomato) cells was 
examined using SDS-PAGE western blotting. For these experiments, cells 
were maintained in differentiation medium (DM) for 7 days. After 7 days in DM, 
both G-actin and F-actin were detected in all cell lines following the protocol 
described in Materials and Methods 2.9 (fig. 3.4A). Quantifications from 
several independently generated blots (n=8) showed a significant G:F actin 
ratio increase in KO19 cells (Fig. 3.4B). A trend towards rescuing this defect 
was observed in the KO19+V1 cell line (fig. 3.4A and B). The three cell lines 
showed similar levels of expression of total actin relative to GAPDH (fig 3.4C), 
indicating that higher G:F actin ratios in the KO19 cells were not caused by 
actin expression levels but from lower polymerization activity.  It would thus 
appear that IGFN1_V1 contributes positively to the actin polymerization 
activity in C2C12 cells. 
Stretching of differentiated cells was attempted to measure the effect of 
mechanical tension on G:F actin ratio in differentiated cells. However, 
differentiated cells detached from the base of the plates when stretching was 
applied. Coating of the plates with collagen was attempted to increase 
adherence but this proved unsuccessful. 
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Figure 3.4. IGFN1 knockout cells have a higher G:F actin ratio than wildtype 
which can be rescued through IGFN1_V1 expression. A) SDS-PAGE western blot 
against actin from globular (G) or filamentous (F) actin fractions of 7 day differentiated 
wildtype (C2C12), IGFN1 knockout (KO19) and rescue (KO19+IGFN1_V1) cells.  B) 
G:F actin ratio of C2C12, KO19 and KO19+v1 (n=8). One-way ANOVA was 
performed, there was a significant effect of cell type at the p<0.05 level [F(2, 22) = 
4.665, p = 0.02]. Post-hoc comparisons using the Tukey HSD test revealed a 
significant difference between the mean G:F ratio of C2C12 and KO19 cells (p<0.05) 
and a close to significant difference between KO19 and KO19+v1 cells (p=0.056). 
Error bars represent standard error. C) Confirmation via western blotting that total 
actin in all cell types is similar (top), using GAPDH as a loading control (bottom). 
 
3.4 IGFN1 Knockout Cells Display a Fusion and Differentiation Defect 
A distinct morphology in IGFN1 knockout cells was observed in figure 3.3. To 
quantify these changes the fusion index, differentiation index, and myotube 
diameter were calculated in differentiated wildtype, IGFN1 knockout, and 
IGFN1_V1 rescued cells (fig 3.5). Cells were stained with an anti-α-actinin 
antibody in order to identify differentiating cells. 
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To compare the size of multinucleated structures the diameter of cells 
containing three or more nuclei was measured in images from C2C12 and 
KO19 cells (fig 3.5A). A value of three or more nuclei was chosen to distinguish 
between myotubes originated from multiple fusion events from cells 
undergoing division. KO19 multinucleated cells have a significantly larger 
mean diameter than C2C12 myotubes (fig 3.5D), indicating that disruption of 
Igfn1 exon 13 causes loss of cell size control in differentiating cells. The 
differentiation index was quantified by calculating the proportion of nuclei 
within an α-actinin positive structure to the total number of nuclei in a given 
field. This value was significantly lower in the KO19 cell line (fig 3.5B), 
indicating a delay in expression of the differentiation programme. This was 
also the case when measuring the fusion index, expressed as the percentage 
of α-actinin positive cells with three or more nuclei to the total number of cells 
expressing α-actinin. The data showed a significantly lower fusion index in 
KO19 cell line (fig 3.5C). Thus, KO19 shows reduced fusion, reduced 
differentiation and larger multinucleated structures. 
To test whether the above phenotypes are caused by disruption of Igfn1 exon 
13, and not the result of an off target genetic disruption, a construct coding for 
recombinant IGFN1_V1-tdTomato (pDEST47_IGFN1_V1_tdTomato) was 
transfected into the KO19 cell line. Transfected cells were selected by G418 
treatment and the mixed resulting population was evaluated for size of 
multinucleated structures, differentiation index and fusion index, as above. 
The overall morphology of these cells appeared more like that of the C2C12s 
(fig 3.5A) and quantifications demonstrated partial but significant rescue of 
fusion and differentiation defects in the KO19 transfected cells (fig 3.5B–D). 
Therefore IGFN1_V1 plays a critical role in myoblast fusion and differentiation 
in vitro. 
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Figure 3.5. The KO19 cell line displays fusion and differentiation defects 
partially rescued by expression of IGFN1_V1. A) Representative widefield 
fluorescence images of myoblasts differentiated for 10 days for C2C12, KO19 and 
KO19 transfected with IGFN1_V1 coding plasmid (KO19+V1). Cells were stained for 
α-actinin (red) and DAPI (blue). Two examples per cell line shown, as labelled. Scale 
bar represents 50µm. B) Differentiation index for the indicated cell lines, calculated 
as the proportion of nuclei within an α-actinin expressing cell to the total number of 
nuclei within the same field. Note that KO19 cells have a significantly lower 
differentiation index than wildtype and rescued cells. (n=35) C) Fusion index 
calculated as the percentage of α-actinin positive cells with three or more nuclei. 
KO19 cells have significantly lower fusion index than wildtype and rescued cells. 
(n=35) D) Mean diameter of α-actinin positive cells containing three or more nuclei, 
average diameter is significantly higher in knockout cells compared to both the 
wildtype and the rescue (n=40). (**) p<0.01, (*) p<0.05.(Li et al., 2017). Error bars 
show standard error. 
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3.5. IGFN1 Knockout Myoblasts Migrate and Proliferate Normally 
As well as myoblast fusion and differentiation, cell migration and proliferation 
rely heavily on actin remodelling. To assess whether changes to the actin 
cytoskeleton specifically affect myoblast fusion and differentiation, and not 
these other processes, a scratch wound assay was performed (fig 3.6). Cells 
were grown to 100% confluency before the application of a wound using 
pipette tip, cells were imaged immediately and at six hours post scratch wound 
(fig 3.6A). No significant changes in wound closure at six hours were observed 
(fig3.6B) indicating equivalent rates of proliferation and migration in both 
wildtype and IGFN1 knockout cell lines. Thus, IGFN1 does not play a role in 
cell migration or proliferation, and the observed changes to the actin 
cytoskeleton specifically affect myoblast fusion and differentiation. 
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Figure 3.6. Scratch wound assay suggesting migration and proliferation 
of IGFN1 knockout cells is unaffected. A) Images of wildtype cells (C2C12) and 
two IGFN1 knockout cell lines (KO19 and KO33) immediately following scratch wound 
application (left) and 6 hours post scratch wound application (right). Scale bar 
represents 500 microns. B) Mean wound closure from 5 wells per cell type, three 
measurements were taken for each well and an average calculated. One-way ANOVA 
revealed there was no significant effect of cell type on wound closure [F(2,9)=3.49, 
p=0.078]. Error bars show standard error. 
 
 
3.5 Co-culture of Wildtype and IGFN1 Knockout Cells Leads to Fusion 
To further examine the role of IGFN1 in myoblast fusion a co-culture 
experiment was designed, to determine whether IGFN1 was required in both 
cells for fusion to occur. Wildtype C2C12 cells were transfected with 
pDEST47-tdTomato, and IGFN1 knockout cells were transfected with pMax 
GFP. The transfected cells were seeded together in equal numbers to 100% 
confluency before growth media was replaced with differentiation media for 3 
days (fig 3.7A). Multiple cells were observed to express both pDEST47-
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tdTomato and pMax-GFP, demonstrating fusion between wildtype and IGFN1 
knockout cells. Additionally, these cells appeared to have morphologies 
comparable to those of wildtype myotubes. Therefore, IGFN1 is only required 
on one of two fusing myoblasts for fusion to occur, and the morphology 
observed in IGFN1 knockout cells following fusion can be rescued by the 
fusion of a wildtype cell. 
 
 
Figure 3.7. Co-culture of Wildtype and IGFN1 Knockout Cells Leads to Fusion. 
A) Schematic of experimental design for co-culture experiments. It should be noted 
that transfections were not 100% efficient, indicated by cells in grey, meaning that it 
is possible that there was a much higher incidence of fusion between cell types than 
it appears. B) Widefield images of wildtype (C2C12) cells transfected with pDEST47-
tdTomato and knockout cells (KO19) transfected with pMax-GFP, grown in a 1:1 co-
culture and differentiated for 3 days. Arrowheads indicate myotubes expressing both 
Td-tomato and GFP. Scale bar represents 75 microns. 
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3.6 IGFN1_V1 is Not Sufficient to Induce Fusion Between 3T3 Cells 
The recent identification of myomaker and myomerger as “fusogens” are the 
first examples of muscle-specific proteins able to induce fusion between non-
muscle cells (Millay et al., 2016; Millay et al., 2013; Zhang et al., 2017). Due 
to IGFN1 being implicated in myoblast fusion it was important to determine 
whether it could elicit similar activity as the fusogens. To this end, a similar 
experimental model was used as was used for myomaker and myomerger. 
Initially, 3T3 cells were transfected with either pDEST47-tdTomato or 
pDEST47-IGFN1_V1-tdTomato, before being grown in differentiation media 
for 3 days. Cells were fixed and imaged after 3 days (fig. 3.8A). No examples 
of fusion between 3T3 cells were observed in either condition. Thus, 
IGFN1_V1 is not sufficient to drive fusion between two non-muscle cells. Next 
it was determined whether IGFN1_V1 was sufficient to induce fusion between 
a non-muscle cell and a myoblast. C2C12 cells were transfected with pMax-
GFP and 3T3 cells were transfected with pDEST47-IGFN1_V1-tdTomato. The 
transfected cells were seeded together in equal numbers, before growth media 
was replaced with differentiation media for 3 days. Again, no fusion was 
observed between transfected C2C12 and 3T3 cells (fig. 3.8B). These results 
show that IGFN1_V1 is not sufficient to induce fusion in a non-muscle cell 
type. 
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Figure 3.8. IGFN1_V1 expression is not sufficient to induce fusion of non-
muscle fibroblasts. A) Representative widefield images of 3T3 cells transfected with 
either tdTomato or IGFN1_V1 tdTomato and induced to differentiate for 3 days, no 
examples of fusion were observed. B) Representative images of 3T3 cells transfected 
with either tdTomato or IGFN1_V1 tdTomato, grown in co-culture with C2C12 cells 
transfected with GFP and induced to differentiate for 3 days. No examples of fusion 
involving 3T3 cells were observed. For both A and B a minimum of 3 wells of a 6-well 
plate were observed for each condition. Scale bars represent 50μm. 
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3.7 IGFN1 Localisation Throughout Differentiation 
The localisation of IGFN1 was tracked, via antibody staining, at numerous time 
points throughout differentiation. Staining at days 1,2,3, and 10 following the 
change of growth media to differentiation media was performed (fig. 3.9). 
During days 1-3 cells that appear to be undergoing fusion show higher IGFN1 
expression. At day 10 IGFN1 was shown to clearly localise along the edge of 
cells fusing to a myotube. It should be noted that observation of this was 
relatively rare, possibly due to the transient, temporal nature of myoblast 
fusion. 
 
 
Figure 3.9. IGFN1 expression localisation throughout differentiation. Widefield 
images of wildtype C2C12 myotubes (1,2,3 and 10 days differentiated) stained with 
phalloidin against actin (green) and Kip1 against IGFN1 (red). Arrowheads indicate 
cells with high IGFN1 expression which appear to be undergoing fusion. Exposure 
was adjusted so that myotubes were more clearly visible. Scale bar represents 50 
microns. 
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3.9 Conclusions 
The CRISPR/Cas9-generated, C2C12-derived, IGFN1 knockout cell line used 
in this chapter had previously been validated via qPCR (Li et al., 2017). 
However, no protein-level analysis had been performed. Western blots 
demonstrated a complex banding pattern from IGFN1 antibodies, as was 
expected based on previous work using these antibodies (Baker et al., 2010). 
The IGFN1 locus is complex and produces multiple isoforms from multiple 
promoter regions. As well as this, there is evidence that IGFN1 fragments tend 
to show different than expected molecular weights when analysed by SDS-
PAGE and western blot detection, possibly due to dimerization or aggregation. 
However, the consistent absence of at least one IGFN1 isoform (most likely 
IGFN1_V1, based on its molecular weight) was demonstrated. 
Initial investigation of the effects of IGFN1 knockout in C2C12 cells was to 
examine the morphological changes in these cells compared to wild-type cells, 
especially under mechanical tension. While no morphological changes were 
observed, because phalloidin staining was used for the imaging of cells, 
changes in the actin cytoskeleton could be observed. Mechanical tension 
resulted in increased fluorescence of phalloidin staining in wild-type cells. This 
effect was not observed in knockout cells, with cells showing either reduced 
phalloidin staining or no change in response to mechanical tension. This 
suggested that IGFN1 may play a role in actin polymerisation in response to 
mechanical load. This warranted further investigation due to the previously 
observed interaction between IGFN1 and actin, and the localisation of IGFN1 
to the z-disc, a sarcomeric region which undergoes a large amount of 
mechanical load (Baker et al., 2010). 
Similar experiments could not be performed in differentiated cells, due to cells 
detaching from the growth surface under tension. However, a western blot 
assay could be used which demonstrated lower levels of actin polymerisation, 
even in the absence of mechanical tension, in IGFN1 knockout cells. 
Examination of these differentiated cells revealed significant fusion and 
differentiation defects, as well as significant morphological changes in IGFN1 
knockout cells. These phenotypes were then at least partially rescued through 
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expression of IGFN1_V1, the isoform confirmed to be knocked out. These 
results imply that IGFN1 is involved in both the remodelling of the actin 
cytoskeleton, and in myoblast fusion and differentiation, two processes that 
significantly interact with one another (Rochlin et al., 2010). Therefore, it is 
possible that IGFN1 influences myoblast fusion and differentiation through the 
remodelling of the actin cytoskeleton. 
The fact that a wildtype cell and an IGFN1 knockout cell are able to fuse 
demonstrates that only one of the fusing cells requires IGFN1. This implies 
that IGFN1 does not act symmetrically and is either required in the fusing 
myoblast, or in the myotube during fusion, but not in both. IGFN1 antibody 
staining of myoblasts undergoing differentiation demonstrated increased 
expression of IGFN1 localised to the site of contact between the on the fusing 
myoblast and the myotube, within the fusing myoblast. It is therefore likely that 
any requirement for IGFN1 in myoblast fusion is performed in this cell rather 
than in the myotube. Similar asymmetry has been observed with myomerger 
with efficient fusion requiring myomaker expression in both fusing cells but 
myomerger in only one fusing cell (Quinn et al., 2017). When fusion did occur 
between wildtype and knockout cells the observed myotubes appeared 
morphologically normal, demonstrating the rescue of the IGFN1 knockout 
phenotype via IGFN1 expression from the wildtype nucleus. 
It could not be shown that IGFN1 displays any fusogenic activity. IGFN1 was 
unable to induce fusion between two non-muscle cells or between a muscle 
and non-muscle cell. Such activity has been observed with the membrane-
bound fusogens myomaker and myomerger, which play a direct role in 
myoblast fusion. Therefore, the role of IGFN1 in myoblast fusion is likely to be 
indirect, possibly through interaction with other effector proteins. The structure 
of IGFN1 supports this, it lacks any predicted catalytic domains, and contains 
globular domains often involved in protein-protein interactions. It is possible 
that IGFN1 regulates myoblast fusion, through changes to the actin 
cytoskeleton, via interactions with other proteins. 
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In summary, IGFN1 knockout myoblasts display altered actin remodelling 
dynamics, both in response to mechanical load, and during myoblast fusion 
and differentiation. As well as this, IGFN1 knockout myoblasts display a fusion 
and differentiation defect, and morphological changes which can be rescued 
through the expression of IGFN1_V1. While it appears that IGFN1 is required 
for normal myoblast fusion, IGFN1 is not sufficient to drive fusion between non-
muscle cells or between a muscle cell and a non-muscle cell. Finally, it 
appears that IGFN1 is required in the fusing myoblast, rather than in the 
myotube during fusion. 
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CHAPTER 4: IGFN1 
AND ATROPHY 
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Chapter 4: IGFN1 and Atrophy 
4.1 Introduction 
The goal of the research presented in this chapter was to examine any role for 
IGFN1 in skeletal muscle atrophy using IGFN1 knockout and IGFN1 
overexpressing C2C12-derived myoblast cell lines. 
IGFN1 expression is associated with increases in atrophic signals, and 
denervation of a muscle fibre is a common model for muscle fibre atrophy in 
vivo (Pellegrino and Franzini, 1963). Mansilla et al (Mansilla et al., 2008) found 
that denervation-induced atrophy is accompanied by an increase in 
transcription of IGFN1. As well as this, IGFN1 expression is positively 
correlated with myostatin signalling. Evidence for this comes from gene 
expression analysis whereby myostatin signalling was downregulated in mice, 
using soluble activin type B receptors (ActRIIB) to sequester myostatin. As 
expected, muscle mass increased, this was also associated with changes in 
the expression of many genes. IGFN1 expression was found to be significantly 
reduced (Rahimov et al., 2011). The opposite is also true, when myostatin 
signalling is increased, via injection of adenoviral vectors in mice, muscle mass 
decreases and IGFN1 expression increases (Chen et al., 2014). This raises 
the possibility that IGFN1 is involved in atrophy, specifically as an effector of 
the myostatin pathway.  
The glucocorticoid dexamethasone is often used to induce atrophy in 
myotubes in vitro (Menconi et al., 2008; Qin et al., 2013; Raffaello et al., 2010; 
Xu et al., 2013). Dexamethasone results in the upregulation of myostatin 
expression, at least partially through interaction with GRE (glucocorticoid 
response elements) within the promoter of myostatin (Qin et al., 2013).  
Dexamethasone was used in this chapter to induce myostatin expression and, 
as a consequence, atrophy in differentiated cells. The atrophic response of 
wildtype, IGFN1 knockout, and IGFN1 overexpressing cells was analysed. 
Further, IGFN1 expression levels in response to dexamethasone treatment 
were measured by SDS-PAGE western blot analysis. 
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4.2 Dexamethasone Induces Atrophy in Differentiated Wildtype 
Myotubes but not in IGFN1 Knockout Cells 
A range of concentrations from 100nM to 100µM (Menconi et al., 2008; Xu et 
al., 2013) of dexamethasone have previously been reported to induce atrophy 
in differentiated myotubes. Because of this, a dose response experiment was 
performed to determine the concentration required to induce atrophy in 
myotubes, in both wildtype and IGFN1 knockout cells. Myotubes were 
differentiated for 7 days before dexamethasone was added to the media for 3 
days. Cells were imaged, and their diameters measured, both before the 
addition of dexamethasone, and after 3 days of dexamethasone treatment.  
In wildtype cells, as dexamethasone concentration increased, the hypertrophy 
observed between days 0 and 3 decreased. The highest concentration of 
dexamethasone (100µM) resulted in atrophy of wildtype C2C12-derived 
myotubes. This effect was not observed in the IGFN1 knockout myotubes, 
where myotube size remained relatively constant throughout the experiments 
for all dexamethasone concentrations (fig 4.1). However, this may have been 
confounded by the fusion and differentiation defects, and morphological 
differences between wildtype and knockout cells discussed in chapter 3.These 
differences made consistent, like-for-like measurements of the knockout cells 
difficult compared to the wildtype cells which had a regular morphology. 
Because of this, it was determined that the IGFN1 knockout cells were not a 
viable tool for investigating the role of IGFN1 in atrophy, and that 
overexpression of IGFN1 may prove a more insightful experiment. 
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Figure 4.1. Dexamethasone treatment induces atrophy in wildtype 
myotubes but not in IGFN1 knockout cells. A) Representative images of cells 
after 7 days of differentiation at D0 (before dexamethasone addition) and D3 
(following 3 days of 100µM dexamethasone treatment). Examples are shown for both 
wildtype (C2C12) and IGFN1 knockout cells (KO19). Scale bar represents 200 
microns. B) Quantification of percentage change in average myotube diameter after 
3 days treatment with varying concentrations of dexamethasone. Concentrations 
given in µM. Min of 50 myotubes measured for each condition.  
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4.3 Overexpression of IGFN1_V1 Does Not Result in Myotube Size 
Decreases 
To determine whether IGFN1 overexpression would lead to myotube size 
decreases, a cell line overexpressing IGFN1_V1 was generated. Wildtype 
C2C12 cells were transfected with pDEST47-IGFN1_V1-tdTomato, followed 
by en masse selection with puromycin. pDEST47-IGFN1_V1-tdTomato 
expression was confirmed through observation of red fluorescence. The 
resulting cell line was differentiated for 7 days alongside wildtype cells. After 7 
days the cells were fixed and stained using an antibody against α-actinin. The 
diameter of the resulting α-actinin positive cells was measured. It was found 
that there was a small, non-significant, decrease in diameter in the IGFN1_V1 
overexpressing cell line, suggesting IGFN1 is not sufficient to induce atrophy 
in myotubes (fig. 4.2). 
Due to the above, it was hypothesised that IGFN1 may only contribute to 
myotube atrophy when an upstream signal is present. Therefore, IGFN1 
overexpression may exacerbate the atrophy induced by dexamethasone 
treatment. To test this, wildtype and IGFN1 overexpressing cells were 
differentiated for 7 days, followed by 3 days of either 100µM dexamethasone 
treatment or control treatment, as in figure 4.1. Cells were imaged, and their 
diameters measured before and after treatment. As in figure 4.1, untreated 
myotubes underwent hypertrophy over the 3 days, this was observed in both 
cell types, suggesting that overexpression of IGFN1_v1 is not sufficient to 
stunt hypertrophy. On top of this, in the presence of dexamethasone, both cell 
types atrophied to a similar extent (fig.4.3). These data indicate that in vitro 
IGFN1 is not sufficient to induce atrophy, or stunt hypertrophy, nor does IGFN1 
overexpression exacerbate atrophy under pharmacological induction of 
atrophy. 
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Figure 4.2. IGFN1_V1 overexpression does not lead to a change in 
myotube diameter. A) Representative widefield images of wildtype (C2C12) and 
IGFN1_V1 overexpressing (C2C12+IGFN1_V1) myotubes after 7 days of 
differentiation. Cells stained with anti-alpha actinin antibody (green) and DAPI (blue). 
Scale bar represents 100 microns B) Quantification of mean myotube diameter of 
wildtype and IGFN1_V1 overexpressing myotubes. A minimum of 60 myotubes were 
measured per cell line. No significant difference in myotube diameter was detected 
(P=0.058). 
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Figure 4.3. C2C12 myotubes and C2C12 myotube overexpressing 
IGFN1_V1 display a similar atrophic response to dexamethasone 
treatment. A) representative images of myotubes differentiated for 7 days before 
dexamethasone treatment (D0), following control treatment of differentiation media 
for 3 days (D3), and following dexamethasone treatment for 3 days (D3 + 
Dexamethasone). Scale bar represents 200 microns B) Average myotube diameter 
on D3 as a percentage of D0. Minimum of 40 myotubes measured per condition.  
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4.4 Dexamethasone Treatment Does Not Induce IGFN1 Expression 
Because of the association of IGFN1 transcript expression with atrophy, and 
myostatin signalling in particular (Chen et al., 2014; Rahimov et al., 2011), it 
was expected that dexamethasone treatment would lead to an increase in 
IGFN1 protein expression levels. To test this, wildtype C2C12 cells were 
differentiated for 7 days followed by treatment with 100µM dexamethasone. 
Protein lysates were then taken at 0, 2, 8, and 24 hours post-treatment. SDS-
PAGE western blots against IGFN1 were then performed (fig. 4.4).  
The band pattern was complex, reflecting that observed in figure 3.1 chapter 
3. No significant intensity increases in any band were observed throughout the 
time course. Overexposure of the blot did reveal one lower molecular weight 
band at 24 hours that was not observed in any other lane, which may reflect 
an increase in expression of at least one IGFN1 isoform. However, this result 
was inconsistent between replicates and is likely only an artefact caused by 
overexposure of the blot. Thus, this level of dexamethasone treatment does 
not increase the expression of IGFN1 at the protein level in differentiated 
myotubes. 
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Figure 4.4. No change in IGFN1 expression is detected at the protein level 
in response to dexamethasone treatment. Top, representative western blot 
against IGFN1 (Kip1b antibody) with samples of 7 day differentiated cells following 0, 
2, 8, and 24 hours of treatment with 100µM dexamethasone. Two exposures (3 and 
10 minutes) are shown. Red arrow indicates band at ~35kDa which may be 
upregulated. Bottom, anti-GAPDH western blot demonstrating equal loading of the 
samples. 
 
 
4.5 Conclusions 
The observation that dexamethasone induces atrophy in wildtype C2C12 
myotubes was expected, and in line with the previously published data. 
However, the concentration of dexamethasone required to induce atrophy was 
surprising. Concentrations as low as 100nM (Xu et al., 2013) have been shown 
to induce atrophy. Here however, 100µM of dexamethasone was required, 
96 
 
with lower concentrations merely stunting the atrophy observed in the control. 
This concentration is supraphysiological, assuming the concentration of 
dexamethasone in the blood and muscle tissue is equal (Faggioni et al., 2000), 
but has been used in previous studies (Raffaello et al., 2010). A potential 
explanation for these discrepancies is the presence of albumin within the 
serum added to growth media, which is known to bind to steroids (Baulieu, 
1990). This makes it difficult to establish the actual amount of free 
dexamethasone present in the growth media and may lead to significant 
fluctuation between experiments. 
There was no apparent effect of dexamethasone on IGFN1 knockout cells. 
While this may suggest that IGFN1 plays a role in dexamethasone-induced 
(and therefore myostatin-induced) atrophy, there are several confounding 
factors which may contribute to this result. Firstly, the morphological 
differences between the wildtype and IGFN1 knockout cells when 
differentiated, outlined in chapter 3, mean that it is much more difficult to define 
and measure a diameter in these cells compared to the wildtype. Furthermore, 
because of the fusion and differentiation defect in the IGFN1 knockout cells 
(chapter 3.4) (Li et al., 2017), it is likely that they are at a different stage of 
differentiation than the wildtype cells.  
Dexamethasone has been demonstrated to have different effects on 
proliferating and differentiated C2C12 cells. Dexamethasone treatment of 
myoblasts has been shown to increase proliferation (Desler et al., 1996; 
Guerriero and Florini, 1980). As well as this, dexamethasone treatment at the 
single cell stage of myoblast differentiation results in larger myotubes (Han et 
al., 2017). Therefore, disruption of differentiation in IGFN1 knockout myoblasts 
may explain the absence of atrophy when treated with dexamethasone. 
Due to the upregulation of IGFN1 under atrophic conditions it was expected 
that IGFN1 would influence myotube size if overexpressed. Myotubes derived 
from a cell line overexpressing IGFN1_V1 had a slightly smaller diameter than 
wildtype myotubes. However, this decrease was found to be not statistically 
significant. Atrophy was induced through dexamethasone treatment in both 
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cell lines to determine if overexpression of IGFN1_V1 would exacerbate the 
size decrease observed. Again, no significant difference was found between 
the change in size of the wildtype and IGFN1 overexpressing myotubes. Taken 
together, it can be concluded that IGFN1_V1 does not play a direct role in 
atrophy in myotubes. 
From the previously published data it is not possible to determine which 
isoform of IGFN1 is upregulated in response to denervation or myostatin 
overexpression (Chen et al., 2014; Mansilla et al., 2008), or downregulated 
when myostatin signalling is inhibited (Rahimov et al., 2011). It is therefore 
possible that another IGFN1 isoform, not IGFN1_V1 as tested here, is directly 
involved in inducing atrophy.  
Western blots against IGFN1 were used to determine which, if any, of the 
isoforms of IGFN1 were upregulated. Only one of the isoforms detected by the 
antibody used were upregulated in response to dexamethasone, with a band 
observed at around 35kDa. However, this was not consistent in all replicates 
and required overexposure of the blot, casting doubt on its reliability. This 
result suggests that dexamethasone treatment is not sufficient to induce 
IGFN1 expression. This may be because dexamethasone acts to induce 
atrophy indirectly and may contribute to other cellular processes, unlike the 
direct inhibition or upregulation of myostatin signalling used in the literature 
previously. It should also be noted that the previous data was produced in vivo, 
compared to the cellular model used here. 
Taken together these data show that IGFN1_V1 is not directly involved in 
atrophy induced by dexamethasone treatment, and that IGFN1 is not 
overexpressed at a protein level in this model of atrophy. These data support 
recently published data in vivo demonstrating that overexpression of IGFN1 
through electroporation does not change muscle fibre cross-sectional area. 
Nor does mutagenesis of IGFN1, through electroporation of a CRISPR/Cas9 
construct targeting IGFN1, lead to a change in fibre size, although the 
effectiveness of this mutagenesis was not confirmed (Li et al., 2017). Indeed, 
it is possible that IGFN1 expression is increased during atrophy in order to 
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protect the integrity of critical sarcomeric components, especially those at the 
z-disc.  
More work is required to determine the purpose of IGFN1 upregulation in 
atrophy. This work should focus on the use of in vivo models and the direct 
inhibition or upregulation of the myostatin signalling pathway, rather than the 
use of dexamethasone in cellular models, which has proved an unreliable 
model here.   
 
 
 
 
 
 
 
 
99 
 
CHAPTER 5: 
EXPRESSION AND 
PURIFICATION OF 
SOLUBLE IGFN1 
FRAGMENTS 
 
 
 
 
 
 
 
100 
 
Chapter 5: Expression and Purification of Soluble 
IGFN1 Fragments 
5.1 Introduction 
This chapter concerns the development of a protocol for the production and 
purification of IGFN1 fragments for use in biochemical and biophysical 
analysis. 
Recombinant IGFN1 is required for pull-down experiments to identify 
interacting partners (outlined in Chapter 6). Further, with recombinant IGFN1 
the physical properties of the protein’s domains could be better understood, 
shedding light on their roles. Skeletal muscle proteins with similar domain 
compositions to IGFN1 have been shown, through atomic force microscopy 
(AFM), to act as molecular springs with domains unfolding and refolding to 
respond to the tension placed on the sarcomere throughout contraction and 
relaxation (Rief et al., 1997; Schoenauer et al., 2005). It is possible that IGFN1 
performs a similar role. The production of recombinant protein is required to 
allow for these AFM experiments to take place. 
Previous attempts to produce IGFN1 in E. coli have been unsuccessful (J 
Baker, personal comm). These attempts have focused on the large isoforms 
of IGFN1 including the full-length IGFN1 protein and IGFN_V1. These proteins 
were largely insoluble, likely due to their size, and could not be expressed and 
purified in sufficient quantities, with precipitates forming following elution from 
Ni-NTA agarose beads. In this chapter smaller IGFN1 fragments are used to 
ascertain whether these would produce higher yields. Additionally, a number 
of different expression protocols are trialled to optimise IGFN1 expression and 
solubility. Finally, an IGFN1 fragment is cloned into the pQE2-Im9 vector, 
resulting in the production of a soluble, folded protein. 
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5.2 Full-length IGFN1 Isoforms are Largely Insoluble When Expressed 
in E. coli 
Previous attempts from our group to purify full-length IGFN1 proved 
unsuccessful, largely due to insolubility. There had however been some 
progress in producing and purifying IGFN1_V1 (see table 5.1 for domain 
composition), albeit at very low concentrations with high insolubility. These 
previous attempts had used an overnight expression at 37°C. Expression of 
insoluble proteins at lower temperatures can increase their solubility, through 
slowing of transcription and translation rates, and decreasing the strength of 
hydrophobic interactions (Baneyx and Mujacic, 2004). Therefore, a 20°C 
overnight incubation was trialled.  
 
Table 5.1. Summary of purified recombinant IGFN1 peptides. Schematics show 
domain type and linker regions. Domain compositions are not to scale. 
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Glycerol cultures of BL21-AI™ E. coli containing the pET161-DEST-
IGFN1_V1 vector were plated on LB agar (+ampicillin) and a single colony 
inoculated into LB (+ampicillin) and grown to OD600=0.6 (t=0). At this point both 
IPTG (1mM) and L-arabinose (0.02%) were added to the media. Addition of L-
arabinose induces expression of T7 RNA polymerase from the BL21-AI™ 
genome under the control of the araBAD promoter. Addition of IPTG allows 
the expression of the His-tagged IGFN1_V1 from the pET plasmid. The 
cultures were then moved to 20°C and samples were taken at multiple 
timepoints (values for t given in hours). This was followed by purification using 
the ProBond Purification System (see Materials and Methods 2.13.2 for 
details). 
Figure 5.1A demonstrates robust expression of IGFN1_V1, which increases 
at each timepoint. However, upon separation of the soluble and insoluble 
fractions it was revealed as previously that most, if not all, of the IGFN_V1 
expressed was insoluble (fig 5.1B). Therefore, it was decided to attempt to 
purify smaller IGFN1 fragments which may prove more soluble in E. coli and 
lead to higher yields. These included domains 1-3 of IGFN1 (IGFN1_d1-d3) 
and domains 6-11 (IGFN1_d6-d11) which had been previously cloned into 
pET161-DEST. 
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Figure 5.1. IGFN1_V1 is insoluble when expressed in BL21-AI™ E. coli 
via the pET161-DEST vector. A) Top Coomassie and bottom anti-His western 
blot of E. coli lysates throughout induction of pET161-DEST-IGFN1_V1 expression in 
BL21-AI™ E. coli. At t=0 OD
600
=0.6, IPTG was added to media to a final concentration 
of 1mM, and L-arabinose to 0.2%. Samples were then taken at 1,2,3, and 4 hours 
(t=1/2/3/4) and following overnight incubation at 20°C. A non-induced control was also 
used demonstrating that IGFN1_V1 was not being expressed in the absence of 
induction by IPTG and L-arabinose. All lanes were loaded with the same 
concentration of cell lysate by normalising using OD600 readings. Red arrows indicate 
bands corresponding to the molecular weight of IGFN1_V1 (~135kDa) which increase 
in intensity throughout the experiment.  B) Top Coomassie and bottom anti-His 
western blot of total, soluble, and insoluble fractions of E. coli expressing pET161-
DEST-IGFN1_V1 overnight, as well as elution fractions following purification via the 
ProBond Purification System. Red arrows indicate bands corresponding to the 
molecular weight of IGFN1_V1 (~135kDa). IGFN1_V1 was not detectable in the 
soluble fraction. 
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5.3 Soluble IGFN1 Fragments can be Expressed and Purified in E. coli 
but form a Precipitate in the Absence of Imidazole 
To alleviate the insolubility observed in the larger recombinant IGFN1 
isoforms, two smaller constructs were transformed into BL21-AI™ E. coli. 
These were pET161-DEST-IGFN1_d1-d3 and pET161-DEST-IGFN1_d6-d11 
coding for His-tagged IGFN1 fragments, containing domains 1-3 of IGFN1 
(IGFN1_d1-d3) and domains 6-11 (IGFN1_d6-d11), respectively (table 5.1). 
As well as this, and lower incubation temperatures, sequential induction was 
trialled. This involved the addition of L-arabinose when the culture had reached 
OD600=0.6 (t=0), to release expression of T7 RNA polymerase from the BL21-
AI™ genome. This was followed by the addition of IPTG after 2 hours (t=2) to 
induce the expression of the His-tagged IGFN_d1-d3 from the pET plasmid. 
In theory, this would reduce the metabolic load on cells, therefore increasing 
the solubility and the yield of the over expressed recombinant protein 
fragment. The different protocols tested are summarised in table 5.2.  
The most successful protocol for obtaining soluble IGFN1_d1-d3 described in 
table 5.2 included sequential induction, 30°C overnight incubation, and a 
change of media between addition of L-arabinose and IPTG. This is described 
in figure 5.2A. Robust expression of IGFN1_d1-d3 was seen at t=3 after the 
addition of IPTG, demonstrating the sequential induction was successful in 
producing high levels of IGFN1_d1-d3, with a large amount of protein in the 
soluble fraction (fig. 5.2B).  
Purification of the His-tagged protein was performed using the ProBond 
Purification System, this resulted in relatively high yields of IGFN1_d1-d3 (fig. 
5.2C). The band observed at ~37kDa was analysed through LC-MS, 
confirming its identity as IGFN1. However, upon dialysis to remove imidazole 
from the buffer, a precipitate formed (fig. 5.2D). The removal of imidazole is 
required to allow the His-tagged protein to bind to Ni-NTA-coated coverslips 
for use in AFM experiments. The protein could, however, be left bound to 
beads for use in pull-down experiments (as in chapter 6).  
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Table 5.2. Summary of conditions trialled to optimise expression of 
protein in the soluble fraction. Simultaneous addition of L-arabinose and IPTG 
refers to L-arabinose and IPTG being added at the same time point, while sequential 
describes addition at different time points as described in figure 5.2.A. Media 
changed refers to whether the cells were pelleted, and the media changed between 
the addition of L-arabinose and the addition of IPTG. Overnight culture temperature 
refers to the temperature at which the culture was left overnight to express protein 
following the addition of both L-arabinose and IPTG. Success was determined by 
examining the amount of protein expressed in the soluble fraction compared to the 
insoluble fraction (Y=yes N=no P=partial).
 
 
 
A similar pattern was observed when attempting to produce IGFN1_d6-d11 
using the same protocol, with expression observed at t=4, slightly later than 
for IGFN1_d1-d3 (fig. 5.3A). Soluble protein could then be purified, albeit at 
lower yields than IGFN1_d1-d3 (fig. 5.3B). However, the same issue occurred 
following dialysis, with a precipitate forming upon the removal of imidazole (fig. 
5.3C). Again, leaving the purified protein bound to the Ni-NTA beads would 
allow for pull-down experiments. However, it would not be possible to use the 
recombinant protein in any biophysical analysis. 
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Figure 5.2. Production and Purification of IGFN1_d1-d3. A) Schematic 
representation of induction protocol used. Values for t given in hours. B) Top 
Coomassie and bottom western blot against His-tagged IGFN1_d1-d3 of lysates from 
time points during the induction protocol, time points correspond to time points in A. 
All lanes were loaded with the same concentration of cell lysate by normalising using 
OD600 readings. Bands at 37kDa correspond to IGFN1_d1-d3. C) Top Coomassie and 
bottom western blot against His-tagged IGFN1_d1-d3 following purification using the 
ProBond Purification System. Total and soluble fractions of E. coli expressing 
pET161-DEST-IGFN1_d1-d3 overnight are included, as well as elution fractions 
following purification via the ProBond Purification System. Wash and flow through 
samples are also shown representing a sample of wash buffer following the first wash, 
and a sample of E. coli lysate following bead incubation, respectively. Red box 
highlights bands identified as IGFN1 through LC-MS. Gels were loaded separately 
with the same samples. D) Image of IGFN1_d1-d3 following purification and dialysis 
to remove imidazole, red arrows indicate clearly visible precipitate. 
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Figure 5.3. Production and Purification of IGFN1_d6-d11. Expression was 
induced as for IGFN1_d1-d3 in figure 5.2 A) Top Coomassie and bottom western blot 
against His-tagged IGFN1_d6-d11 of lysates from time points during the induction 
protocol, time points correspond to time points in fig.5.2A. All lanes were loaded with 
the same concentration of cell lysate by normalising using OD600 readings. B) Top 
Coomassie and bottom western blot against His-tagged IGFN1_d6-d11 following 
purification using the ProBond Purification System. Red box highlights band identified 
as IGFN1 through LC-MS. C) Image of IGFN1_d6-d11 following purification and 
dialysis to remove imidazole, red arrows indicate clearly visible precipitate. 
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5.4 Cloning of IGFN1_d1-d3 into the pQE2-Im9 Expression Vector 
Allows Purification of a Soluble, Folded IGFN1_d1-d3 Fragment  
Due to the formation of a precipitate upon removal of imidazole from the 
storage buffer, IGFN1_d1-d3 was cloned into a vector containing the Im9 
solubility tag pQE2-Im9 (Jared Cartwright, Bioscience Technology Facility, 
University of York). This expression vector results in a fusion of a His-tagged 
variant of the bacterial colicin E9 immunity protein (His7-Im9) to the N-terminus 
of the recombinant protein-of-interest. The Im9 domain has been used to 
enhance the solubility of recombinant proteins. The mechanism that underlies 
this is not fully understood, but may be due to its rapid folding upon exiting the 
ribosome, thus facilitating the folding of the larger polypeptide to which it is 
fused (for a review of solubility tags see (Malhotra, 2009)). 
IGFN1_d1-d3 was amplified using primers designed for use with the NEBuilder 
assembly cloning kit (Materials and Methods 2.12.4) (fig. 5.4A and B), and the 
NEBuilder assembly reaction was performed to ligate the two IGFN1 
fragments into the vector (fig. 5.4.D). Colony PCR was then performed on 
BL21-AI™ E. coli colonies transformed with the pQE2-Im9-IGFN1_d1-d3 
vector, to confirm the presence of the construct (fig. 5.5). Bands were 
observed in all colonies of the pQE2-Im9-IGFN1_d1-d3 transformed colonies 
at the expected size. 
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Figure 5.4. Cloning of IGFN1_d1-d3 into pQE2-Im9 using NEBuilder High-
fidelity assembly cloning. A) Primer design, text in grey represents gene-
specific primer sequence, text in red represents sequence overlapping the 
digested Im9 vector. B) Amplification of IGFN1_d1-d3 from pDEST47-
IGFN1_V1-TdTomato vector using primers in A, with water control, band 
present for IGFN1_d1-d3 at ~1.2Kb. C) Digestion of pQE2-Im9 using NdeI and 
BlpI to produce a linear construct of 4962bp (arrow) to be used for NEBuilder 
HiFi assembly reaction, and a fragment of 66bp (run off gel). D) Schematic of 
NEBuilder HiFi cloning reaction (taken from NEBuilder manual). 
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Figure 5.5. Colony PCR of colonies of pQE2-Im9-IGFN1_d1-d3 transformed 
BL21-AI™ E. coli. Primers described in figure 5.4A were used and identified pQE2-
Im9-IGFN1_d1-d3 at ~1.2Kb in all colonies tested.  
 
 
The same expression protocol as in figure 5.2A was used with the BL21-AI™ 
E. coli harbouring pQE2-Im9-IGFN1_d1-d3. Robust expression was observed 
(fig. 5.6A), and soluble protein was purified (fig. 5.6B). Two main bands were 
observed in purified fractions, one was identified as Im9-IGFN1_d1-d3 through 
LC-MS, the other as Elongation Factor Tu (EF-Tu). Crucially, no precipitate 
formed following dialysis to remove imidazole from the storage buffer (fig. 
5.6C). 
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Figure 5.6. Production and Purification of IGFN1_d1-d3. A) Top Coomassie 
and bottom western blot against His-tagged Im9-IGFN1_d1-d3 of lysates from time 
points during the induction protocol (as in figure 5.2A). At t=0 both L-arabinose and 
IPTG were added. All lanes were loaded with the same concentration of cell lysate 
by normalising using OD600 readings. B) Top Coomassie and bottom western blot 
against His-tagged Im9-IGFN1_d1-d3 following purification using the ProBond 
Purification System. Red box highlights band identified as IGFN1 through LC-MS, 
contaminant highlighted in blue box was identified as Elongation Factor Tu. C) 
Comparison of Im9-IGFN1_d1-d3 and original recombinant IGFN1_d1-d3 from figure 
5.2 following dialysis to remove imidazole. No precipitate is observed in the Im9-
IGFN1_d1-d3 sample. 
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Finally, thermal unfolding of the recombinant Im9-IGFN1_d1-d3 was 
performed to determine whether it contained folded domains. Differential 
scanning fluorimetry was performed using the Prometheus NT.48 Nano DSF 
with PR.ThermControl v2.1.2 software (NanoTemper). The fluorescence 
emission wavelength of intrinsic tryptophan residues buried in a folded protein 
structure will shift upon thermal unfolding. This unfolding transition is 
monitored by detecting the fluorescence emission at wavelengths of 330 nm 
and 350 nm as the temperature is increased. The two separate wavelengths 
monitor the change in emission from intrinsic tryptophan residues as they 
move from a non-polar (buried) to a polar (not buried) environment during 
protein unfolding. This is used to determine the protein melting point Tm, 
where half of the protein is folded, and the other half is unfolded. The first 
derivative of the F350/F330 fluorescence intensity ratio is used to calculate 
this parameter.  
Distinct peaks were observed in the first derivatives of the 350nm/330nm ratio, 
which revealed two distinct unfolding events at ~58°C and ~73°C (fig.5.7). 
These may represent the sequential unfolding of two domains at different 
temperatures. It may also be that one of the peaks is from the contaminant 
Elongation Factor Tu. These possibilities will be discussed below. 
Mechanical unfolding using atomic force microscopy was attempted with the 
above samples, as described in Materials and Methods 2.16. Unfortunately, 
this work proved unsuccessful. The peaks generated did not fit a worm-like 
chain model (For a review see (Fisher et al., 1999; Ott et al., 2017)). This 
meant that the unfolding and refolding dynamics of the IGFN1 domains could 
not be measured during the timeframe of this project. 
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Figure 5.7. Thermal Unfolding of Im9-IGFN1_d1-d3. Thermal unfolding 
(differential scanning fluorimetry) was performed using the Prometheus NT.48 Nano 
DSF with PR.ThermControl v2.1.2 software (NanoTemper). Three technical replicas 
are shown. Unfolding was performed from 15-95°C with a 1.3°C/min gradient, 
200μg/ml of protein in PBS was used. A) 350nm/330nm ratio against temperature B) 
First derivatives of 350nm/330nm ratio. Peaks at ~58°C and ~73°C reveal two distinct 
unfolding events.  
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5.5 Conclusions  
As was previously reported, the production and purification of any IGFN1 
peptide proved a difficult undertaking. Most of the difficulty stemmed from the 
insolubility of the recombinant protein. This was particularly apparent for the 
larger IGFN1 isoforms, and some of the issues were overcome by using the 
smaller IGFN1 fragments IGFN1_d1-d3 and IGFN1_d6-d11. However, upon 
removal of imidazole, a precipitate was present. Cloning of IGFN1_d1-d3 into 
the pQE2-Im9 vector allowed for production and purification of recombinant 
protein, free from precipitate in the absence of imidazole. 
This protein was not entirely pure, with the elongation factor EF-Tu detected 
as co-purifying with IGFN1. The eukaryotic homologue of EF-Tu is the alpha 
subunit of eEF1A, which itself has been previously shown to interact with 
IGFN1 (Mansilla et al., 2008). It is therefore likely that the co-purification of 
IGFN1 and EF-Tu is the result of a specific interaction between the two. This 
lends weight to the idea that IGFN1 may play a role in elongation during 
translation, possibly as a scaffold or inhibitor, and may be related to the 
association of IGFN1 expression with atrophic signalling. 
The resulting recombinant protein was then thermally unfolded. This would 
provide some insight into whether the protein was properly folded, thus 
allowing for mechanical folding experiments using AFM. Two distinct unfolding 
events at ~58°C and ~73°C were detected. As mentioned above, a 
contaminant protein was present which was identified as EF-Tu. However, it 
is unlikely that either unfolding event was that of EF-Tu. The Tm of E. coli EF-
Tu is 42.4°C or 46.5°C depending on whether the protein is GTP or GDP bound 
(Sanderova et al., 2004), much lower than either peak detected here.  
The Tm of titin modules made up of Ig-like domains mostly range from 54.0°C 
to 72.6°C, with only one example outside of this range having a Tm of 35.3°C 
(Politou et al., 1995). Assuming that the Ig-like domains of titin and IGFN1 are 
structurally similar, it is likely that the unfolding events seen at ~58°C and 
~73°C for Im9-IGFN1_d1-d3 represent the unfolding of its Ig or Ig-like 
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domains. On that basis, we consider the recombinant protein of sufficient 
purity and integrity for mechanical unfolding experiments.  
The objective at the outset of this project was to be able to perform mechanical 
unfolding experiments to ascertain whether IGFN1 plays a biophysical role at 
the z-disc, possibly acting as a mechanical spring to absorb the contractile 
forces placed on the sarcomere. Proteins with similar domain compositions 
have been demonstrated to perform this role, therefore it is possible that 
IGFN1 also performs this role (Rief et al., 1997; Schoenauer et al., 2005). 
Initial attempts to unfold the purified domains using AFM were undertaken and 
distinct peaks in the force versus extension data were observed (data not 
shown). Worm-like chain analysis of these force peaks (analysis completed by 
William Rochira and Christoph Baumann) suggested they were due to 
adsorption of the AFM tip to the functionalised glass surface, rather than 
unfolding of a single protein domain. Issues including a delay in the full 
installation of the atomic force microscope, and scheduling issues with the 
relevant people, meant that, despite protein being ready for use, the 
mechanical unfolding experiments could not be repeated and refined for 
inclusion in this thesis.  
Now that a protocol has been established for the purification of one IGFN1 
fragment, future work should include fresh attempts at the AFM experiments 
to investigate the mechanical unfolding properties of the purified IGFN1 
fragment. Alongside this, other IGFN1 fragments should be cloned into the 
pQE2-Im9 vector, to establish a full picture of the unfolding, and refolding, 
dynamics of all the predicted IGFN1 domains. 
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Chapter 6: Validation of a Protein-Protein Interaction 
Between IGFN1 and COBL 
6.1 Introduction 
This chapter outlines the identification and validation of an interaction partner 
of IGFN1 in skeletal muscle. 
The domain composition of IGFN1, consisting of a series of evenly spaced 
globular domains at the N and C-terminal ends of the protein, suggests that 
IGFN1 acts as a scaffolding protein. These immunoglobulin and fibronectin-
like domains are typically present in other sarcomeric proteins (e.g. titin and 
myomesisn) and have been implicated in protein-protein interactions. It is 
therefore hypothesised that IGFN1 may act by bringing together protein 
complexes and that its main biological function may be revealed by exposing 
these interaction partners, since IGFN1 itself lacks any enzymatic activity. In 
order to identify potential interaction partners of IGFN1, proteomic analysis of 
pull-downs of mouse muscle against IGFN1 fragments was performed. 
Because of the fusion defect and the altered actin remodelling phenotypes 
observed in IGFN1 knockout myoblasts outlined in previous chapters, any 
proteins involved with myoblast fusion or in actin remodelling were of particular 
interest, and these interactions were to be validated further. Validation was 
performed using co-immunoprecipitation, as well as co-localisation both in-
vitro and in-vivo.  
 
6.2 Proteomic Identification of Potential IGFN1 Interaction Partners 
To identify interaction partners of IGFN1 pull-downs were performed using 
mouse muscle extracts against either LacZ (as a negative control), IGFN1 
domains 1-3 (IGFN1_d1-d3), or IGFN1 domains 6-11 (IGFN1_d6-d11) 
immobilised on Ni-NTA agarose beads (fig. 6.1). The eluate was sent for LC-
MS/MS analysis, which was performed by Adam Dowle at the University of 
York Biology Technology Facility (see Materials and Methods 2.17 for details). 
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Figure 6.1. Confirmation of purified protein immobilisation to Ni-NTA agarose 
beads. Anti-His western blots of Ni-NTA agarose beads following immobilisation of 
protein show bands at the expected sizes for all three His-tagged proteins (LacZ-His, 
IGFN1d1-d3-His, and IGFN1d6-d11-His) in all three replicas of each protein. All gels 
were run alongside one another with blot development performed in tandem. It should 
be noted that the concentration of immobilised protein was relatively low for d6-d11 
replica 3, however protein was clearly present. LacZ concentration was higher in all 
samples than either IGFN1 fragment. 
 
Several potential interaction partners were identified. The following criteria 
were applied to determine presence or absence in each pull-down: 1) Inclusion 
required protein identification probability of greater than 95% in at least two of 
three biological replicas; 2) Exclusion required protein identification probability 
of less than 95% in all three biological replicas. The filtered data set indicating 
proteins identified with fragment IGFN1(d1-d3), IGFN1(d6-d11) or both, and 
not with LacZ, is presented in Table 1. Functional enrichment as determined 
by STRING-db (Szklarczyk et al., 2015) highlighted the cytoskeleton and the 
proteasome as the main components. STRING-db identified significantly more 
interactions between the proteins identified than would be expected of a 
random set of proteins, suggesting the potential interactions are functionally 
relevant (fig. 6.2). The cytoskeletal crosslinker alpha-actinin, located at the Z-
disc, and the actin nucleation protein cordon-bleu (COBL) were found in 
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eluates from both IGFN1 fragments. A number of proteasome subunits were 
also detected. 
 
Table 6.1. IGFN1 interaction partners. Filtered data set including proteins identified 
as potential interaction partners of fragment IGFN1(d1-d3), IGFN1(d6-d11), or both, 
and not with the LacZ control. Protein ID required a minimum of 2 peptides (<1FDR), 
for a protein to be included in a set a >95% ID probability in >1 sample was required 
and for the protein to be classed as not identified in the LacZ control. p values from 
ANOVA testing represent the probability of obtaining the given LC-MS/MS results for 
each protein across all experiments to minimise false positives from multiple tests. 
Therefore, for proteins identified as an interacting partner of more than one fragment 
the p value is the same. 
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Figure 6.2. STRING-Db summary of IGFN1 interaction partners. STRING-Db 
output of proteins found to interact with either IGFN1_d1-d3 or IGFN1_d6-d11, or 
both, and not LacZ, through LC-MS/MS. Lines between nodes represent interactions 
found in the STRING database, with colours denoting how the interaction was 
identified as described in the legend. The number of interactions is higher than would 
be expected from a random set of proteins (PPI enrichment p-value=0.00983). 
Functional enrichments in the cytoskeleton (blue) and the proteasome (red) are 
shown (FDR=0.033 and 0.0038 respectively). 
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6.3 Confirmation of COBL Expression in vivo and in C2C12 Myoblasts 
COBL is a protein containing tandem repeats of WASP-homology 2 (WH2) 
domains, these domains are multifunctional regulators of actin assembly. They 
contribute to filament nucleation, severing, and barbed end capping or 
tracking, depending on the context in which they are found (Carlier et al., 
2011). COBL specifically has been shown to play a role in development 
including in neural tube formation (Carroll et al., 2003), as well as playing a 
role in promoting the growth of brush border microvilli in the intestine (Grega-
Larson et al., 2015). No specific function has been found for COBL in skeletal 
muscle thus far.  
The specificity of a COBL antibody was tested to determine if it could be used 
to reveal the localisation of COBL in vivo and in vitro (fig.6.3). SDS-PAGE and 
western blots were performed on samples from the soluble fraction of mouse 
brain, heart, skeletal muscle, and 7-day differentiated C2C12 cells. A complex 
band pattern was observed. Initially it was assumed that this represented a 
number of COBL isoforms, and that the full-length COBL isoform was 
represented by a band at ~144kDa, its predicted molecular weight. However, 
upon examining the literature (Ahuja et al., 2007; Haag et al., 2018), and 
through the generation of a C2C12-derived COBL knockout cell line (outlined 
in chapter 7.5), it was determined that the band at ~170kDa was the genuine 
COBL band (fig.6.3A). COBL was shown to be expressed in the brain (as 
expected) and in myoblast cells. However, expression was not apparent in the 
soluble fraction of skeletal muscle or the heart. It is possible that COBL is not 
found in the soluble fraction of skeletal muscle due to a strong association with 
the cytoskeleton. Insoluble COBL may be detected in skeletal muscle through 
antibody staining, rather than through western blots. 
Longitudinal sections of mouse gastrocnemius muscle that had been 
electroporated with a KY-tdTomato construct, to mark the z-disc, were 
incubated with anti-COBL antibody (fig 6.3B). Co-localization of KY-tdTomato 
and COBL indicate that COBL may be localized to the Z-disc where IGFN1 is 
also expressed. However, due to the lack of isoform specificity, and potential 
cross-reactivity observed from this COBL antibody, it could not be determined 
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whether this was indeed COBL at the z-disc. To confirm this localisation, and 
to perform other interaction assays, COBL was to be cloned into a mammalian 
expression vector containing a fluorescent tag, as described below. 
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Figure 6.3 COBL antibody validation. A) Anti-COBL western blot with samples from 
the soluble fraction of mouse brain, heart, and skeletal muscle, and 7-day 
differentiated C2C12 cells. Yellow box indicates bands at the approximate predicted 
size of full-length COBL (~144kDa), red box indicates the band confirmed to represent 
full-length COBL (~170kDa).  B) Widefield longitudinal cross-sections of mouse 
gastrocnemius muscle. Sections are from mice electroporated with a KY-tdTomato 
vector to identify the z-disc (red) and incubated with anti-COBL antibody (green). Note 
that COBL antibodies identify a striated pattern that coincides with the z-disc. The 
insets (blue squares) are shown magnified above. Scale bar represents 50 microns. 
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6.4 Cloning of cobl into Gateway vectors 
To provide a tool for further validation of the potential interaction between 
IGFN1 and COBL, and because of the lack of antibody specificity, a mouse 
muscle cDNA library was used to amplify cobl transcripts present in muscle. 
Primers compatible with the TOPO cloning system were used (fig.6.4A, B). 
Several amplicons were amplified including the full length cobl isoform (COBL-
201) matching the larger isoform observed in figure 6.3A, and a number of 
smaller amplicons representing either non-specific amplification, or smaller 
COBL isoforms (fig. 6.4C). The resulting PCR product was cloned into the 
pENTR/SD/D-TOPO vector, using the pENTR Directional cloning TOPO 
Cloning Kit (Invitrogen), the vectors produced were then transformed into 
chemically competent E. coli.  
Colony PCR was performed to identify colonies containing a cobl insert (fig. 
6.5A), followed by minipreps and a double restriction digest to identify the size 
of the cobl insert (fig. 6.5B). Only 1/40 of the colonies screened contained the 
full length cobl insert. This colony was grown in LB in order to perform a 
miniprep to extract the pENTR/SD/D-TOPO vector containing an insert coding 
for the full length COBL isoform. This construct was then used to shuttle the 
full length cobl insert into the “Gateway” compatible destination vector 
containing a tdTomato C-terminal tag: pDEST47-tdTomato. The presence of 
an ORF was confirmed via transfection of the COBL-tdTomato construct into 
COS7 cells. The resulting red fluorescence likely indicates translation of a full 
length in frame fusion of COBL and tdTomato, although the presence of 
alternative translation starts within the COBL ORF cannot be ruled out (fig. 
6.6A). The construct was then sequenced using primers spaced at 500bp 
intervals along the ORF, this confirmed that the insert was indeed the cobl 
isoform COBL_201 (UniProt identifier: Q5NBX1-1) (fig. 6.6B). Sequencing of 
the smaller inserts (seen in fig. 6.5B) was unable to identify any as COBL 
isoforms, meaning that these were likely artefacts, rather than isoforms of 
COBL.   
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Figure 6.4 Amplification of COBL from a mouse muscle cDNA library. A) Above, 
intron/exon structure of the mouse Cobl gene with exons numbered according to the 
predicted ENSEMBL Cobl-201 (ENSMUST00000046755.13). ENSEMBL Cobl-201 
matches the sequence from the mouse cDNA amplified from a skeletal muscle library 
using the indicated primers (arrow tips). The mouse skeletal muscle cDNA predicts a 
protein of 1337 AA identical to UniProtKB Q5NBX1. Below, the mouse COBL protein 
with domains annotated as follows: Cobl, ubiquitin-like fold domain (IPR019025); Pro-
rich, indicates a proline rich region (compositional bias); WH2, Wiskott-Aldrich 
homology 2 domain (IPR003124). The antigen used for anti-Cobl antibodies is 
indicated by the red bar. B) Sequence of two sets of primers designed to amplify 
COBL, grey represents sequence complementary to cobl gene, red represents CACC 
sequence required for cloning into pENTR/SD/D-TOPO vectors. Primer pair 1 
designed to amplify entire ORF excluding the stop codon, primer pair 2 skips 9 5’ 
codons and 2 3’ codons (including the stop codon) in order to increase primer 
efficiency. C) PCR amplification with NEB Q5 high fidelity DNA polymerase (to 
produce blunt ends for TOPO cloning) using both primer pairs on two cDNA libraries; 
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lexA (human) and cDNA (mouse) bands are present in both libraries at expected sizes 
for a number of COBL isoforms. PCR product from primer pair 1 was taken forward 
for cloning into pENTR/SD/D-TOPO as it contains the complete cobl ORF. 
 
Figure 6.5. Validation of cobl cloning into pENTR/SD/D-TOPO. A) Colony PCR of 
E. coli transformed with pENTR-COBL using primers spanning exons 11 and 12 of 
the cobl transcript. Confirmation of presence of cobl in majority of the transformants 
with a band at 585bp (black arrows). B) Double restriction digests (using BsrGI) of 
plasmid DNA following minipreps from cobl positive colonies in A. The band at ~2.5Kb 
represents the vector backbone (white arrowheads). Inserts of various sizes were 
observed as expected, one construct contained an insert of the predicted size of the 
full-length cobl isoform at ~4Kb (white arrow).  
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Figure 6.6. Validation of destination vectors containing cobl inserts. A) COS7 
cells were transfected with the pDEST47-COBL-TdTomato construct, fluorescence 
indicates the presence of an open reading frame. B) Schematic of sequencing 
strategy, primers were designed at ~500bp intervals along the cobl full length open 
reading frame, each primer gave a sequence length of ~1000bp meaning that 
sequences could be assembled using the overlapping regions, this allowed 
confirmation that a full-length cobl ORF was present. 
 
6.5 IGFN1_V1 and COBL Co-immunoprecipitate Following Co-
transfection in COS7 
To test the specificity of the IGFN1-COBL interaction COS7 cells were co-
transfected with either pDEST47-IGFN1_V1-V5 and pDEST47-COBL-
tdTomato or with pDEST47-V5 and pDEST47-COBL-tdTomato and were left 
for 48 hours to express the transfected constructs. Cells were then lysed, and 
this lysate was incubated against either anti-V5 IgG agarose beads or IgG 
Agarose beads. Beads were then washed and processed via SDS-PAGE and 
a western blot performed with the anti-COBL antibody, followed by stripping 
and reprobing with anti-V5 antibody. A band at the expected molecular weight 
of COBL-tdTomato was detected in samples from COS7 cells transfected with 
pDEST47-IGFN1_V1-V5 and pDEST47-COBL-tdTomato confirming that the 
two proteins interact (fig. 6.7). A lack of COBL bands in the with pDEST47-V5 
and pDEST47-COBL-tdTomato samples rules out non-specific binding of 
COBL to the V5 tag, and the lack of bands in the IgG Agarose bead samples 
rules out non-specific binging of COBL or tdTomato to the beads themselves, 
indicating that the interaction between COBL and IGFN1_V1 is likely to be 
specific. 
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Figure 6.7. IGFN1_V1 and COBL coimmunoprecipitate following IgG Agarose 
bead pull-down. Representative blots are shown from pulldowns of cell extracts from 
COS7 cells co-transfected with either pDEST47-IGFN1_V1-V5 and pDEST47-COBL-
tdTomato or with pDEST47-V5 and pDEST47-COBL-tdTomato to control for non-
specific binding between the two tags. Pull-downs were performed against either anti-
V5 IgG agarose beads or IgG Agarose beads as a control for protein binding directly 
to the beads. Blots were incubated with anti-COBL antibody before being stripped 
and re-probed with anti-V5 antibody. A band is present at the expected size of COBL-
tdTomato in the pDEST47-IGFN1_V1-V5 and pDEST47-COBL-tdTomato co-
transfection extract but not in the pDEST47-V5 and pDEST47-COBL-tdTomato co-
transfection extract suggesting a specific interaction between IGFN1_V1 and COBL. 
Transfections and pull-downs were repeated in triplicate. 
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6.6 COBL and IGFN1_V1 Co-localise in COS7 Cells 
In order to look for possible changes in the subcellular localization of these 
proteins when co-transfected in a heterologous system, COS7 cells were 
transfected with either pDEST47-IGFN1_V1-GFP and pDEST47-COBL-
tdTomato or pDEST47-IGFN1_V1-GFP and pDEST47-tdTomato. Initial 
analysis concerned the location of IGFN1_V1 and COBL expression. For 
singly transfected cells, IGFN1_V1 was found to be highly expressed in the 
nucleus of cells only expressing IGFN1_V1-GFP whilst COBL-tdTomato was 
expressed predominantly in the cytoplasm. However, in cells expressing both 
IGFN1_V1-GFP and COBL-tdTomato a shift of IGFN1_V1-GFP expression 
was observed with a higher proportion of cells expressing IGFN1_V1-GFP in 
the cytoplasm, suggesting that COBL may prevent IGFN1_V1 from 
translocating to the nucleus. This nuclear to cytoplasmic expression shift for 
IGFN1_V1-GFP was not observed in cells co-transfected with IGFN1_V1-GFP 
and tdTomato (fig. 6.8). 
Confocal microscopy was then used in order to quantify the levels 
colocalization for IGFN1 and COBL in COS7 cells transfected with either 
pDEST47-IGFN1_V1-GFP and pDEST47-COBL-tdTomato or pDEST47-
IGFN1_V1-GFP and pDEST47-tdTomato. Volocity software was used to 
quantify the Pearson’s correlation coefficient, with the Costes method (Costes 
et al., 2004) used for setting thresholds. It was found that the Pearson’s 
correlation coefficient was significantly higher in the pDEST47-IGFN1_V1-
GFP and pDEST47-COBL-tdTomato transfected cells than in the or 
pDEST47-IGFN1_V1-GFP and pDEST47-tdTomato transfected cells (fig. 6.9) 
showing that IGFN1_V1 and COBL interact and colocalise even outside of the 
context of a muscle cell. 
Attempts were made to co-transfect and express pDEST47-IGFN1_V1-GFP 
and pDEST47-COBL-tdTomato in C2C12 cells. However, the transfection 
efficiency was very low, meaning that no cells expressing both IGFN1_V1-
GFP and COBL-tdTomato could be observed. To circumvent this the 
interaction of IGFN1_V1 and COBL was explored in vivo using 
electroporations of adult mouse muscles 
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Figure 6.8. Localisation of IGFN1_V1 shifts from nuclear to cytoplasmic in the 
presence of COBL in COS7 cells. A) Representative widefield images of COS7 
cells co-transfected with either pDEST47-IGFN1_V1-GFP and pDEST47-COBL-
tdTomato or with pDEST47-IGFN1_V1-GFP and pDEST47-tdTomato. IGFN1_V1-
GFP is localised to the nuclei of cells co-transfected with pDEST47-tdTomato, 
cytoplasmic expression is observed in cells co-transfected with pDEST47-COBL-
tdTomato. Scale bar represents 30 microns. B) Quantification of IGFN1_V1-GFP 
localisation in COS7 cells co-transfected with either pDEST47-IGFN1_V1-GFP and 
pDEST47-COBL-tdTomato or with pDEST47-IGFN1_V1-GFP and pDEST47-
tdTomato. IGFN1_v1-GFP distribution is similar in cells expressing IGFN1_V1-GFP 
alone and in cells expressing both IGFN1_V1-GFP and tdTomato with mainly nuclear 
localisation observed. In cells expressing both IGFN1_V1 and COBL-tdTomato a 
higher proportion of cytoplasmic expression is observed (n>30 in each condition). 
131 
 
 
Figure 6.9. IGFN1_V1-GFP colocalises with COBL-tdTomato in COS7 cells. A) 
Representative widefield images of COS7 cells co-transfected with either pDEST47-
IGFN1_V1-GFP and pDEST47-COBL-tdTomato or with pDEST47-IGFN1_V1-GFP 
and pDEST47-tdTomato. The selected range of interest (ROI) for individual cells 
expressing both constructs are shown as are images showing pixels where co-
localisation is apparent. B) Mean Pearson's correlation coefficient values. Volocity 
software was used for analysis with the Costes method used to set thresholds. For 
cells co-transfected with pDEST47-IGFN1_V1-GFP and pDEST47-COBL-tdTomato 
n=25 and for cells transfected with pDEST47-IGFN1_V1-GFP and pDEST47-
tdTomato n=12. Colocalisation was significantly higher in cells co-transfected with 
pDEST47-IGFN1_V1-GFP and pDEST47-COBL-tdTomato than cells transfected 
with pDEST47-IGFN1_V1-GFP and pDEST47-tdTomato (students t-test, p<0.01). 
6.7 COBL and IGFN1_V1 are Present at the Z-disc in vivo 
The TA/EDL muscles of C3H/HeH mice were electroporated with either 
pDEST47-COBL-tdTomato, pDEST47-IGFN1_V1-GFP and pDEST47-COBL-
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tdTomato, or pDEST47-IGFN1_V1-GFP and pDEST47-tdTomato to 
investigate the interaction between IGFN1_V1 and COBL in vivo and establish 
whether the z-disc localisation in figure 6.3B was genuine. Following 10 days 
of expression longitudinal sections were made of the EDL of electroporated 
mice. Unfortunately, the co-electroporations of IGFN1_V1-GFP and COBL-
tdTomato were unsuccessful. However, in sections from mice electroporated 
with COBL-tdTomato alone, clear striations were observed, as had previously 
been observed using anti-COBL antibodies (fig. 6.3B). In order to confirm that 
the striations observed were from COBL-tdTomato expression at the z-disc 
the sections were incubated with EA-53, an anti α-actinin antibody. Confocal 
analysis of these sections revealed that the expression of COBL in the 
electroporated muscles was localised to the z-disc with the striations observed 
from COBL-tdTomato aligning with those from the anti α-actinin antibody (fig. 
6.10). 
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Figure 6.10. COBL localises to the Z-disc in vivo. Mouse EDL muscles were 
electroporated with pDEST47-COBL-tdTomato. After 10 days mice were euthanised 
and longitudinal sections of the electroporated EDL muscle were taken. In order to 
visualise the z-disc sections were stained with the anti-sarcomeric alpha actinin 
antibody EA-53 using the secondary antibody anti-mouse IgG Alexa Fluor 488. 
Images were taken using a Zeiss Upright 710 confocal microscope (confocal slice). 
Scale bar represents 15 microns. 
 
 
6.8 Conclusions 
Initial proteomic analysis revealed a functional enrichment in the cytoskeleton 
with potential interacting partners including the z-disc protein α-actinin (Actn1). 
This gave an indication that the interactions detected were specific as they 
were consistent with the z-disc localisation of KY, the bait originally used to 
identify IGFN1 (Beatham et al., 2004b), which was also found to localise to the 
z-disc (Baker et al., 2010). Functional enrichments in the proteasome were 
also detected through proteomic analysis of the pull-down of mouse muscle 
extract against IGFN1 fragments. IGFN1 expression has previously been 
associated with muscle atrophy (Chen et al., 2014; Rahimov et al., 2011) 
meaning these potential interactions may provide an insight into any function 
IGFN1 plays in atrophy. A similar approach to validating these interactions as 
used for COBL and IGFN1 should be explored in future work.  
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As shown in chapter 3, IGFN1 knockout cells display a fusion defect, as well 
as a higher G:F actin ratio than wildtype cells. Additionally, IGFN1 was shown 
to interact with actin in a Y2H screen (Baker et al., 2010). Actin remodelling 
plays a pivotal role in all steps of myoblast fusion: migration, recognition, 
adhesion, membrane alignment and membrane pore formation and resolution 
(Rochlin et al., 2010). Therefore, validation of the interaction between IGFN1 
and COBL was of particular interest because of its numerous roles in actin 
remodelling in other tissues, including neural tube formation (Carroll et al., 
2003), as well as playing a role in promoting the growth of brush border 
microvilli in the intestine (Grega-Larson et al., 2015). While no role for COBL 
has been identified in skeletal muscle thus far. It is possible that COBL plays 
a role in cytoskeletal remodelling especially during myoblast fusion and 
development. IGFN1 may regulate COBL activity by acting as a scaffold. 
Previous findings have suggested that COBL expression in skeletal muscle is 
relatively low (Ahuja et al., 2007; Carroll et al., 2003). Indeed, the western blot 
showed here would support this. However, COBL was identified by LC-MS/MS 
from a skeletal muscle extract following pull-down experiments, and COBL 
was cloned from a mouse skeletal muscle cDNA library, suggesting that it is 
expressed at some level in skeletal muscle. It may be that COBL is not found 
in the soluble fraction and is only detectable in the cytoskeletal fraction of 
muscle protein extracts. Furthermore, COBL was shown here to be expressed 
in differentiating myoblasts, and is known to be expressed in the somites of 
zebrafish 24hpf (Schuler et al., 2013), at a similar time as Myomerger (Shi et 
al., 2017) and MyoD (Weinberg et al., 1996). This raises the possibility that 
COBL is upregulated in skeletal muscle during myoblast fusion. This may 
occur in the developing embryo and/or in adult skeletal muscle in response to 
injury. 
The interaction between IGFN1 and COBL was validated through pull-down 
and co-localisation experiments. As well as this, COBL was shown to localise 
to the z-disc in vivo. It is significant that interactions between IGFN1 and COBL 
were detected in COS7 cells, this demonstrates that the two proteins interact 
outside of the context of a muscle cell and therefore the interaction is likely to 
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be direct. It is also noteworthy that COBL promotes actin assembly at the 
barbed end of the actin filament (Ahuja et al., 2007), and that sarcomeric actin 
filaments are orientated such that the barbed ends are anchored at the z-disc 
(Ono, 2010). These observations indicate that the localisation of COBL to the 
z-disc in vivo is potentially functionally relevant.  
The research presented in this chapter outlines a novel interaction between 
IGFN1_V1 and the actin nucleator COBL in skeletal muscle, with evidence to 
suggest that this interaction occurs at the z-disc. This interaction may provide 
an insight into the underlying causes of the actin remodelling phenotype 
observed in IGFN1_V1 knockout cells as well as the fusion defect observed. 
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Chapter 7: Investigating a Role for COBL in Myoblast 
Fusion and Differentiation 
7.1 Introduction 
This chapter describes experiments performed to examine the role of COBL 
in muscle cells, in particular during myoblast fusion and differentiation. 
The previous chapter details the identification of COBL as an interaction 
partner of IGFN1 in skeletal muscle. COBL contains multiple WH2 domains, 
involved in actin filament nucleation, severing, and barbed end capping or 
tracking, depending on the context in which they are found (Carlier et al., 
2011). Overexpression and knockdown experiments have revealed a role for 
COBL in dendritogenesis of dissociated hippocampal neurons and of 
cerebellar Purkinje cells (Ahuja et al., 2007; Haag et al., 2012). COBL has also 
been implicated in the formation of microvilli (Grega-Larson et al., 2015; Wayt 
and Bretscher, 2014).  
In vivo, a zebrafish knockout model displays impaired swimming and balance 
keeping, caused by defects in the development of sensory hair cells (Schuler 
et al., 2013). Most recently, a COBL knockout mouse line has demonstrated a 
role for COBL in postnatal planar cell polarity refinement and cochlea function, 
with knockout mice having impaired hearing (Haag et al., 2018). No stringent 
examination of the skeletal muscle of COBL knockout mice (Haag et al., 2018) 
has thus far been reported. Clearly COBL plays diverse roles across several 
tissues, with no specific role for COBL elucidated in skeletal muscle at this 
time. 
Given its interaction with IGFN1, and the actin remodelling, and fusion 
phenotypes observed in IGFN1 knockout cells, it is possible that COBL acts 
as an effector of IGFN1 in remodelling the cytoskeleton during myoblast fusion 
and differentiation. Here the role of COBL in myoblast fusion and differentiation 
is investigated. First, by examining its expression profile throughout 
differentiation. Followed by examining morphological changes induced by 
COBL in C2C12 cells. Finally, a CRISPR/Cas9 knockout cell line is developed 
and characterised. 
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7.2 COBL Expression Changes Throughout Differentiation and is 
Affected by IGFN1 
For COBL to play a role in myoblast fusion and differentiation it must be 
expressed during these processes. Therefore, the expression of COBL at both 
the protein and transcript level was investigated throughout fusion and 
differentiation.  This was performed for both wildtype and IGFN1 knockout cells 
to determine whether IGFN1 influences COBL expression. 
SDS-PAGE followed by western blotting revealed that the largest COBL 
isoform, a band migrating to ~170kDa, was not detectable in proliferating 
myoblasts of either cell type (fig.7.1). Although this band does not appear at 
the predicted molecular weight of full-length COBL (~144kDa) it has been 
previously reported to be the full-length COBL isoform (Ahuja et al., 2007; 
Haag et al., 2018), and is confirmed by CRISPR/Cas9 knockout (below). 
COBL protein expression was apparent at full confluency (D0, before addition 
of differentiation media) in both cell types and was maintained throughout 
differentiation (fig.7.1). This demonstrates that COBL protein expression is 
associated with the myoblast fusion and differentiation programmes. COBL 
expression did appear more variable in IGFN1 knockout cells maintained in 
differentiation media for 7 days, but the direction of the change in expression 
was not consistent between blots (fig.7.1). 
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Figure 7.1 COBL protein expression throughout in vitro differentiation. 
Representative anti-COBL western blots from wildtype C2C12 (C2C12), and IGFN1 
knockout (KO19) cells at the following time points: proliferating (P), fully confluent 
(D0) in differentiation medium for one (D1) or seven (D7) days. Two independent 
samples are shown for each cell line/timepoint from a total of 4 repeats. 
 
 
A very different COBL expression pattern is observed at the transcript level, 
especially in the IGFN1 knockout cell line, as shown through qPCR. In wildtype 
cells, COBL transcript expression remains relatively stable throughout 
differentiation (fig.7.2A). In IGFN1 knockout cells, COBL transcript expression 
is higher than in wildtype cells at every timepoint observed, with the difference 
growing as differentiation progresses (fig.7.2A). As expected, the IGFN1 
knockout cell line had drastically lower expression of the differentiation marker 
myosin heavy chain 7 (MYH7) at day 7 of differentiation (fig.7.2B), further 
emphasising the role of IGFN1 in myoblast differentiation. Taken together 
these results suggest that IGFN1 plays a role in the regulation of COBL 
expression, and that this may be important during myoblast fusion and 
differentiation. 
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Figure 7.2 COBL transcript expression throughout in vitro differentiation. A) 
qPCR analysis from wild type (C2C12) and IGFN1 knockout cells (KO19) at the 
indicated growing conditions. Fold changes compared to C2C12 proliferating cells 
were calculated using the ΔΔCt method relative to the housekeeping gene HPRT. A 
statistically significant interaction between cell type and time point on Ct values was 
shown by one way ANOVA [F(5,12)=11.5 p<0.001], post-hoc comparisons (Tukey 
HSD) revealed COBL expression was significantly higher in confluent (D0, *p<0.01) 
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and differentiating (D7, *p<0.05) KO19 cells. B) Relative MYH7 expression as 
differentiation marker in C2C12 and KO19 cells. One way ANOVA revealed that there 
is a statistically significant interaction between cell type and time point on Ct values 
[F(5,12)=68.4 p<0.001]. Post-hoc comparisons using Tukey HSD revealed that at D7 
of differentiation MYH7 expression was significantly higher in C2C12 cells (*p<0.01). 
 
7.3 COBL Colocalises with Actin and Affects the Morphology of C2C12 
Myoblasts  
Previous work has shown that COBL induces the formation of actin-rich ruffles 
in COS7 cells (Ahuja et al., 2007). A similar effect was observed here in the 
context of a muscle cell, where C2C12 cells were transfected with pDEST47-
COBL-tdTomato. Actin-rich protrusions were observed in COBL transfected 
cells (fig 7.3A) this was accompanied by high levels of colocalization between 
F-actin and COBL (fig 7.3B). This was not observed in pDEST47-tdTomato 
transfected cells.  
To quantify the morphological changes induced by COBL expression in 
C2C12 myoblasts, the circularity of cells transfected with either pDEST47-
COBL-tdTomato or pDEST47-tdTomato was measured using the analyse 
particles tool in ImageJ. This method was selected as an objective way of 
measuring the changes in morphology induced by COBL expression, as 
opposed to the more subjective counting of ruffles. Circularity of pDEST47-
COBL-tdTomato transfected cells was significantly lower than that of 
pDEST47 -tdTomato transfected cells (fig 7.4), reflecting an increase in 
cellular protrusions as a result of COBL expression. The above experiments 
were also attempted in IGFN1 knockout cells, to determine whether IGFN1 
was required for COBL to affect the morphology of the myoblast. 
Unfortunately, these experiments were not successful. Transfection of IGFN1 
knockout cells with pDEST47-COBL-tdTomato resulted in cell death or 
detachment from the growth surface, with very low transfection efficiencies in 
the cells which remained attached. 
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Figure 7.3 COBL colocalises with F-actin in actin-rich cellular 
protrusions in myoblasts. A) Representative widefield images of C2C12 cells 
transfected with either pDEST47-COBL-tdTomato or pDEST47-tdTomato, then 
stained with phalloidin (F-actin) and DAPI (nucleus). Arrows indicate actin and COBL 
rich protrusions. Scale bar represents 20 microns. B) Mean Pearson's correlation 
coefficient values for colocalization of COBL and F-actin. Volocity software was used 
for analysis with the Costes method used to set thresholds. Mean Pearson's 
correlation coefficient was significantly higher for pDEST47-COBL-tdTomato 
transfected cells than for pDEST47-tdTomato transfected cells (n=30, p<0.01). 
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Figure 7.4 COBL overexpression reduces circularity in C2C12 
myoblasts. A) Representative widefield images of C2C12 cells transfected with 
either pDEST47-COBL-tdTomato or pDEST47-tdTomato. Scale bar 50 microns. B) 
Mean circularity quantified using ImageJ. Mean circularity was significantly lower for 
pDEST47-COBL-tdTomato transfected cells than for pDEST47-tdTomato transfected 
cells (n≥40, p<0.01). 
 
 
7.4 COBL Overexpression Increases Myoblast Fusion 
To examine the effect of COBL overexpression on the differentiation of 
myotubes pDEST47-COBL-tdTomato and pDEST47-tdTomato transfected 
C2C12 cells were differentiated for 7 days. At day 7 cells were fixed and the 
number of nuclei within a cell expressing either COBL-tdTomato or tdTomato 
alone was counted. The fusion index of these cultures could not be calculated 
because not every cell in each frame expressed the transfected constructs. It 
was observed that pDEST47-COBL-tdTomato expressing myotubes 
contained significantly more nuclei than pDEST47-tdTomato expressing 
myotubes, suggesting that COBL induces myoblast fusion (fig 7.5).  
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Figure 7.5. COBL overexpression increases myoblast fusion. A) 
Representative widefield images of C2C12 cells transfected with either pDEST47-
COBL-tdTomato or pDEST47-tdTomato and differentiated for 7 days. Scale bar 
represents 50 microns. B) Mean number of nuclei within a pDEST47-COBL-tdTomato 
or pDEST47-tdTomato expressing myotube (minimum of 3 nuclei to exclude non-
fusing cells). The mean number of nuclei (crosses) was significantly higher in 
pDEST47-COBL-tdTomato expressing myotubes than in pDEST47-tdTomato 
expressing myotubes (n≥50, p<0.01). A minimum of 4 independent transfections were 
performed per condition. 
 
Next, the localisation of COBL during myoblast fusion and differentiation was 
examined. pDEST47-COBL-tdTomato transfected cells were differentiated for 
4 days before being fixed and stained with phalloidin. Figure 7.6 shows an 
example of COBL and F-actin accumulation along the membrane of a myotube 
with an adjacent myoblast, which may be a precursor to fusion. These events 
were relatively rare, probably reflecting their transient nature. However, this 
does suggest that COBL is located in the right place at the right time to be 
involved in myoblast fusion. 
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Figure 7.6. COBL and F-actin colocalise along the membrane of 
myotubes. pDEST47-COBL-tdTomato transfected cells at 4 days of differentiation 
stained with phalloidin and DAPI. White arrowheads indicate expression of COBL and 
F-actin along the cell membrane in close proximity to a myoblast aligned with the 
myotube. Scale bar represents 100 microns. 
 
 
 
7.5 Generation of a C2C12-derived COBL Knockout Cell Line 
A COBL knockout C2C12-derived cell line was generated to examine the 
effects of COBL deficiency, especially on myoblast fusion, and to determine 
whether a similar phenotype as in the IGFN1 knockout cells would be 
observed. To this end, two cocktails of pre-designed plasmids were ordered 
(sc-419728 and sc-419728-HDR, Santa Cruz). The first cocktail contained 
three plasmids coding for three unique CRISPR/Cas9 gRNAs (targeting exons 
2, 3, and 4), and the Cas9 enzyme. The second cocktail contained three 
homology-directed repair (HDR) plasmids complementary to the three target 
sites with a selectable marker, puromycin (fig. 7.7). These, in theory, would 
cause a frame shift upon integration of the HDR cassette at the target site, 
resulting in a loss of function of the cobl gene. 
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Figure 7.7. CRISPR/Cas9 COBL targeting strategy. Top: map of 
CRISPR/Cas9 knockout and homology-directed repair plasmids used to generate 
COBL knockout cells with schematic of their mechanism of action shown. Three pairs 
of plasmids were contained within the cocktail, targeting the three independent target 
sites shown (bottom).  
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Wildtype C2C12 cells were co-transfected with both cocktails. 24 hours later, 
growth media was replaced with growth media containing 4μg/ml puromycin 
for selection. Cells were then selected en masse, or through clonal selection, 
as outlined in methods. Cells were maintained at less than 60% confluency to 
minimise the loss of fusion competence caused by cells in contact with one 
another during expansion. To identify potential COBL knockout clones, PCR 
spanning each target site was performed, alongside PCR of α-actinin (Actn1) 
to control for DNA quality (fig. 7.8A). Integration of the HDR cassette at the 
target site would result in a lack of amplification due to the increased distance 
between the primers. Target site 3 was focussed on due to specificity and 
efficiency issues with primers targeting sites 1 and 2 (not shown). Absence of 
amplification in target site 3 was observed for clones 15, 18, 23, and 24, 
identifying them as having successful integration of the HDR cassette at target 
site 3. Interestingly, amplification was observed in cells selected en masse. 
Upon sequencing a loss of sequence quality was observed at the target site, 
likely representing a mixed population of cells, some with off-target integration 
of the HDR plasmid (fig. 7.8B). 
 
SDS-PAGE and western blot detection was used to verify COBL knockout at 
protein level in the isolated clones. As expected, cells selected en masse 
display similar COBL expression levels to wildtype cells. In contrast, clones 
15, 18, and 23 display a complete lack of COBL expression, confirming 
successful knockout of COBL through CRISPR/Cas9 targeting and HDR 
cassette integration in exon 4 (fig. 7.8C). Clone 24 was not examined as it was 
slow to re-establish following freezing. Crucially, COBL knockout revealed the 
relevant band representing COBL in western blots to be the band at ~170kDa, 
as no other band is affected by COBL knockout. Thus, full-length COBL does 
not migrate to its predicted molecular weight of ~144kDa, and the smaller 
bands detected in chapter 6 figure 6.3A are not COBL isoforms. 
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Figure 7.8. Generation of COBL knockout C2C12-derived cell lines. A) 
PCR of DNA from wildtype C2C12 cells as well as COBL knockout clones and cells 
from an en masse selection following knockout. Primers for CRISPR/Cas9 target site 
3 and Actn1, to confirm DNA integrity, were used. Primers for target site 1 and 2 were 
also trialled however these has lower specificity and efficiency so target site 3 was 
focussed on. B) Sequencing of target site 3 PCR product from wildtype and cells 
selected en masse (target site indicated by red box). Note the loss of sequence quality 
following the target site in the en masse selection cells. C) Western blot of wildtype 
C2C12 cells, COBL knockout cells selected en masse, and knockout clones 15, 18, 
and 23 at full confluency. Loss of COBL in clones 15, 18, and 23 is clearly shown. 
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7.6 Characterisation of COBL Knockout Cells 
Initial characterisation of the COBL knockout cell lines was performed on 
single proliferating cells to determine if absence of COBL influenced myoblast 
morphology. Wildtype C2C12 cells, and COBL knockout clones 15 and 23 
(COBL KO15/23) were fixed and stained with crystal violet (fig. 7.9A). Clone 
18 was not examined here as it had not yet re-established after freezing. 
Images were then taken, and ImageJ used to identify individual cells using the 
threshold tool. The analyse particles tool was then used to measure the area, 
circularity, and aspect ratio of the cells. Aspect ratio refers to the ratio of the 
major and minor axes of an ellipse fitted to a cell and is a measure of 
elongation.  
Mean cell area was lower in both COBL knockout clones than in the wildtype. 
However, this effect was only statistically significant between wildtype cells 
and COBL KO15, with COBL KO23 cells significantly larger than COBL KO15 
(fig. 7.9B). Significant differences in mean circularity and mean aspect ratio 
between wildtype and COBL knockout cells were also observed, but again 
these effects were not consistent between both COBL knockout cell lines (fig. 
7.9C&D). Thus, the differences observed here at the single cell stage are most 
likely caused by an artefact of clonal selection, rather than knockout of COBL.  
Next, attempts were made to differentiate the COBL knockout clones. Initial 
attempts failed due to the detachment of the COBL knockout clones during the 
differentiation process, usually observed shortly after replacing growth media 
with differentiation media, whereas wildtype cells mostly remained attached 
(fig.7.10A). To improve the adherence of the cells to the growth surface, 6-well 
plates were collagen-coated prior to seeding with wildtype and COBL knockout 
cells. This proved successful with cells remaining attached for at least 7 days 
in differentiation media. COBL knockout cells appeared to successfully align, 
but no obvious myotube formation was observed under brightfield microscopy, 
as was observed in wildtype cells (fig.7.10B). 
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Figure 7.9. No consistent morphological changes are observed in COBL 
knockout clones. A) Representative images of wildtype (C2C12), COBL knockout 
clone 15 (COBL KO15), and COBL knockout clone 23 (COBL KO23) stained with 
crystal violet. Scale bar represents 50 microns. B-D) Mean cell area, circularity, and 
aspect ratio measured through the ImageJ analyse particles tool. One way ANOVA 
revealed a significant effect of cell type on mean cell area [F(6,630)=9.76 p<0.001], 
circularity [F(6,630)=78.21 p<0.001], and aspect ratio [F(6,630)=19.91 p<0.001]. 
Tukey-HSD post-hoc analysis revealed significant differences as indicated (*p<0.05 
**p<0.01). 
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Figure 7.10. COBL knockout cells detach from the growth surface and show an 
apparent fusion defect. A) Representative brightfield images of wildtype (C2C12), 
and C2C12-derived COBL knockout clones 15 and 23 (COBL KO15/23) after 1 day 
in differentiation media (D1), grown on plastic 6-well plates. Detachment of the 
knockout clones was consistently observed. B) Representative brightfield images of 
wildtype (WT), and COBL knockout clones 15 and 23 (COBL KO15/23) after 7 days 
in differentiation media (D7), grown on collagen-coated plastic 6-well plates. 
Knockout clones remain attached to the growth surface but lack obvious fusion to 
form myotubes. Scale bars represent 100 microns. 
 
 
To examine the apparent lack of fusion of COBL knockout cells, cells were 
grown on collagen coated wells in differentiation media for 7 days, and stained 
with EA53, against α-actinin. The aim of this experiment was to calculate 
fusion and differentiation indices of the knockout cells, as in chapter 3. COBL 
knockout clone 18 had been re-established for these experiments.  Fusion was 
clearly observed in the wildtype C2C12 cells as expected. However, COBL 
knockout clones 15 and 18 showed very little α-actinin expression with only a 
few small myotubes forming, while COBL knockout clone 23 did fuse to some 
extent. 
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Unfortunately, differentiation indices could not be calculated for the COBL 
knockout clones. This was because of the extremely high density of nuclei 
observed in the images of these cells, making counting individual nuclei 
impossible (fig.7.11A). The high density of nuclei most likely represents cells 
continuing to proliferate, rather than following the differentiation pathway, after 
transfer to differentiation media. More evidence for differentiation defects 
comes from the aberrant expression of α-actinin observed in COBL knockout 
clone 23. Wildtype cells display striations of α-actinin, representing the 
formation of z-discs and the development of sarcomeres. This was not 
observed in COBL knockout clone 23, with α-actinin appearing to aggregate 
in a punctate pattern, rather than forming striations (fig.7.11A). 
Fusion indices were calculated for wildtype cells and COBL knockout clone 
23, expressed as the percentage of α-actin positive cells containing three or 
more nuclei (as in chapter 3 and (Li et al., 2017)) (fig.7.11B). The fusion index 
of COBL knockout clones 15 and 18 could not be calculated due to the lack of 
α-actinin expression. It was found that the fusion indices of wildtype cells and 
COBL KO23 were not significantly different. However, this measure does not 
consider the number of nuclei per frame, which appears higher for COBL 
KO23 but cannot be accurately measured due to the high density of the nuclei. 
It is therefore possible that more fusion events per nucleus are occurring in 
wildtype cells. As a proxy for this, the mean number of α-actinin positive cells 
with 3 or more nuclei per frame was calculated (fig.7.11C). This value was 
significantly higher in the wildtype cells. Therefore, assuming the COBL KO23 
cells have more nuclei per frame, there are more fusion events occurring per 
nucleus in the wildtype cells. 
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Figure 7.11. Myoblast fusion and differentiation are altered in C2C12-derived 
COBL knockout cells. A) Representative widefield images of anti-α-actinin (green) 
and DAPI (blue) stained cells after 7 days in differentiation media, grown on collagen-
coated 6-well plates. Two examples per cell line shown, cell lines shown are: wildtype 
C2C12 (C2C12), and COBL knockout clones 15 and 23 (COBL KO15/23). Zoomed 
in panels show α-actinin striations in the wildtype cells, and aberrant α-actinin 
aggregation in COBL knockout clone 23.  Scale bar represents 75 microns. B) Mean 
fusion index per frame for wildtype and COBL knockout clone 23 (COBL KO15 could 
not be measured due to lack of α-actinin expression), expressed as the percentage 
of α-actin positive cells containing three or more nuclei. Students t-test revealed no 
significant difference (p=0.212, n>25). C) Mean number of α-actinin positive cells with 
3 or more nuclei per frame. Students t-test revealed a wildtype cells had significantly 
higher values than COBL knockout clone 23 (*p<0.01, n>25). 
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7.7 Conclusions 
The expression of COBL at the protein level was found to be similar in both 
wildtype and IGFN1 knockout cells, with expression apparent when cells are 
fully confluent, and then throughout differentiation. This demonstrates that 
COBL is expressed when cells are ready to begin fusion and throughout the 
fusion process. The expression of COBL at the transcript level did differ 
between the cell types, with COBL mRNA levels higher than the wildtype at all 
time points and increasing throughout differentiation. Given the relatively 
similar protein levels, it is possible that IGFN1 acts to stabilise COBL and 
protect it from degradation. Therefore, in the absence of IGFN1 COBL 
transcription is upregulated to maintain COBL protein levels. Numerous IGFN1 
isoforms are present throughout myoblast differentiation in vivo (Li et al., 
2017), which may help to stabilise COBL at the right time and place to carry 
out its role. 
Next, COBL overexpression in wildtype C2C12 cells was performed. COBL 
overexpression resulted in an increase in actin-rich protrusions in C2C12 cells, 
as has been reported in COS7 (Ahuja et al., 2007). Actin-driven protrusions 
are required for myoblast fusion (Shilagardi et al., 2013). While it cannot be 
assumed that these protrusions are directly involved in myoblast fusion in this 
case, it does provide evidence that COBL is able to alter the actin cytoskeleton 
of myoblast cells.  
When COBL overexpressing cells were differentiated more nuclei per cell were 
observed than in cells expressing the tdTomato control. This result directly 
implicates COBL in myoblast fusion. This however may be driven by several 
cells overexpressing COBL with extremely high nuclei counts. The median 
number of nuclei between the two conditions was relatively similar, whereas 
the mean values were significantly different. COBL is known to remodel actin 
in different ways depending on its concentration (Husson et al., 2011). It may 
be that COBL expression must reach a specific concentration to drive 
myoblast fusion, something which is difficult to control using basic 
transfections to induce overexpression. This concentration may have been 
reached in some COBL overexpressing cells and not others. It should also be 
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noted that the more fusion events that occur, the more likely one of the nuclei 
fusing to the myotube is expressing the transfected construct. Therefore, it is 
more likely that myotubes with more nuclei express the transfected construct, 
potentially confounding these results. However, this is the case for both 
constructs. 
COBL knockout was used to reveal whether COBL was required for myoblast 
fusion. CRISPR/Cas9 targeting successfully produced COBL knockout clones. 
It would have been preferable to use en masse selection, to reduce the 
likelihood of artefacts from clonal selection, but cells selected en masse still 
expressed COBL. However, consistency between clones can also indicate 
whether an observed phenotype is caused by the loss of COBL. Rescue 
experiments should be performed in the future to validate the observed 
phenotypes. It should also be noted that an ideal experimental setup would 
include a non-targeted control cell line which also underwent clonal selection 
to allow decoupling of any fusion phenotype observed from the potential 
effects of clonal selection. Due to time constraints this was not possible but 
should be addressed in future experiments. 
Proliferating COBL knockout myoblasts did not display any consistent 
morphological changes, with the differences observed likely an artefact of 
clonal selection. This was expected as COBL expression is not observed at 
the protein level until confluency is reached in wildtype cells. However, on 
reaching confluency, where COBL is expressed in wildtype cells, the knockout 
clones tended to detach from the growth surface. Further, when collagen 
coating was used to maintain attachment through differentiation, COBL 
knockout clones did not appear to fuse when examined through brightfield 
microscopy. 
α-actinin staining revealed a lack of fusion in two of the COBL knockout clones, 
with apparently reduced fusion in another. On top of this, when fusion did occur 
in COBL knockout clone 23, aberrant α-actinin expression was observed, 
reflecting an inability of these cells to develop z-discs after 7 days in 
differentiation media. These findings further implicate COBL in myoblast fusion 
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and differentiation to some extent. However, because fusion did occur in clone 
23, it is clear that COBL is not essential for myoblast fusion. Further work 
including rescue of wildtype phenotypes in the knockout cell lines, through 
COBL expression, is required before definitive conclusions can be drawn.  
It is noteworthy that the COBL knockout mouse is viable and does not display 
any overt skeletal muscle phenotype (Haag et al., 2018). However, in depth 
analysis has not been reported, with no muscle histology shown in the paper 
characterising the COBL knockout phenotype. Examples of mutations 
resulting in a myoblast fusion defect in vitro which still allow survival in vivo 
have been reported (Schwander et al., 2003). Muscle phenotypes were 
revealed using histological and ultrastructural analysis. It is likely that the ECM 
and other structures in vivo help to facilitate myoblast fusion where it is 
disrupted in vitro. More stringent examination of the COBL knockout mouse is 
required to reveal potential defects in their skeletal muscle. 
This chapter has outlined the expression pattern of COBL throughout myoblast 
fusion and differentiation. Phenotypes associated with COBL overexpression 
were characterised and correlate with COBL being involved in myoblast fusion. 
Finally, COBL knockout cell lines were developed. Characterisation of these 
cell lines provided further evidence that COBL is involved in myoblast fusion 
and differentiation, but these findings should be treated cautiously until more 
work is completed.  
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Chapter 8: Discussion and Future Work 
8.1 Overview 
The aim of the research presented in this thesis was to gain insights into the 
functional role of IGFN1 in skeletal muscle, primarily through the 
characterisation of a C2C12-derived IGFN1 knockout cell line, and the 
identification and validation of IGFN1 interaction partners. The hypotheses 
outlined at the outset of this thesis were as follows:  
• Because of its domain composition and localisation, IGFN1 is a 
structural protein. 
• IGFN1 is a scaffold for signalling/effector proteins, due to its 
globular domains, its multiple interaction partners, and its lack of 
catalytic activity.  
• IGFN1 is a mechanosensor. Unfolding of proteins with similar globular 
domain compositions has implicated them in mechanotransduction. 
The interaction with KY and the CASA pathway may provide a 
mechanism for this. 
• Fusion defects in IGFN1 knockdown C2C12 cells suggest IGFN1 is 
part of the myoblast fusion machinery.  
• The association between atrophic signalling and IGFN1 expression 
suggests IGFN1 is a facilitator of atrophy.  
A direct role for IGFN1 in atrophy could not be determined, however, this may 
have been a result of the model used. Evidence of IGFN1 performing a role in 
myoblast fusion through cytoskeletal remodelling was revealed, with IGFN1 
potentially acting through the actin nucleator COBL. Finally, progress was 
made in producing recombinant IGFN1 for biophysical analysis, providing a 
tool for examining any role for IGFN1 in maintaining sarcomeric structural 
integrity or in mechanotransduction. 
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8.2 Discussion 
Until recently, many large immunoglobulin and fibronectin domain containing 
proteins had simply been considered to have structural roles, maintaining the 
integrity of the sarcomere through contraction and relaxation cycles. However, 
it is now known that many of these proteins are involved in processes ranging 
from mechanotransduction to determining sarcomeric length. A similar pattern 
has emerged here with IGFN1. Based on the domain composition of IGFN1 it 
would appear that its function is merely structural. However, several potential 
roles in skeletal muscle have been uncovered for IGFN1 beyond z-disc 
structural integrity, with the main hypotheses outlined above. 
One of the main hypotheses regarding the function of IGFN1 at the outset of 
this work was that it plays a role in atrophy. Here it was shown that IGFN1 is 
not able to induce atrophy directly in vitro, in concurrence with the lack of 
atrophy from IGFN1 overexpression in vivo (Li et al., 2017). Its upregulation 
during atrophic processes may be a compensatory mechanism, to protect the 
structure of the sarcomere even during atrophy. Or, IGFN1 may indirectly 
facilitate atrophy by providing a scaffold for other proteins to perform their roles 
at the z-disc, or by blocking the activity of its interaction partners, of which the 
translational elongation factor eEF1a is an example (Mansilla et al., 2008). 
Given that several proteasome subunits were identified as potential interaction 
partners through pull-downs and LS-MS/MS analysis, IGFN1 may also aid in 
bringing the proteasome subunits to the z-disc and facilitate protein 
degradation.  
Alongside this, IGFN1 interacts with key components of the CASA machinery 
KY and FLNC. IGFN1 may contribute to the breakdown of damaged proteins 
through this pathway, but CASA has been demonstrated to be required for 
muscle mass maintenance (Arndt et al., 2010). Meaning if IGFN1 does play a 
role in CASA its upregulation during atrophy is likely compensatory, ensuring 
turnover of damaged proteins at the z-disc. Despite the attempts here it is still 
unclear whether IGFN1 is a factor in maintaining the balance of muscle mass 
maintenance and, if it is, which end of the scale it fits on. 
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Away from atrophy, the most significant finding of the work presented here is 
of a role for IGFN1 in myoblast fusion and differentiation. Many proteins have 
been implicated in myoblast fusion in vitro, but the effects of clonal selection 
often confound these results. Rescue of the phenotypes here, however, clearly 
demonstrates that IGFN1 is involved in myoblast fusion. As expected, IGFN1 
was not demonstrated to be able to induce fusion directly as with the fusogens 
myomaker and myomerger so its contribution to fusion was likely to be indirect, 
acting through interacting partners. 
Further investigation of the role of IGFN1 in myoblast fusion revealed that it 
may act asymmetrically, with wildtype and IGFN1 knockout cells able to fuse 
with one another. This asymmetry is observed with several proteins associated 
with myoblast fusion, notably myomaker (Millay et al., 2013). Contributing to 
the idea that mammalian myoblast fusion follows a Drosophila-like model, with 
a founder cell and a fusion competent myoblast expressing different 
components of the fusion machinery.  
A connected phenotype identified in IGFN1 knockout cells, that was rescuable 
through IGFN1_V1 expression, was decreased actin polymerisation. It is 
known that actin dynamics play a crucial role in all stages of myoblast fusion 
and IGFN1 is known to interact with actin (Baker et al., 2010). The Arp2/3 
complex is the main driver of actin nucleation and polymerisation during 
myoblast fusion, regulated by N-WASP and Rac1 (Berger et al., 2008; Gildor 
et al., 2009; Richardson et al., 2007). It was therefore surprising that neither 
Arp2/3 or any of its upstream regulators were identified as interacting partners 
of IGFN1. It was, however, demonstrated that IGFN1 interacted with the actin 
nucleator COBL and that COBL localised to the z-disc in vivo.  
COBL was subsequently demonstrated to be capable of inducing changes to 
the actin cytoskeleton in myoblasts, and even increase myoblast fusion when 
overexpressed. These results raise the possibility that COBL acts as an actin 
nucleator during myoblast fusion and differentiation, a previously unidentified 
role. This would also mean that Arp2/3 is not the sole actin nucleator 
responsible for myoblast fusion. It is possible that IGFN1 acts as a scaffold to 
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bring together a complex of proteins including COBL during myoblast fusion 
that is entirely separate from the Arp2/3 complex and is regulated by other 
upstream factors. It is evident that there is much more research to be done 
before this conclusion can be drawn, but it remains a possibility. 
The research presented here demonstrates IGFN1, and potentially COBL, are 
involved in myoblast fusion in vitro. More widely, in vivo, this implicates IGFN1 
in either muscle tissue development; or in adult skeletal muscle during the 
repair of damaged muscle tissue, and in hypertrophy and hyperplasia. In adult 
skeletal muscle this would mean IGFN1 contributing to the fusion of satellite 
cells to existing muscle fibres. The robust expression of IGFN1 in adult skeletal 
muscle does suggest that it plays a role beyond a developmental one. This 
role may be unrelated to fusion of satellite cells and may be connected to 
atrophy, or simply maintaining the structure of the z-disc. However, the 
possibility that IGFN1 is a factor in the fusion of satellite cells to the adult 
muscle fibre cannot yet be ruled out. In vivo studies would be invaluable here, 
examining the effect of IGFN1 knockout on the repair of damaged muscle 
tissue. 
It is now clear that IGFN1 is involved in a number of processes in the muscle 
fibre and that more work is required to fully uncover and understand its 
importance, especially in vivo. 
 
8.3 Future Work 
8.3.1 In Vitro Models 
To validate the fusion phenotypes observed in C2C12-derived COBL knockout 
clones, the phenotype should be rescued through stable expression of COBL. 
This will result in a return to the wildtype fusion phenotype if COBL deficiency, 
rather than clonal selection, is indeed causing the fusion defects. Failing this, 
en masse selection of CRISPR/Cas9 targeted cells could be trialled again to 
remove the confounding effects of clonal selection. It is crucial to validate this 
phenotype in vitro as this may justify in vivo experiments investigating the role 
of COBL in skeletal muscle (as will be discussed below). 
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One of the most insightful techniques that should be employed in future work 
examining the role of IGFN1 and COBL in myoblast fusion is live cell imaging. 
This could not be performed during this project due to equipment and cost 
limitations. Live cell imaging of both the IGFN1 and COBL knockout myoblast 
lines and wildtype cells expressing fluorescently tagged IGFN1 and/or COBL 
could be used to examine different aspects of myoblast fusion. Imaging of the 
knockout cells would allow the identification of the differences between 
knockout and wildtype cells during fusion, revealing the precise changes to the 
morphology of the cell that either protein is responsible for. Live imaging of the 
actin cytoskeleton in these knockout cells would prove particularly informative. 
Live Imaging of wildtype cells expressing fluorescently tagged proteins would 
allow the proteins to be tracked in real-time through fusion both independently 
and together. This would provide information as to where and when in the 
process the proteins are required. A proximity ligation assay could also be 
used to track the interaction through fusion and differentiation. However, this 
method would require fixation of the cells and not provide real-time 
information. 
To investigate the hypothesis that IGFN1 stabilises COBL, outlined in chapter 
7, tracking of COBL protein levels in the presence and absence of IGFN1 
should be performed. This experiment would involve co-transfection of a cell 
type that does not endogenously express either COBL of IGFN1, such as 
COS7. Cells would be transfected with either; a vector conferring IGFN1(+a 
tag such as V5) expression, and a vector conferring the expression of COBL 
in an inducible manner (such as the Tetracycline Off system (Gossen and 
Bujard, 1992)), or a vector conferring expression of the V5 tag as a control, 
and a vector conferring the expression of COBL in an inducible manner. After 
24hours COBL expression could be inhibited pharmacologically and the 
protein level of COBL traced through SDS-PAGE western blot analysis. COBL 
protein levels should be expressed as a proportion of those observed at t=0 to 
account for different COBL expression levels between samples.  If IGFN1 does 
stabilise COBL and prevent its degradation, COBL protein levels would fall 
less quickly in the IGFN1 and COBL transfected samples than in the control 
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samples. Transfections followed by cycloheximide treatment could also be 
used, however this would rely on IGFN1 remaining stable throughout. 
Finally, to further examine the potential role of IGFN1 in atrophy, similar 
experiments as performed in chapter 4 should be repeated with recombinant 
myostatin, rather than dexamethasone. Dexamethasone was used to 
indirectly induce myostatin expression and atrophy (Menconi et al., 2008; Qin 
et al., 2013). However, dexamethasone has other off target effects and 
induces different effects based on the differentiation state of the cell (Guerriero 
and Florini, 1980; Han et al., 2017; Qin et al., 2010), something which may 
have confounded results in the IGFN1 knockout cell line in which a 
differentiation defect is observed. The use of recombinant myostatin, while 
more costly than dexamethasone, may provide a clearer picture as to whether 
IGFN1 contributes to, and is upregulated in response to, myostatin signalling-
induced atrophy in vitro. 
 
8.3.2 In Vivo Experiments 
Previous attempts at determining the effects of loss of IGFN1 function in vivo 
have involved electroporation of adult mice with the same CRISPR/Cas9 
constructs used to produce the IGFN1 knockout cell lines used in this work. 
These electroporations were performed with the goal of examining the role of 
IGFN1 in atrophy and not myoblast fusion and differentiation (Li et al., 2017). 
To examine the role of IGFN1 in myoblast fusion and differentiation in vivo an 
IGFN1 knockout mouse line should be generated. It should be noted that the 
generation of such a mouse line was attempted through an external company. 
Unfortunately, this work failed and there was a lack of time and budget for 
another attempt within this project.  
The Knockout Mouse Project (KOMP, The Jackson Laboratory) have reported 
the development of an IGFN1 knockout mouse. Phenotyping of this animal 
has been limited and did not include any skeletal muscle analysis. The 
prohibitive cost and time-scale of re-deriving and importing this line meant that 
this mouse could not be examined within this project. Additionally, the 
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genotyping of this mouse is not clear, and no western blots were performed. 
Owing to the complexity of the IGFN1 locus, and the isoforms produced from 
it, it is possible that this mouse is not a genuine knockout. 
The generation, or import following validation, of an IGFN1 knockout mouse 
line would allow it to be determined whether the fusion and differentiation 
phenotypes observed in vitro are relevant in vivo. However, other tissues and 
structures such as the ECM could aid myoblast fusion in the absence of IGFN1 
and result in the formation of muscle which displays other pathologies. In this 
case analysis should focus on myofiber size and structure, especially at the z-
disc, where electron microscopy could reveal z-disc phenotypes if IGFN1 is 
playing a role in maintaining its structure. In addition to this, the expression of 
COBL in the muscles of IGFN1 knockout mice should be examined; both on a 
whole tissue level, through qPCR and western blotting, and in terms of its 
localisation through immunostaining. It would be expected that COBL would 
not localise to the z-disc in IGFN1 knockout mice if IGFN1 does act as a 
scaffold for COBL. 
To confirm any role for COBL in skeletal muscle in vivo the knockout mouse 
line generated by Haag et al (Haag et al., 2018) should be extensively 
examined for muscle pathology. While the animals are viable and display no 
overt muscle phenotypes, there may be some pathology. Often mice with 
muscle pathologies are overtly unaffected without muscular challenge, or 
appear even stronger, as is the case with the mdx mouse (Stedman et al., 
1991). If COBL KO mice are subjected to a protocol whereby mechanical 
tension is placed upon the muscle, any underlying pathology may be 
exacerbated, revealing muscular defects. Even without mechanical tension, 
histology and electron microscopy may reveal phenotypes associated with 
COBL loss of function. It is important for this work to be completed as in vitro 
evidence alone is not sufficient to conclusively demonstrate a role for COBL in 
skeletal muscle. 
IGFN1 and COBL may play a role in repairing muscle damage in vivo, 
contributing the fusion of satellite cells to the damaged myofibres to regenerate 
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the tissue. Upregulation of either protein in response to muscular injury would 
provide evidence for this and could be examined in the future. Following this, 
the injury response of the COBL knockout mice and IGFN1 knockout mice, if 
generated, should be compared to the response in wildtype mice.  
 
8.3.3 Biophysical and Biochemical Experiments 
As stated above, the AFM unfolding experiments could not be repeated and 
refined within the timeframe of this project. Future work should therefore focus 
on optimising conditions to allow for the collection of high-quality mechanical 
unfolding/refolding data for the purified IGFN1 fragments. Fresh recombinant 
His-tagged protein should be purified to ensure that the samples are intact and 
fully folded prior to surface immobilisation on Ni-NTA-coated glass coverslips 
for the AFM experiments. In addition, other IGFN1 fragments should be cloned 
into the pQE2-Im9 vector and purified to allow for a complete characterisation 
of all the predicted domains inIGFN1. 
Further examination of the potential interactions, identified through LC-MS/MS 
analysis of pull-downs, between IGFN1 and several proteasome subunits 
should be performed. The association of IGFN1 expression with atrophic 
signalling raises the possibility that these interactions may be functionally 
relevant. A similar experimental design to that used to validate the IGFN1-
COBL interaction should be used, with immunoprecipitation and colocalization 
experiments employed. It should be noted that initial analysis of these 
interactions was performed by another student in our lab, yielding negative 
results. However, this work relied on the immunoprecipitation of endogenous 
proteasome subunits, and their identification using antibodies which proved 
unreliable. More work is required to conclusively prove or disprove these 
potential interactions. 
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8.4 Overall Conclusions 
This thesis has described the characterisation of a C2C12-derived IGFN1 
knockout cell line, revealing a role for IGFN1 in myoblast fusion and 
differentiation, associated with the remodelling of the actin cytoskeleton. Pull-
down analysis revealed the actin nucleator COBL as a potential interacting 
partner of IGFN1, and this interaction was subsequently validated. The role of 
COBL in myoblast fusion was investigated through overexpression 
experiments and the generation of a C2C12-derived knockout cell line. Initial 
characterisation points towards a role for COBL in myoblast fusion, with more 
work required to confirm this. It is possible that IGFN1 influences actin 
remodelling, and therefore myoblast fusion, through its interaction with COBL.  
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Glossary of Abbreviations 
Abbreviation Name 
ActRII Activin type II receptor  
AFM Atomic Force Microscopy 
AKT Protein Kinase B 
Arp2/3 Actin-Related Protein 2/3 
ATCN1 Alpha Actin 
BAG3  Bcl2 Associated Athanogen 3 
BAI1/3 Brain-Specific Angiogenesis Inhibitor 1 /3 
BDL Bile Duct Ligation 
BSA Bovine serum albumin 
CASA Chaperone Assisted Selective Autophagy 
COBL Cordon-Bleu WH2 Repeat Protein 
COS7 CV-1 in Origin, carrying the SV40 genetic material 
CRISPR Clustered regularly interspaced short palindromic repeats 
CTCF Corrected total cell fluorescence  
DAPI 4′,6-diamidino-2-phenylindole 
DM Differentiation Media 
DMD  Duchenne muscular dystrophy  
DOCK1 Dedicator of Cytokinesis 1 
DUF Dumbfounded 
ECM Extracellular matrix 
EDL Extensor digitorum 
EF-Tu Elongation Factor Tu  
eIF4E Eukaryotic Translation Initiation Factor 4E 
ERK Extracellular Signal-regulated Kinase  
FBS Foetal bovine serum  
FC Founder Cell 
FCM Fusion Competent Myoblast 
FLNC Filamin C 
FOXO Forkhead Box Transcription Factors  
GEF Guanine nucleotide exchange factors 
GH Growth Hormone 
GM Growth Media 
HBS Hibris 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
IGF1 Insulin-like growth factor 1 
IGF-1R Insulin-like growth factor 1 Receptor 
IGFN1 
Immunoglobulin-like and fibronectin type III domain containing 
1 
IgSF Immunoglobulin superfamily 
IRS-1 Insulin Receptor Substrate 1 
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KY Kyphoscoliosis peptidase 
LC-MS/MS Liquid Chromatography with tandem mass spectrometry 
MAPK mitogen-activated protein kinase 
MBC Myoblast City 
mTOR Mammalian Target of Rapamycin 
MURF1 Muscle Ring Finger1  
MYOD Myogenic Differentiation 
NAP1 Nucleosome Assembly Protein 1  
Ni-NTA Nickel-nitrilotriacetic acid  
OD Optical density 
p70s6k Ribosomal protein s6 kinase beta 1 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate-buffered saline 
PCR Polymerase Chain Reaction  
PI3K Phosphatidylinositol 3 kinase 
qPCR Quantitative Polymerase Chain Reaction 
RAC1 Rac Family Small GTPase 1 
RHEB Ras Homolog Enriched in Brain 
RIPA Radioimmunoprecipitation assay 
RST Roughest 
SCAR Suppressor of cAR 
SDS Sodium dodecyl sulphate 
Smad2/3 SMAD Family Member 2/3 
SNS Sticks and Stones 
TA Tibialis anterior 
TAZ Tafazzin 
TCS2 Tuberous sclerosis complex 2 
TNFα Tumour Necrosis Factor α 
WASP Wiskott-Aldrich syndrome protein 
WAVE WASP family Verprolin‐homologous protein  
XIN Xin Actin Binding Repeat Containing 1 
Y2H Yeast 2 Hybrid 
YAP Yes Associated Protein 
ZAK Leucine Zipper-and Sterile Alpha Motif-Containing Kinase 
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